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ABSTRACT 
The important group of antibiotics used mainly to treat serious bacterial 
infections is the aminoglycosides. It includes tobramycin, gentamicin, 
streptomycin, amikacin and kanamycin. Compounds derived from 
Streptomyces are called "mycins" e.g. streptomycin whereas those derived from 
Micromonospora are called "micins" e.g. gentamicin. They have broad 
antimicrobial spectrum extending from gram positive aerobic cocci to gram 
negative bacilli. 
The inherent toxicity of these antibiotics have limited their clinical use. 
Nephrotoxicity is one such major adverse side effect. They are nephrotoxic 
because after glomerular filtration, a small but sizeable portion of administered 
doge (« 5%) is retained in the cortical and epithelial cell lining the proximal 
tubules, which is the major functional site in the kidney, damaged by these 
drugs. 
Antibiotics in general accumulate in renal cortex intracellularly and have long 
half lifes. All aminoglycosides are toxic to kidney however, differences exists 
in their nephrotoxic potential in both humans and animals. Aminoglycosides 
nephrotoxicity and its protection still remains a subject of clinical 
pharmacological and biochemical investigations. Till now, most studies 
involving modulation of aminoglycoside nephrotoxicity have only partially 
fulfilled the task of restoring the normal fijnction of kidney. With this 
background, a trial to benefit not only in renal function but also on several other 
tissue parameters including the antioxidant potential was investigated with the 
use offish oil and the results obtained are compared with oli'^ 'e oil. Fish oil and 
olive oil has many attractive properties, with a favourable beneficial profile 
ranging from cardiovascular diseases to diabetes and cancer as well. This 
prompted us to select them as therapeutic agents to modulate the toxicit}' 
induced by various antibiotics. 
This study provides a safe and cheaper approach to investigate the protective 
effect of fish oil in amehorating the antibiotic induced nephrotoxicity. For a 
better understanding of the use of fish oil and olive oil in reversal of induced 
toxicity, the following studies were perfomied. 
1. Five commonly used antibiotics were selected for the present study. 
These are gentamicin, tobramycin, streptomycin, amikacin and 
Kanamycin. These antibiotics are actively used to treat urinary tract 
infections, meningitis, septic bums, pneumonia, tularemia, plague and 
respiratory tract infections. All of them are water soluble with maximum 
antibacterial activity in alkaline medium, however they differ in their 
nephrotoxic potential which depends on their dosage. 
2. Rats were divided into eight groups, each having eight rats, which are as 
follows: (a) Control group, which is a nornial one receiving saline 
injections only, (b) Antibiotic treated group, which received a high dose 
of particular antibiotic to induce maximum damage, (c) The rest six 
groups were given two oil in three different modes (pre, 
coadministration and post treatment) along with antibiotic. Thus three 
groups received fish oil and other three olive oil in the above given three 
modes of treatment. Pretreatment group received oil dosage before 
antibiotic exposure; coadministration group received both oil and 
antibiotic simultaneously whereas post treated group received oil dosage 
after the antibiotic injections. These three modes of treatment were 
selected detemiine which mode gives the maximum reversal effects on 
antibiotic induced nephrotoxicity. 
3. To get the ineasure of maximum nephrotoxicity induced by antibiotics, 
these drug were given at a higher therapeutic dose via intrapertionial 
route for 10-14 days. Animals were then sacrificed 12 H after last 
injection. Blood was collected, centrifuged and serum was collected. 
5. The various serum parameters i.e. urea, creatinine, cholesterol, inorganic 
phosphate, SGOT and SGPT were carefully monitored in antibiotic 
treated groups as well as in other groups, in which fish oil and olive oil 
was used with antibiotic in various combinations. 
6. To establish the beneficial role of the two oils on the antibiotic induced 
nephrotoxicity, activities of various marker enzyme of tubular renal 
membrane and lysosomes i.e. AlP and Ac? were determined in kidne} 
and liver homogenates, of all animal groups, given drug in combination 
with fish oil and olive oil. 
7. The beneficial role offish oil and oli\'e oil in enhancing the antioxidant 
potential was determined, by the quantitative estimation of CAT, SOD 
and GST in all animal groups. 
9. Lipid peroxidafion in liver homogenates of all animal groups was done 
to see the extent of damage caused b}' the drug and its prevention by the 
two oils. 
The results of the study clearly indicate that antibiotics used in the study are 
nephrotoxic as was evident by elevated lexels of serum urea and creatinine. 
This nephrotoxicity was dose related and for each antibiotic, a particular dose 
for a particular time (days) regimen produced serious alterations in kidne\ 
function. Fish oil was found to give beneficial effects as was evident from 
normalized levels of serum urea and creatinine in animal groups receiving 
different modes of fish oil treatment. The results obtained suggested that post 
fish oil treatment resulted in maximum reversal of tobramycin induced toxicit}' 
whereas coadministration of fish oil was a beneficial mode of treatment for 
gentamicin, streptomycin, amikacin and kanamycin induced nephrotoxicit}'. 
The protection was probably due to the reason that with antibiotic exposure, 
renal membrane gets badly damaged, supplementation of essential fatty acids 
from fish oil helps in stabilizing membrane structure just when the damage by 
drug begins, which inturn helps in restoration of renal function thereby 
reducing (he severity of nephrotoxicity induced. 
Olive oil treatment was although beneficial in bringing any such profound 
effects in protection of induced nephrotoxicity. However, it did help in some 
recovery of the damaged membranes probably due to presence of tocopherols in 
it. 
Antibiotic administration was also found to be hypercholesterolaemic. Fish oil 
administration proved to have more hypocholesterolaemic effect than olive oil. 
Similarly increased level of inorganic phosphate, SGOT and SGPT were 
nomialized by the use of fish oil, for each antibiotics used. Olive oil, on the 
other hand could not produce consistent effects in restoration of levels of above 
serum metabolites studied. 
The altered levels of AlP and Ac? were also restored to normal (~ 70-80% 
recovery) with fish oil administration. Among the two oils, this beneficial effect 
in recovery of levels of AlP and AcP to normal was done maximally by fish oil. 
Further, the induced oxidative stress by aminoglycosides was reduced 
maximally by fish oil through induction of antioxidant potenfial. Olive oil did 
help in restoration of the decreased level of antioxidant. Post fish oil gave a 
maximum increase in levels of CAT, SOD and GST in tobramycin treated rats 
where as coadministration of fish oil gave a higher induced antioxidant level in 
gentamicin, streptomycin, amikacin and kanamycin treated rats. However, we 
are not able to interpret the result why post fish oil treatment was maximally 
beneficial mode for tobramycin as compared to fish oil coadministration for all 
other anfibiofics. 
The composifion of fatty acid as well as non fatty acids of the two oils that is 
fish and olive oil is well characterized. Fish oil essentially is rich in 
polyunsaturated fatty acids of n-3 type like linolenic acid, eicosapentaneoic acid 
and docosahexaneoic acid besides it contains a rich level of antioxidants 
vitamin E. Mammals camiot synthesise linolenic acid whereas EPA and DHA 
can be made out of linolenic acid via elongation processes. Olive oil on the 
other hand, is rich in monounsaturated fatty acids of n-6 series i.e. oleic acid. 
Although olive oil also possess tocopherols but the level is much less than fish 
oil. Therefore, it was thought worthwhile to investigate the effect of 
components of fish oil that help in reverting the nephrotoxic effects of 
tobramycin. Linolenic acid (n-3 FA) and vitamin E (antioxidant) were selected 
for the study. These components were given along with tobramycin which 
showed the beneficial role of n-3 FA in restoration of structure and thereby the 
function of renal membrane. Vitamin E played a role in prevention of 
lipoperoxidation and acted as scavenger of free radicals. Both these 
components i.e. linolenic acid and vitamin E when given separately could not 
give beneficial effects in ameliorating the toxic effects of tobramycin. 
Comparative data of all the antibiotics included in the study, suggest that 
maximum protection is obtained for tobramycin with administration of fish oil 
as post treatment. Next in line was gentamicin, where coadministration of fish 
oil gave similar effects on reversal of induced nephrotoxity. Thus it can be 
concluded fish oil coadministration helps in reversal of damage caused by 
antibiotics, as kidney regained its normal function, making it a better and safe 
approach to be included with antibiotic therapy. Olive oil also helped in 
reversal of nephrotoxic effects of antibiotics but the effect produced is less than 
fish oil. 
Ontfoductlon 
A. KIDNEY: STRUCTURE AND FUNCTION 
Kidney is a complex organ that regulates the amount of ^^ 'aler lost from the 
body and aids in removal of waste products of protein catabolism especially 
urea and creatinine as well as ketone bodies from fat catabolism. They control 
and regulate the acid-base balance of body fluids including the blood [1]. Thus, 
it plays an important role in health, disease, growth and overall development of 
the mammalian system. Kidneys are the two bean shaped organs, one on each 
side of vertebral column in the lumbar region of the body. Human kidney 
represent about 0.5% of total body weight. Each kidney is 10 cm long, 5 cm 
broad and 4 cm thick. The outer surface of kidney is convex and the inner side 
is concave. The inner face of it has a deep notch called hilus, from where renal 
artery, renal vein and ureter enters the kidney. Kidney receives 20-25% of total 
arterial blood. About 180 liters of water is filtered through the kidney everyday 
but only 1.5 liter finally leaves the body as urine. Thus, kidney helps to 
maintain total body fluid volume and its composition. 
Mammalian kidney which apparently looks homogenous, has many segments. 
Each kidney has two portions, the peripheral dark reddish brown region known 
as cortex and the central light red portion known as medulla (Figure la). Each 
kidney contains about 2 million nephrons, which is the basic functional unit. 
Each nephron is a tube like structure, closed at one end and open at the other. 
The basic anatomy of nephron is described as follows (Figure lb): Blood enters 
the glomerulus through the afferent arteriole and then lea\es through the 
efferent arteriole [2] The glomerulus is a network of upto 50 parallel branching 
and anatomizing capillaries covered by epithelial cells and encased in 
bowman's capsule, pressure of blood in the glomerulus causes fluid to filter 
into bowman's capsule and form it, the fluid flows into the proximal tubule, 
that lies in the cortex of the kidney along with the glomerulus. The proximal 
convoluted tubule then lead to a "U" shaped part, the loop of Henle [3]. The 
Henle's loop has a descending limb, thin middle limb and a thick ascending 
limb. The ascending limb then leads to distal tubule, that lies in renal cortex. 
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Figure lb: Structure of a nephron 
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About eight of distal tubules coalesce to form the collecting duct. The largest 
collecting ducts empty into the renal pelvis. In each kidney, there are about 250 
large collecting ducts, each of which transmits the urine from about 4000 
nephrons. As the glomerular filtrate flows through the tubules, about 99% of its 
water and varying amounts of the solutes are normally reabsorbed into the 
vascular system and the remaining tubular water and dissolved substances 
becomes urine (Fig.2). Reabsorption through the tubular membrane is both 
active as well as passive. The transport of ions and solutes is mostly driven by 
metabolic energy yielding reactions. Amino acids, sugars, inorganic phosphate 
(iP) and ions like sodium (Na"^ ), potassium (K^), chloride (Cf) and bicarbonate 
(HCO3') are selectively reabsorbed by brush border membrane (BBM) of 
proximal tubule [4]. There are numerous extensions in luminal membrane of 
the proximal tubule, the function of which is to increase the total surface 
available for contact with tubular fluid, from which many components ion and 
solutes are reabsorbed at high rates [5]. The transport of sodium ions (Na~) is 
the major function in mammalian kidney, as in the absence of Na"^  transport, 
the transport of other solutes such as amino acids and hexoses approaches zero 
[6]. Fromter et al. [7] suggested that one third of the net transepithelial Na' flux 
is transported actively. 
To discuss the functions of the kidney, it is necessary to know the function of a 
single nephron. Nephrons have various subsegments which show distinct 
structural and functional differences. The nephron heterogeneity adds to the 
variation in kidney function as a whole. Depending on the origin and location 
of the nephrons in cortical regional of kidney, both inter and intranephronal 
heterogeneit} exists in mammalian kidney [8]. Those nephrons whose 
glomerule lie close to the surface of the kidney (i.e. approximately 0.5 - 1 mm 
below the capsular surface) are called cortical nephrons or superficial 
nephrons. Nephrons with glomeruli situated in the mid cortex deep to the 
superficial nephrons are referred to as midcortical nephrons. Generalh', the 
most superficial nephrons have short loops of Henle and the loops penetrae 
only a very short distance into the outer portion of the medulla. Between one 
fifth and one third of the nephrons have glomeruli that lie deep in the renal 
cortex near the medulla; these are called juxtamedullary nephrons. These 
nephrons have very long loop of Henle that penetrate deeply into the inner 
zone of the medulla [9]. All these populations of nephrons have been found to 
be structurally and functionally distinct [8]. Glomerular diameter, filtration 
rate, proximal tubular length, epithelial permeability, transport characteristics, 
transepithelial voltage differences and distribution of various enzyme activities 
contribute to disfinguish different nephron populations [10]. The proximal 
convoluted tubules of superficial nephrons always touch the surface of the 
kidney, while convolutions from midcortical nephrons do so infrequently. 
Whereas proximal convolutions from juxtamedullary nephron run 
perpendicular to and inter wine with medullary rays. 
In intra-nephron or axial heterogeneity, the proximal tubules have been divided 
into three distinct morphological subsegments namely, SI, S2 and S3. Proximal 
convoluted tubules (PCT) both in superficial and juxtamedullary nephrons is 
defiend as SI subsegment and can be identified by its attachment with 
glomeruli on one side [11]. S2 is defined as the late superficial PCT and 
includes the rest of convolutions and entire pars recta (straight portion) in 
cortical portion of the kidney [11]. S3 is located principally in the outer stripe 
of outer medulla and terminal superficial PCT. S3 is identified by its medullary 
location and by its connection with thin limbs on distal part. All S2 
subsegments as they descend from cortex into the outer stripe of outer medulla, 
change from the S2 to S3 cell type. 
Besides morphological differences, the functional inter and intra-nephronal 
differences have also been observed in proximal tubule. The reabsorption of 
solutes i.e. aminoacids, sugars, inorganic phosphate (iP) and sodium ion (Na"*^ ) 
occurs maximally at proximal tubules of the cortical region, by brush border 
membrance [12]. In SI subsegment of early PCT, Na''-K^ ATPase activity, 
oxidative metabolism and active transport is relatively high, resuldng in very 
efficienl Na^  coupled net reabsorption of glucose, amino acids, phosphate and 
net secretion of hydrogen ions [8]. Transport capacities of glucose, iP and H^ 
by S2 decrease progressively along the proximal convolutions. Finally, in S3 
segment transport of organic acids and bases mainly takes place; Na'^ -K'' 
ATPase activity and Na"^  transport are found to be relatively low. The retention 
of Na^ ions and iP in body by kidney is required for proper growth and 
development. 
B. RENAL FAILURE 
It refers to any condition that seriously interferes with kidney function. 
Nephrons are susceptible to damage due to many factors such as poisons, 
drugs,aging, infection, trauma, drugs, cancer, autoimmune diseases and genetic 
predisposition. If any of these occurs, the entire nephron stops functioning. 
When the number of functioning nephrons drops below 25 percent or when 
damage occurs too suddenly for the remaining nephrons to compensate, kidney 
failure occurs. There are two types of renal failure, which are as: 
(1) Chronic renal failure, which is an irreversible loss of function that 
occurs, progressively over months or years. 
(2) Acute renal failure, in which there is sudden loss of function that is 
sometimes but not always reversible. 
ACUTE RENAL FAILURE 
It is a clinical situation where kidney function is seriously interfered. It occurs 
so suddenly that surviving nephrons do not have time to recompense. Failing 
kidneys cannot adequately clear the blood from certain toxins. These include 
urea (a nitrogen containing by product of protein metabolism) and creatinine (a 
chemical byproduct of muscle exertion). As a result when the kidney fails, 
there is an abnormally high level of these wastes products in plasma [13]. Other 
components such as phosphorus, calcium, sodium, potassium and chloride, 
may also rise or fall abnormally. Failing kidney may also produce extremely 
dilute urine or urine that contains too much protein (proteinuria). ARF is 
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caused either by ischemia or toxic insult to the kidney which interferes with 
energy production, thereby leading to loss of active a absoiption and secretion 
functions of the kidney [14]. In ARF, both kidneys stop their function in a short 
period of time. It begins with tubular necrosis and continues until renal 
function and structure have essentially recovered due to reperfusion of blood or 
by administration of various drugs, hormones or antioxidants [15-18]. 
However, the time course of injury and recovery overlap remain variable due to 
the extent of damage. 
Pathophysiology of ARF 
ARF can be grossly divided into three phases: 
1) Pathogenic phase, 2) Manifestation phase and 3) Recovery phase. In the 
pathogenic phase, a progressive disintegration and necrosis of tubular epithelial 
cells occur, leading to the functional loss of the kidney which is manifested by 
the reduction in creatinine clearance [19]. In the second phase, long lasting 
effects are observed that severely effect the clearance of creatinine and which 
can continue for several days depending on the degree of renal damage. In the 
recovery phase, there is an increase in the concentrating ability of the kidney 
with eventual normalization of kidney function. 
Acute renal failure may occur due to certain factors [20-23]. The classical 
e\'ents that lead to the loss of renal function in ARF include tubular leakage 
across the damaged epithelium, tubular obstruction or interstitial compression, 
a decrease in renal blood flow and glomerular membrane permeability. 
Physiologic and morphologic studies suggest that there are four major possible 
pathogenic mechanisms of ARF, which include renal vasoconstriction, 
glomerular permeability, tubular obstruction and tubular leakage [24]. 
However, the extensive research of the past 40 years using morphology, 
clearance and micropuncture techniques were unable to provide a universal 
view regarding the mechanism for the pathogenesis of ARF. A decrease in 
glomerular permeability explains the reduction in filtration rate but not loss of 
tubular function. The reason ibr not reaching to a conclusion, could be due to 
the fact that most of the evidences are based on structural alterations rather than 
on functional parameters. 
C. ANTIBIOTIC NEPHROTOXICITY 
The clinical use of antibiotics as antibacterial agents have been found to be 
associated with renal dysfunction. The clinical and morphological expression 
of antibiotic nephrotoxicity represents a spectrum of alterations ranging from 
acute renal failure and tubulointersitial nephrotoxicity to selected renal tubular 
disorders. 
General features of antibiotics 
Aminoglycosides form a class of antibiotics that are highly polar cations 
composed of various sugar molecules in glycosidic linkage with amino group 
containing side chains. Aminoglycosides have low lipid solubility and a low 
capacity for penetrating membranes. They are poorly absorbed from gut, 
therefore are given intramuscularly or intravenoush". They have a broad 
antimicrobial spectrum, extending from gram positive aerobic cocci to gram 
negative bacilli. However, their exact mechanisms of action is unknown [25]. 
Aminoglycosides act by inhibiting the synthesis of bacterial proteins \ia 
interference with the activity of ribosomes. However, serious toxicity is a 
major limitation to usefulness of these drugs. The nephrotoxic potential varies 
among individual aminoglycosides. 
The commonly used, clinically available aminoglycoside antibiotics are 
gentamicin, tobramycin, streptomycin, amikacin and kanamycin. 
TOBRAMYCIN, belongs to the family of nebramycins and is derived from 
the actinomycetes Streptomyces tenebrarius. It is acti\e against Pseudomonas 
aeroginosa but less active against proteus. Chemicalh', it is a six-membered 
aminocyclitol ring with amino group side chain (Fig.2). It is used to treat 
bacterial conjunctivitis, cystic fibrosis and abdominal infections. However, 
about 30% of patients treated with it show signs of nephrotoxicity [26]. 
GENTAMICIN, is produced by Microspora purpura and is effective against 
Pseudomonas, E. coli, Proteus and Mycobacterium tuberculosis. Chemically, it 
is a sugar in glycoside linkage with side chain amino groups (Fig.2). 
Nephrotoxicity, is the most unavoidable effect associated with its use [27,28]. 
Therefore, proper dosage schedule of the drug becomes important. 
STREPTOMYCIN, is obtained from Streptomyces griseus. It is an organic 
base which forms water soluble salts (Fig.2). The organisms sensitive to 
strephtomycin are Mycobacterium tuberculosis, Shigella species, E. coli, 
Proteus and Pseudomonas aeroginosa. The drug is more effective at alkaline 
pH. therefore its activity is reduced in blood and serum. Renal irritation, 
however, occurs in patients receiving streptomycin [26]. 
AMIKACIN, is a semisynthetic derivative of kanamycin A with 
pharmacokinetic properties similar to the kanamycin (Fig.2). It is active against 
Klebsiella, E. coli and Proteus. However, acute renal deterioration occurs with 
its usage which manifests as enzymuria and polyuria [29]. 
KANAMYCIN, is a water soluble antibotic derived from Streptomyces 
kanamyceticus. It is effective against many gram-negative organism like E. 
coli. Klebsiella, Aerobacter, Salmonella, Shigella, Vibrio and Brucella. The 
chemical structure of kanamycin is given in Fig.2. Acute tubular necrosis 
however, develops characterized with polyuria and proteinuria [30]. Therefore, 
utmost care is taken during its administration. 
Studies indicate that gentamicin and tobramycin are equally nephrotoxic and 
are slightly more nephrotoxic than amikacin [31]. In animal studies, 
streptomycin is the least nephrotoxic. The nephrotoxicity of kanamycin 
Figure 2 : The chemical structures of various commonly used antibiotics. 
Aminoglycosides are sugars in glycosidic linkage with side chain 
containing amino groups. 
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lies between that of streptomycin and neomycin [32]. Concentration of drug 
found in renal cortex in experimental animals has been used to measure the 
relative nephrotoxicity produced by an antibiotic. However, some controlled 
clinical trials have given different estimates of their relative nephrotoxicity 
[33-36]. 
Antibiotics are rapidly distributed throughout the extracellular fluid. Because of 
their polar nature, these are largely excluded from most cell. The potential for 
aminoglycoside nephrotoxicity seems to depend on the number of ionizable 
amino groups (NH2^) contained on their molecule and on the derived 
cationicity. The cationic charge of these aminoglycosides is correlated with the 
degree of their interaction with the membrane and interference with 
mitochondial function. Although a good correlation exists between the 
cationicity and specific (renal, ototoxicity or neurotoxicity) or whole animal 
toxicity but aminoglycosides with similar cationic charges may exhibit 
different clinical or experimental toxicities Studies show that aminoglycosides 
containing equal number of aminogroups (five NH2^ groups) exhibit different 
nephrotoxicities [37]. Therefore, factors other than the molecular cationic 
charge are of importance. These may include charge orientation, position and 
an inherent propensity of the aminoglycoside molecular structure for causing 
toxic injui7 to intracellular organelles. 
Molecular and pharmacologic aspects 
Antibiotics are nephrotoxic because a small concentration 5% is retained in the 
epithelial cells linning in the SI and S2 segments of the proximal tubules after 
glomerular filtration. The drugs accumulated by these cells are mainly 
localized with endosomal and lysosomal vacuoles and with golgi complex [36-
38]. They elicit an array of morphological and functional alterations of 
increasing severity (Fig.3). In humans, only after few days of administration of 
clinical dose, aminoglycosides induces conspicuous changes in lysosomes of 
proximal tubular cell [38]. These changes are accompanied by signs of tubular 
dysfunctions i.e. release of BBM and lysosomal enzymes, decreased 
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reabsorplion of filtered proteins, wasting of ions and glucose and 
phosphlipiduria. High doses of aminoglycosides (more than 40 mg/kg body 
weight) in animals rapidly induce cortical necrosis and renal dysfunction 
[30,39]. At this stage a number of structural, metabolic and functional 
alterations occur in tubular cells that lead to cell dysfunction or death. Many 
changes occur due to the direct effect of drug on apical membrane during its 
initial stages of uptake in proximal tubules [40, 41], where as effects like 
inhibition of protein synthesis mitochondrial alterations, modulation of gene 
expression must involve uptake and intracellular distribution of the drug to 
corresponding targets (Fig. 3). 
Tubular necrosis 
Although histopathological studies strongly support the concept that tubular 
necrosis is the primary causes of functional toxicity. However, the mechanism 
of this necrosis remains unsettled. Different hypothesis have been given to 
explain the unambiguity. First hypothesis assumes that antibiotics exert their 
toxicity in direct relation to their local concentration. This would therefore 
designate lysosomes as key site and lysosomal alterations as a main target. 
However, so far, links between lysosomal alterations and cell necrosis ha\'e not 
been found. A second hypothesis is that aminoglycosides become toxic once 
they are released from lysosomes. This means if triggered abruptly, the release 
of large quantities of aminoglycosides from lysosomes could indeed cause the 
simultaneous development of a number of other\\'ise unrelated metabolic 
changes, many of which are capable of causing cell death. The question, then is 
to distinguish between real toxic events from trival or secondary effects. A 
typical example is inhibition of mitochondrial respiration and Ca transport or 
lipid peroxidation, both of which were claimed to cause irreversible cell 
damage but detailed studies showed that they occur after cell death [42]. 
Finally a third hypothesis is that drug stored in lysosomes is in parallel to 
endocytic uptake and a small amount of aminoglycosides reaches a critical, 
nonlysosomal target and causes toxicity. 
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Figure 3 : Ultrastructural alterations induced in proximal tubular cells during 
antibiotic treatment. 
(A) Control 
(B) Low dose of aminoglycoside showing enlargement of lysosomes and 
deposition of polar lipids as myeloid bodies. 
(C) High doses giving apparent rupture of lysosomes, extensive 
mitochondrial swelling and damage, dilation of the endoplasmic 
reticulum cistemae, shedding of the apical brush-border villi, 
pericellular membrane discontinuities, and the occurrence of 
apoptotic nuclei. 
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While the determinants of cell damage still remain undefined, more knowledge 
concerning the mechanisms causing the impairment of the renal function is to 
be available. Activation of the renin-angiotensin system and the ensuring local 
vasoconstriction appear to be primarily responsible for the decrease in 
glomerular filtration [40]. This explains very well the aggravating effect of 
nonsteroidal antiinflammatory drugs on aminoglycoside nephrotoxicity, since 
these drugs inhibit the production of vasodilatatory prostaglandin PGE2 
[42,43]. 
Interaction of Aminoglycosides with Phospholipids: 
The kidney has a large capacity to compensate for tubular insults but it has 
been found that tubular cells undergo a marked proliferative response, even 
after low-dose treatment with antibiotics [44]. While the molecular 
mechanisms of toxicity themselves are still unclear, it remains that the drugs 
must physically interact with one or several cellular constituents to initiate the 
cascade of events leading to toxicity. Two phenomena appear to be essential in 
this context, namely the uptake of antibiotics into proximal tubular cells and 
their interactions with phospholipids in cell [45]. 
Aminoglycosides binds to the BBM in cationic form. The initial points of 
attachment are probably the acidic phospholipids mainly phosphatidylserine 
[46]. Thereafter, they are transferred to the transmembrane protein megalin, 
with which they become internalized in endosome. N-Acetyl neuraminic acid, 
the cortical content of which is increased in the kidneys during gentamicin 
treatment [47] could also be involved. Perhaps the most interesting aspect of 
this uptake process, from toxicological point of view is its saturable character 
at concentrations which are clinically relevant (apparent Km in rats, 15)ig/ml) 
[48]. 
Once transferred from endosomes to lysosomes through the physiological 
process of endosome lysosome ftision, aminoglycosides will be exposed to a 
fairly acidic pH, at which they will be ftilly protonated and therefore expected 
to bind tightly to negatively charged structures. In vitro studies show that 
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Figure 4 : Skeleton view of the mode of assembly of Gentamicin (green) with 
phosphatidylinositol (hydrocarbon is in grey and oxygen and phosphorus 
atom in red). The molecular modeling approach suggests that the N-6 
amino group are oriented in opposite direction (towards the lipophilic 
phase). Gentamicin lies above the plane of inositol moieties and far way 
from the water phase (bottom) 
Gentamicin 
these drugs bind tightly to acidic phosphoHpids, primarily by electrostatic 
forces and cause a marked decrease in the mobility of the phosphate heads in 
membrane bilayers [49]. As shown in Fig. 4, gentamicin bound to 
phosphatidylinositol lies close to the interface, being inserted in the monolayer 
at the level of the phosphogroup and extending toward the hydrophobic phase 
upto the level of the ester linkage of the fatty acids [50]. The binding of 
aminoglycosides to lipid bilayers causes their aggregation as well as the 
inhibition of the activities of phospholipases [51]. The later is due to the 
neutralization of the surface negative charge, which these enzymes require to 
fully express their activity [52,53]. 
Enzyme inhibition and membrane aggregation most likely account for the 
accumulation of myeloid bodies in lysosomes. Myeloid bodies isolated from 
the renal cortex essentially contain phospholipids and proteins. The 
phospholipid accumulation, inhibiton of phospholipase activity together with 
extent of phospholipidosis induced by the aminoglycosides correlates with their 
nephrotoxic potential [45]. 
D. PROTECTION AGAINST ANTIBIOTIC NEPHROTOXOCITY 
Protection against antibiotic nephrotoxicity has attracted much effort and 
attention over the last decade. These efforts can be subdivided into several 
types of approaches, which are as illustrated in Table 1. Some of these are 
discussed below. 
I. Decreasing or preventing antibiotic accumulation by kidney: 
Antibiotic accumulation could be reduced either by impairing their uptake or 
by enhancing their release. Reduction of uptake has been obtained by 
complexing the aminoglycosides extracellular/ or by competing with / 
decreasing drug binding to the BBM. Various compounds have been used in 
this context however, all such approaches could not be translated into clinical 
applications [54]. Early studies with animals also revealed that administration 
of the daily dose of gentamicin as a single dose was considerably less toxic. 
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TABLE 1. Main approaches toward reduction of aminoglycoside nephrotoxicity 
Mechanism Compound 
I. Decrease or prevention of drug 
accumulation by kidneys 
(a) Intracellular complexation of 
aminoglycosides with 
(i) Polyanionic compounds 
(ii) Acidic drugs 
(b) Competition with or decrease in 
aminoglycoside binding to brush border 
membrane by 
(i) Raising the urine pH 
(ii) Competitors 
(iii) hicrease in exocytosis 
II. Prevention or decrease of lysosomal 
nhospholipase inhibition by using 
(a) Derivatives with lesser intrinsic binding 
(i) N substitution 
Dextran sulfate 
Inositol hexasulfate 
Piperacillin 
Latamoxef-moxalactam 
Fosfomycin 
Pyridoxal-5'-phosphate 
Bicarbonate 
Ca^ -^
Lysine 
Fleroxacin 
Isepamicin, arbekacin. l-^ V- and 6'-N-
peptidic and aminoacid derivative of 
netilmicin 
(ii) Other substitution 
(iii) Fluorinated derivatives 
(iv) Disaccharidic aminoglycosides 
6"-substituted kanamycin B 
5, 3'" or 3' fluoro derivatives of 
dibekacin or arbekacin 
Astromicin (fortimicin) 
Dactimicin (2-7V"-formidoyi-
astromicin) 
(b) Coadministration of agent preventing 
intralysosomal phospholipidosis lead to 
(i) Intralysosomal sequestration of 
aminoglycosides 
(ii) Increase of membrane negative charge 
(iii) Other 
III. Protection against necrosis and other 
gross cellular alterations using 
(i) Antioxidants 
(ii) Antioxidant and multifactorial factors 
IV. Protection against vascular and 
glomerular effects 
(i) Suppression of renin-angiotensin 
activation 
(ii) Protection against Ca' influx 
(iii) Undefined mechanism 
V. Increase in kidney regeneration 
capabilities 
(i) Unspecific mitogenic effect 
(ii) Growth factors 
Polyaspartic acid 
Daptomycin 
Torbafylline 
Deferroxamine 
Methimazole 
Vitamin C 
Lipoic acid 
Deoxycortisone and saline drinking 
Ca "" channel blockers 
Platelet activation antagonists 
Ulinastatin 
Fibroblast growth factor 2 
Heparin-binding epidermal growth 
factor 
T ) 
effective, on the basis of finding that genlamicin forms complexes \\ilh 
mitochandrial Fc"^ to catalyse the formation of free oxygen radical [61]. 
However, biophysical and biochemical considerations in use of antioxidants 
like deferroxamine, suggest that the protective effect of such compounds 
depend critically on the dosage of gentamicin [62]. Several other agents like 
epidermal growth factor, endothelin [19], atrial natriuretic factor [63], glycine 
[64], insulin like growth factor [65] and platelet activating factor [66] have 
been reported to ameliorate renal toxicity. However, in above mentioned 
attempts, a generalized mechanism for the damage or repair of acute renal 
failure in kidney particular, is not given. Very recently, protective role of 
melatonin, garlic extracts and gum arabic on antibiotic induced acute renal 
injury has been found [67-69]. Studies have also indicated the role of mixed 
protein diet in ametioration of gentamicin induced nephrotoxicity in rats [70]. 
Compounds like tempol (4-hydroxy tempo), S-allycystein, diallyl disulfide and 
lipoic acids has been shown to attenuate aminoglycoside induced renal damage 
[71-73]. Various herbal extracts like Pongamia Pinnata and Jawarish Zarooni 
Sada also possess nephroprotective effects [74, 75]. Treatment with SOD and 
vitamin E was found to protect against gentamicin induced nephrotoxicit}' in 
rats [76, 78]. More and more extensi\'e research in this field is however, going 
on. 
F. FISH OIL PROTECTION 
Present mainly in seafood, and therefore better known as "fish oils", exert a 
remarkable variety of biological effects [78]; therefore, they are currently 
being tested as therapeutic options in a variety of clinical situations, ranging 
from cardiovascular diseases [79] to hyperlipidemia [80], cancer [81], 
inflammatory disorder [82], respirator}' diseases [83] and diabetes [84]. Fish oil 
is an oil rich in omega 3 fatty acids or n-3 fatty acids (PUFA) (Table 2). 
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Biologic properties offish oil 
Humans like all mammals cannot synthesis fatty acids (FA) with double bonds 
distal to the ninth carbon atom although, they are able to elongate to a certain 
extent and further desaturate the aliphatic chain. Between families of FA 
derived from linoleic acid (CI8: 2n-6) and a-linolenic acid (C18:3n-3) there is 
no practical inter-conversion. Although humans can desaturate and elongate a-
linolenic acid to eicosapentaenoic acid (EPA) and further, to docosahexaenoic 
acid (DHA), these processes are likely to be slow and possibly increasingly 
limited by age [85] and disease status like hypertension [86] or diabetes [87]. 
Therefore, linolenic acid, EPA and DHA are to a large extent nutritionally 
essential and are exclusively derived from fish and marine oils (Table 2). 
Effect of n-3 fatty acids on Eicosonoid production 
n-3 FA exert an incredible variety of biologic effects (Fig. 5) many of which 
have implications for kidney diseases. No unifying mechanisms exists, at the 
moment, for all these effects. Most of the multifaceted actions of n-3 FA relates 
to the activities of metabolites derived from EPA as opposed to those derived 
from arachidonic acid (AA) [88-90]. Metabolities of EPA and AA (two fatty 
acids with 20 carbon atoms) are known as "eicosanoids", which include 
prostaglandins (PG), thromboxanes (Tx), leukotrienes (LT), hydroxy fatty 
acids, and more recently lipoxins, epoxy-fatty acids and isoprostanes. 
Alterations in eicosanoid synthesis and metabolism occur when concentrations 
of EPA and DTLA increase relative to AA. Thus, in platelets and in other tissues 
including the kidney, an inactive TXA3 is produced at the expense of TxA2, 
which is a potent vasoconstrictor and inducer-amplifier of platelet aggregation. 
On the other hand, an active prostacyclin (PGI3) with similar effects to PGI2, a 
vasodilator and inhibitor of platelet aggregation, is produced by the 
endothelium after ingestion of n-3 FA. Therefore, the balance between 
proaggregatory and antiaggregatory derivatives is shifted towards inhibition of 
platelet aggregation and a decrease in vasodialators. 
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Figure 5 : Biological effects of n-3 FA and the rationale for their use in renal 
diseases. Tx-thromboxane; PG-prostaglandin, LT-leukotriene; PAF-
platelet activating factor, VLDL-very low density lipoprotein, PDGF-
Platlet - derived growth factor, IL-interleukin, TNF-tumor necrosis 
factor, RBC-red blood cells. 
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With respect to the kidney, renal production of TxA2 is reduced by the 
treatment with n-3 FA. Thromboxane A2 is elevated in lupus erythematosus 
[91], chronic glomerular disease [92], diabetic nephropathy [93], renal damage 
caused by cyclosporine [94] and renal transplant rejection [95] and has been 
linked to proteinuria in some patients [96]. In a recent study, more than 40% 
reduction in urinar>' TxB2 excretion was detected after 6 weeks of treatment 
with 8 g/day of n-3 FA [97]. It has also been found that dietary n-3 FA may 
increase renal vasodilatory reserve, which is likely to be a compensaton.' 
mechanism during the progression of kidney disease [88-99]. It is noteworth\-
in this respect, that n-3 FA exert an effect on renal eicosanoids qualitatively 
and quantitatively different from nonsteroidal antinflammatory agents, which 
have been shown to drastically reduce the production of renal vasodilatory PG 
and to precipitate a reduction in renal function probably consequent to a 
reduction in renal plasma flow [91-99]. EPA and DHA enriched diets have also 
been shown to alter the production of lipoxygenase derivatives, decreasing the 
production of bioactive LT (leukotrine), which are mediators of inflammation, 
vasoconstriction and increased vascular permeability [100]. Decreased 
production of immunomediators may explain the favorable effects of n-3 FA 
supplementation in immune renal disease in animal as well as human studies. 
Fish oil also reduce endothelial cell production of platelet derived growth 
factor like proteins. This reduced production thereby alters proliferati\ e 
responses in the kidney of some forms of glomerular disease [101]. 
Hemodynamic effects offish oil 
One of the most remarkable and consistent effects of n-3 FA supplementation 
in humans in their ability to decrease plasma concentration of triglycerides and 
very low density lipoproteins [102-105]. The effects on cholesterol are much 
more variable and detrimental. Renal failure is accompanied almost invariably 
by alterations of the lipid profile [106], which may contribute to accelerated 
atheroscelerosis in kidney patients. The most frequent lipid abnormality in 
renal patients is indeed hypertriglyceridemia, particularly when glomerular 
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filtration rate is greatly decreased. Less consistent alteratioiis include an 
increase of total cholesterol and a reduction in high density lipoprotein 
cholesterol. Lipid abnormalities may not only be a consequence of renal 
disease, but may contribute to its progression [107]. Furthermore, recent 
studies have suggested that the tissue cortical fatty acid profile of the kidney in 
various models of experimental renal injury, is abnormal and these changes 
which have been correlated with structural injury, may be modified by dietary 
fatty acids [107]. Thus,, treatment with fish oils might be beneficial in 
ameliorating renal as well as systemic consequences of dyslipidemia; other 
"anti-atherogenic" effects may contribute to reducing the risk of coronary heart 
disease [107]. Several studies have reported a hypotensive effect offish oils. 
When hypertension is a consequence of renal damage/disease, it may 
contribute to the rate of progression of the renal disease itself [108]. Reductions 
in blood pressure are generally felt to be beneficial in hypertensive patients 
with renal disease [109]. Fish oils prolong bleeding time and decrease platelet 
function [110]. These effects may be beneficial in patients with 
glomerulonephritis because platelet activation [111] and increased platelet 
consumption [112] have been demonstrated in such patients and because of 
earlier positive results of platelet inhibitor therapy in patients with membrane 
proliferative disease [113]. 
Beneficial Effects of Fish Oil in Various Kidney Diseases 
In normal rats, fish oil supplementation caused a significant increase in single 
nephron glomerular filtration rate and single nephron plasma flow [114]. These 
hemodynamic actions, recently confirmed in humans [99], may have 
consequences in determining the effects of n-3 FA on the course of 
experimental and clinical renal disease. Recent observations have shown that 
n-3 FA of fish oils may act to modulate cell activation by interfering with a 
variety of intracellular signaling mechanism or acting themselves as 
interacellular second messengers in cell activation [115]. In general, n-3 FA 
have been found to reduce the increase in intracellular calcium [116] in 
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particular, the enrichment of cellular phospholipids with DHA was suggested 
to inhibit calcium transients [116]. n-3 FA may also modulate post receptor 
signaling pathways and the formation of second messengers [117]. Several 
studies in experimental animals have supported the idea that fish oils may be 
beneficial in renal disease. 
Dietary supplementation of fish oil was found to prevent proteinuria and 
prolong survival in animal model for human systemic lupus erythematosus 
[115-118]. Fish oils v/ith multiple beneficial effects, including a reduction of 
accelerated atherosclerosis, has emerged as an important cause of decrease in 
human suffering from systemic lupus erythematosus [120]. The finding of 
beneficial effects of n-3 FA has been extended to other mouse models of 
immune renal disease [119-124]. In animal models of progressive glomerular 
sclerosis, supplementation with fish oil particularly its EPA content proved 
beneficial [125]. There are a few clinical studies which also indicate that n-3 
FA reduce proteinuria in patients with chronic glomerular nephritis, chronic 
pyelonephritis, and nephrosclerosis [96,120,126,127]. With regard to other 
animal models of renal disease [particularly of cyclosporine nephrotoxicity], 
fish oil administration was found to be effective in protecting against functional 
and structural consequences of cyclosporine use possibly associated with a 
reduction in renal thromboxane production [124,128,129]. 
Immunoglobulin A nephropathy is one of the most common chronic glomerular 
diseases, often resulfing in a progressive course of proteinuria, hypertension 
and glomerulosclerosis [130]. Recently, favorable results have been reported 
with use offish oil. Researchers have concluded that fish oil supplementation is 
effective in slowing the progression of IgA nephropathy [131]. Besides no 
adverse effects of fish oil supplementation in such a disorder was observed. 
Proteinuria was markedly decreased and glomerular filtration rate significantly 
improved following supplementation in IgA nephropathic patents [132]. 
Kidney transplant patients and the ones requiring hemodialysis after kidney 
failure were also benefited with use of fish oils [133]. The efficacy of fish oil 
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supplementation in patients with active ulcerative colitis [134] as well as on 
psoriasis is well established [135]. 
G. OLIVE OIL 
In the mediterrean regions, olive oil is one of the main sources of dietary fatty 
acids. Olive oil, is an oil rich in monounsaturated fatty acids (MUFA) and 
essentially contains oleic acid and a series of polyphenols [136] (Table 2). 
Olive oil is also related to cardiovascularhealth. It is beneficial in lowering 
LDL-cholesterol but not HDL-chlesterol, and decreasing the susceptibility of 
LDL to oxidation, which in turn reduces the atherogenicity of the LDL and the 
de\elopment of heart disease [137]. It has also been reported that oleic acid is 
not necessarily the only component responsible for this effect and that other 
antioxidant compounds contained in the nonglyceride fraction of olive oil such 
as sterols, polyphenols and tocopherols may contribute to these beneficial 
results [138]. There are reports which suggest olive oil has 
h}.percholesterolaemic effect in serum and liver of rats [139]. However, in 
human hypocholesterolaemic effect of MUFA is well established 
[137,140,141] although the mechanism by which it is brought about remains 
unclear. In comparison to fish oil, olive oil is less hypocholeslerolaemic 
[142.143]'. 
Less attention has been paid to the effect of oleic acid enriched diets. Howe\er, 
in \itro studies indicate that olive oil inhibits platelet function and thromboxane 
synthesis [144] and stimulates the uptake of free radicals by leukocytes 
[89.144]. Olive oil also enhances the glutathione system thereby decreasing the 
induced tissue oxidative stress [145]. The beneficial role of olive oil on liver 
tissue regeneration following hepatic resecfion in rats has also been established 
[146]. In fact, olive oil has been used as placebo in most of studies invoking 
fish oil. 
More and more research is being focused on investigating the effect of olive oil 
on various biological processes. The higher levels of monounsaturated fatty 
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acids and a good content of natural antioxidants are main advantages of olive 
oil. This may constitute an explanation of the ability of the mediterranean diet, 
of which olive oil is a major component, to prevent cardiovascular disease. 
Recent insight into use of fish oil have led to conclude that fish oils have 
attractive properties for use in kidney disorders. Consumption of omega-3 fatty 
acids found in fish oils were found to protect against cardiovascular disease in 
people in developed countries. However, increased consumption of omega-6 
fatty acids found in vegetable oils like olive oil also has beneficial effects. 
Thus, keeping in view the importance of these two oils they were chosen to 
investigate if they have any protective role against toxic effects of commonly 
used antibiotics. 
Table 2 Composition offish oil and olive oil [147]. 
Components 
1. Fatty acids (g/kg) 
14:0 (Myristic acid) 
16:0 (Palmitic acid) 
16:1 n-7 (Palmitoleic acid) 
18:0 (Stearic acid) 
18:1 n-9 (Oleic acid) 
18:ln-7 (Vaccenic acid) 
18:2 n-6 (Linoleic acid) 
18:3 n-3 (Linolenic acid) 
18:4 n-3 (Stearidonic acid) 
20:1 n-9 (Gadoleic acid) 
20:4 n-6 (Arachidonic acid) 
20:5 n-3 (Eicosopentaenoic acid) 
22:5 n-6 (Docosapentaenoic acid) 
22:6 n-3 (Docosahexaenoic acid) 
24:0 (Lignoceric acid) 
2. Cholesterol (mg/kg) 
3. Squalene (mg/kg) 
4. Tocopherols (mg/kg) 
5. Polyphenols (mg/kg) 
Fish oil 
3.90 
9.38 
5.10 
2.10 
6.25 
0.55 
0.86 
0.92 
2.45 
0.81 
0.70 
8.73 
0.27 
4.27 
0.34 
1500 
7400 
300 
-
Olive oil 
1.02 
5.25 
0.32 
1.72 
36.25 
3.8 
0.55 
-
-
-
-
-
-
-
-
2.54 
300 
47 
740 
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Scope of the work 
Aminoglycosides are potent, water soluble antibiotics. Because of their soluble 
nature, they donot cross biological membranes readily. So for systemic therapy, 
they are supplied by intravenous, intraperitonial or intramuscular injection. For 
the same reason, once in body, they are largely confirmed to extracellular 
spaces, having correspondingly small volumes of distribution and mainly 
eliminated unchanged in urine. 
Antibiotics have been one of the commonest causes of drug-induced 
nephrotoxicity [148]. The pathogenesis of such drug induced nephrotoxicity is 
directly related to the accumulation of drug within the renal cortex. Animal 
studies have revealed that antibiotics like gentamicin is absorbed by 
pinocytosis and stored in lysosomes of proximal tubular cells. Once inside the 
cell, they then induce conspicuous changes. Phospholipidosis is caused by a 
decrease in the activity of lysosomal phospholipase and sphingomyelinase. 
These drugs also alter sodium and potassium permeability of inner 
mitochondrial membrane and cause a deterioration of certain parameters of 
oxidative phosphorylation [149]. Prolonged treatment with antibiotics also 
cause release of brush border and lysosomal enzymes, decreased reabsorbtion 
processes and increase in blood urea and creatinine [150]. Despite well 
documented nephrotoxicity, antibiotics are still widely used for treatment of 
severe bacterial infections. Although a clear recognition of the treatment-
related risk factors combined with the schedule of the drug and effective 
monitoring procedures, have improved to some extent the situation, we are still 
short of having brought the safety of main wide-spectrum antibiotics. Chemical 
research aimed at obtaining intrinsically less toxic compounds has met with 
only moderate success and few of the other approaches proposed to reduce the 
toxicities of the available agents have reached practical clinical applications. 
Yet, it seems important to maintain and develop agents to improve their 
therapeutic indices. The present work was designed and undertaken to present 
in a prospective way, a strategy that may eventually lead to their safer use. A 
comparative study of fish oil and olive oil on the reversal of nephrotoxicity 
induced by commonly used antibiotics was done. Antibiotics selected for the 
study included gentamicin, tobramycin, streptomycin, kanamycin and 
amikacin. All these are nephrotoxic but vary in their dosage selected to induce 
maximum nephrotoxicity. Fish oil was selected for the study because of their 
efficacy and potential clinical utility in number of diseases. The study was 
further extended to compare the effects observed in fish oil to olive oil, which 
has some similar constituents on lesser proportion like that of fish oil, in these 
types of drug induced nephrotoxicity. 
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MATERIALS 
Drugs and Oils 
All the aminoglycosides selected for the study were obtained from Aristo 
Pharmaceuticals, India. Fish oil was obtained from Seven Sea Ltd., UK and 
Olive oil from Milano, Italy. 
Miscellaneous 
All other chemicals used for the study were of the finest quality commercially 
available, their sources are indicated against them. Glass double distilled water 
was used in all the experiments. 
Chemical Sources 
Acetic acid E. Merck 
Acetone Qualigens 
Ammonium molybdate 
Ammonium sulfate 
Bovine serum albumin 
1-Chloro 2,4 dinitrobenzene 
Copper sulphate 
Chloroform 
5,5' Dithiobis 2-nitrobenzoic acid 
Di-potassium hydrogen orthophosphate 
Di-sodium hydrogen orthophosphate 
Ferrous sulphate 
Ferric chloride 
Folin's Phenol Reagent 
Glutathione 
Glycine 
Glaxo 
SRL 
SRL 
Sigma Chemicals 
BDH 
SRL 
Sigma Chemicals 
Qualigens 
Qualigens 
Ranbaxy Lab 
SRL 
SRL 
SRL 
E. Merck 
Hydrogen peroxide 
Hydrochloric acid 
Mann i to 1 
Methanol 
Nicotinamide adenine dinucleotide reduced (NADH) 
p-nitrophenol 
p-nitrophenyl phosphate 
Perchloric acid 
Potassium dihydrogen orthophosphate 
Potassium chloride 
Pyrogallol 
Sodium acetate 
Sodium carbonate 
Sodium chloride 
Sodium dihydrogen orthophosphate 
Sodium dodecyl sulphate 
Sodium hydroxide 
Sodium potassium tartarate 
Succinic acid 
Sulphuric acid 
Thiobarbituric acid 
Trichloroacetic acid 
Tris 
Vitamin E 
Linolenic acid 
Qualigens 
SRL 
Qualigens 
Qualigens 
SRL 
SRL 
SRL 
Qualigens 
Qualigens 
Qualigens 
Qualigens 
Qualigens 
Qualigens 
Qualigens 
Qualigens 
Qualigens 
Qualigens 
Qualigens 
BDH 
Qualigens 
SRL 
Qualigens 
SRL 
Sigma Chemicals 
Sigma Chemicals 
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METHODOLOGY 
A. ANIMAL PROTOCOL 
The elTecl of different antibiotics on various biochemical parameters were 
studied in vivo conditions, Male Albino Wistar rats weighing 150-250 g were 
selected for the experiments. The animals were housed in a room at 20-24°C 
and were maintained under standardized condition of light 12 H L; 12 H D) 
Animals were stabilized for 8 days prior to the experiment on standard pellet 
rat diet from Hindustan Lever Limited, the composition of which was as: Crude 
protein 21%, ether extract 5%, crude fiber 4%, ash 8%, calcium 1%, 
phosphorus 0.6%, nitrogen free extract 55%, starch 7%, all vitamins, minerals 
and trace elements. The rats were given free access to pellet diet and water ad 
libitum. The protocols for the experiments were approved by Institute of 
Animal Ethical Committee (lAEC). Guidelines laid by the university 
committee and principles of laboratory animal care were also followed. 
Different antibiotics i.e. gentamicin, tobramycin, streptomycin, amikacin 
and kanamycin at various doses/days was given to rats via intraperitonial 
injections. Further the modulation of toxicity induced by the above antibiotics 
was also evaluated by pre, post and coadministration treatment of fish and olive 
oil. However, the dosage regimen of the two oils remained the same during all 
experimentation. Both fish and olive oil was orally administered to rats at a 
dose of 5ml /Kg body weight/day using catheter [150]. Both circulating and 
tissue levels of various biochemical parameters of the control as well as all the 
treated animal groups was then determined. 
(i) Animal groups 
The general plan of animal protocol followed for study of each antibiotic is 
given below. The rats were divided into eight groups having 8 rats in each 
group. 
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METHODOLOGY 
A. ANIMAL PROTOCOL 
The effect of different antibiotics on various biochemical parameters were 
studied in vivo conditions. Male Albino Wistar rats weighing 150-250 g were 
selected for the experiments. The animals were housed in a room at 20-24°C 
and were maintained under standardized condition of light 12 H L; 12 H D) 
Animals were stabilized for 8 days prior to the experiment on standard pellet 
rat diet from Hindustan Lever Limited, the composition of which was as: Crude 
protein 21%, ether extract 5%, crude fiber 4%, ash 8%, calcium 1%, 
phosphorus 0.6%, nitrogen free extract 55%, starch 7%, all vitamins, minerals 
and trace elements. The rats were given free access to pellet diet and water ad 
libitum. The protocols for the experiments were approved by Institute of 
Animal Ethical Committee (lAEC). Guidelines laid by the university 
committee and principles of laboratory animal care were also followed. 
Different antibiotics i.e. gentamicin, tobramycin, streptomycin, amikacin 
and kanamycin at various doses/days was given to rats '^ia intraperitonial 
injections. Further the modulation of toxicity induced by the above antibiotics 
was also evaluated by pre, post and coadministration treatment of fish and olive 
oil. However, the dosage regimen of the two oils remained the same during all 
experimentation. Both fish and olive oil was orally administered to rats at a 
dose of 5ml /Kg body weight/day using catheter [172]. Both circulating and 
tissue levels of various biochemical parameters of the control as well as all the 
treated animal groups was then determined. 
(i) Animal groups 
The general plan of animal protocol followed for study of each antibiotic is 
gi\en below. The rats were divided into eight groups having 8 rats in each 
group. 
Control rat group was a non treated group, given free access to diet and water. 
Antibiotic via intraperitonial route, as a single dose was given to get measure of 
maximum nephrotoxicity induced in antibiotic rat group. The rest six groups of 
animals received either of the oils in combination, prior to, together with and 
after the antibiotic treatment. Thus making six sets of oil treated groups i.e. 
pretreated group, coadministered group and post treated group. Three rat 
groups were given fish oil in different combinations and other three given olive 
oil. The diet intake, antibiotic dosage and oil dosage was same in all these six 
groups. 
Since, the aminoglycosides differ in their potential to induce nephrotoxicity 
\\'hich depends on their dosage and time of therapy regimen, so different 
antibiotic included in the study here have different dosage and time patterns to 
induce maximum nephrotoxicity. The pharmacokinetics of each antibiotic to 
give maximum damage is discussed later at the beginning in the chapter of 
results under the heading of each antibiotic. 
(ii) Dosage regimen of antibiotics 
Aminoglycoside antibiotics are antimicrobial substances but they difer in their 
antibacterial spectra and their potential toxicities. These subtle differences 
between these antibiotics, were the cause to select a particular high dose for 
each aminoglycoside to be included in the study. Tobramycin is active against 
Enterobacteriaceae and in mild infections is given at a dose of 3-4.5 mg/kg 
body weight/day, given in three divided doses [151]. This dose can be 
increased to 5-8 mg/kg body weight/day for serious infections. Gentamicin is 
prescribed in life threatening gram negative infection [152]. Streptomycin is 
used for treatment of Streptococcal bacterial endocarditis, plague and in 
tuberculosis. It is given at a dose of 15 mg/kg body weight/day. For serious 
infections the dose can be doubled [36]. Amikacin is a semi synthetic 
aminocyclitol, used in treatment of pulmonary infection and urinary tract 
infections [153]. Kanamycin is active against strains of Enterobacteriaceae and 
Mycobacterium and is given at a dose of 15 mg/kg body weight in two doses 
every 12 H [154]. Although, aminoglycosides have been studied in 
considerable detail with regard to their potential use in management of severe 
bacterial infections, controversy persists about their dosage causing toxicity, 
distribution pattern and renal clearance. The nephrotoxic potential of different 
aminoglycoside varies in the following order: gentamicn > tobramycin > 
amikacin > Kanamycin > streptomycin. Thus it is clear that gentamicin is most 
nephrotoxic where as streptomycin is the least [30-32, 155-158]. Earlier animal 
studies have also given different nephrotoxic dosages for different antibiotic 
prototypes [155-158]. Keeping this in view, a dosage regimen specific for each 
aminoglycoside was selected for the study. This nephrotoxic dose is estimated 
to be 20 times the normally employed therapeutic range [30-32, 155-158]. The 
different dosages, thus selected were taken from literature, in the study for 
different antibiotics and these value are as follows: 
Tobramycin 160 mg/kg body weight/day 
Gentamicin 100 mg/kg body weight/day 
Streptomycin 300 mg/kg body weight/day 
Amikacin 250 mg/kg body weight/day 
Kanamycin 200 mg/kg body weight/day 
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B. BIOCHEMICAL ANALYSIS 
The animals were given antibiotics in pre, post and coadministration treatment 
together with either of the oils and sacrificed 12 H after receiving the last 
treatment. The rats were weighed before and after the treatment. After sacrifice, 
kidney and liver were removed, weighed properly and stored at -24°C, till 
further analysis. 
1. ANALYSIS OF SERUM PARAMETERS 
The blood was allowed to clot then centrifuged at 2000 rpm and serum was 
collected. The serum samples were deproteinated with 3%. TCA in a ratio of 
1:3. After incubation for 10 min at room temperature, the samples were 
centrifuged at 4000 rpm (Remi centrifiige, India) for lOmin. The protein free 
supernatant was used to quantitate urea, creatinine, inorganic phosphate, SGOT 
and SGPT. Cholesterol was determined directly in the serum samples. 
(I) UREA 
The level of urea was determined using kit from SPAN DIAGNOSTICS LTD. 
(India) based on the method of Marsh et al [159]. The principle was based on 
reaction between urea and diacetyl monoxine in acidic medium (urea reagent) 
at 95°-100°C to give pink coloured complex, the absorbance of which is 
measured at 520 nm. The intensity of the colour developed is proportional to 
the concentration of urea present in the sample. 
Protocol 
To 10)il of sample, 1.0 ml of urea colour reagent was added and mixed 
thoroughly. The reaction was carried in a boiling water bath for 10 minutes and 
then cooled under tap water for 3 minutes. Absorbance at 520 nm against blank 
ga\e the levels of urea in serum samples. 
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(I) CREATININE 
The level of creatinine was measured using kit from SPAN DIAGNOSTICS 
LTD. (India) based on the method of Tausky [160]. Creatinine in a protein free 
solution reacts with alkaline picrate solution and produces a red coloured 
complex, which was read at 520 nm. 
Protocol 
To 1 ml of deproteinized serum supernatant, I ml of 0.75 N NaOH and 3 ml of 
picric acid were added and incubated for exactly 20 min at room temperature. 
Absorbance at 520 nm against blank gave the levels of creatinine in serum 
samples. 
(Ill) CHOLESTEROL 
Cholesterol levels were determined using the Kit from SPAN DIAGNOSTIC 
LTD (India) following the method of Wybenga [161]. The reaction is based on 
the following principle, cholesterol reacts with hot solution of ferric perchlorate 
in the presence of ethyl acetate and sulphuric acid (cholesterol reagent). It gives 
a lavender coloured complex which was read at 560 nm. 
Protocol 
The protocol involves addition of 5ml of cholesterol reagent to 25\il of serum, 
solution was kept at 100°C for 90 seconds. Absorbance was measured at 560 
nm. 
(IV) ASPARTATE TRANSAMINASE (SCOT or AST, EC 2.6 1:1) 
The activity of asparate transaminase was measured using Kit from SPAN 
DIAGNOSTIC LTD (India) based on the method of Reitman and Frankel 
[162]. The principle was based on the reaction of L-aspartate and 
a-ketoglutarate in the presence of GOT present in the sample to yield 
oxaloacetate and L-elutamate. 
GOT 
a-ketoglutarate + L-Aspartate^ ,^  Oxaloacetate + L-Glutamate 
The oxaloacetate thus formed is coupled with 2,4-dinitrophenyl hydrazine to 
give the corresponding hydrazone, which gives brown colour in alkaline 
medium and was read at 505 nm. 
Protocol 
To 0.25 ml of buffered aspartate-a-Keto glutarate. 0.5 ml serum was added 
and the reaction was incubated for 60 minutes at 37°C. 0.25 ml of DNPH 
colour reagent was added and the reaction was allowed to proceed at room 
temperature for 20 minutes. The reaction gave a coloured complex with 
addition of 2.5 ml of 0.4 N NaOH. The absorbance was measured at 505 nm 
against distilled water. 
(V) PYRUVATE TRANSAMINASE (SGPT or ALT, EC 2.6.1.2) 
This test was done using a kit from SPAN DIAGNOSTICS LTD (India). The 
reaction was based on the method of Reitman and Frankel [162]. The principle 
involved the following reaction. 
a-ketoglutarate + L-Alanine^ ^ Pyruvate + L-Glutamate 
The pyruvate so formed is coupled with 2,4 dinitrophenyl hydrazine to give a 
coloured hydrazone in alkaline medium which was read at 505 nm. 
Protocol 
The reaction involves addition of 0.25 ml of buffered alanine-a-KG substrate 
to 0.5 ml serum. After incubation at 37°C for 60 minutes, 0.25 ml of DNPH 
colour reagent was added and the reaction was kept at room temperature for 20 
minutes. The coloured complex was formed when 2.5 ml of 0.4 N NaOH was 
added, which was spectrophotometrically read at 505 nm against distilled 
water. 
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(VI) INORGANIC PHOSPHATE 
The inorganic phosphate (iP) was measured in the deproteinated serum 
supernatants by the method of Tausky and Shorr [163]. The serum supernatant 
(1 ml) was diluted to 3 ml with glass distilled water and 2 ml of FeS04 reagent 
(5 g FeS04 was dissolved in 10 ml of 10% w/v ammonium molybdate in 10 N 
H2SO4). A calibration curve containing known amounts of KH2PO4 (0.018-
0.28)i moles) was prepared simuhaneously with the test samples. After 
incubation at room temperature for 20 min, the blue colour obtained was read 
at 620 nm against a reagent blank. 
2. PREPARATION OF KIDNEY HOMOGENATES 
Kidney homogenates were prepared for determination of marker enzymes of 
kidney function.The kidneys from different treated and control animals were 
removed, decapsulated and kept in ice-cold buffered saline (154 mM NaCl, 
5mM Tris pH 7.5). The tissues were then homogenized at 4°C in 50mM 
mannitol buffer containing 2mM Tris-HCl, pH 7, using a glass-teflon 
homogenizer at high speed to make a 10% (w/v) homogenate. The 
homogenates were then centrifuged at 16,000 rpm at 4°C for 15 min in sigma 
high-speed refrigerated centrifuge (Sigma Laboratory Centrifuges 3K30, USA). 
The supernatants were then used for enzyme analysis. The activity of each 
enzyme from various groups was determined simultaneously under similar 
conditions by using same solutions to avoid day-to-day experimental 
variations. Absorbance was read in Cintra-5-spectrophotometer or Campsec 
UV-Visible spectrophotometer (Camspec M330B, London UK) with 1.0ml 
quartz cuvettes with light path of 1.0 cm. One unit of enzyme activit} is 
defined as the amount of enzyme required to catalyze the formation of l)i mole 
of product per min under the specific experimental conditions. Specific acti\ity 
is defined as the enzyme unit per mg protein. Aliquots of homogenates were 
diluted with 10 mM Tris-HCl buffer, pH 7.5, to obtain suitable protein 
concentration required for different assays. 
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(I) ALKALINE PHOSPHATASE (AH\ E.G. 3.L3.1) 
The activity of AIP in kidney homogenates was determined by tlie method of 
Shah et al [164]. The reaction mixture contained 1.4 ml assay buffer (55 mM 
glycine, 36 mM NaCl and 45 mM NaOH, pH 10.5) and 100|il (10-28 ^g 
protein for homogenate). The reaction was started by adding 15 ]il of 0.6 M p-
nitrophenyl phosphate (final concentration 6 mM) and incubated at 30°C for 
the required time (5-20 minutes) and the reaction was stopped by addition of 50 
pi of 5N NaOH. A calibration curve was prepared simultaneously by using 
known amounts of p-nitrophenol (0.01-0.2 i^ moles). The yellow colour was 
read at 405 nm against a reagent blank. 
(II) ACID PHOSPHATASE (AcP, E.C. 3.L3.2) 
The activity of acid phosphatase was determined in kidney homogenates by the 
method of Verjee [165]. The reaction mixture contained 2.4 ml of 0.05 M 
sodium acetate, pH 4.5, and lOOpl homogenate (35-50jig protein). The reaction 
was started by the addition of 0.5 ml of 4.8 mM p-nitrophenyl phosphate (final 
concentration 0.8 mM) incubated for 15 min at 30°C and then stopped by 
adding 2 ml of 2N NaOH. A calibration curve of p-nitrophenol (0.05-0.4 }i 
moles) was prepared simultaneously. The yellow colour developed was read at 
405 nm against a reagent blank. 
3. DETERJMINATION OF THE LEVEL OF FREE RADICAL 
SCAVENGING ENZYMES 
Kidney and liver tissues were homogenizd (10% w/v) in chilled 0.15 M KCl 
and centrifuged at 16,000 rpm for 15 min at 4°C. The supernatant was used for 
enzyme assays. 
(I) CATALASE (CAT, E.C.Ln.L6) 
This enzyme was assayed according to the method of Beers and Siezer [166]. 
The enzyme catalyzes the following reaction 
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2H ,0. ^^^>'^s^> 2H2O + O2 
In the UV range H2O2 shows a continual increase in adsorption with decreasing 
wavelength with a maximum at 240 nm. The decomposition of Hydrogen 
peroxide was followed by the decrease in absorbance at 240 nm. 
Protocol 
30 mM of hydrogen peroxide (H2O2) was prepared in 50 mM potassium 
phosphate buffer (pH 7.0). To 3 ml of H2O2 phosphate buffer, 0.025 ml of 
sample was added as enzyme source into a cuvette and the contents were mixed 
thoroughly. The decrease in absorbance at 240 nm was recorded after every 30 
seconds upto 3 minutes. Enzyme activity was calculated using the molar 
extinction coefficient of H2O2 (436 M"' cm"' at 240 nm). The specific activity 
of catalase is defined in terms of micromoles of hydrogen peroxide consumed 
per minute per milligram of protein sample. 
(II) SUPEROXIDE DISMUTASE (SOD, E.G. 1.15.1.1) 
It was assayed by the method of Marklund and Marklund [167]. The procedure 
depends upon autoxidation of pyrogallol. 
„ II , , /-^  autoxidation ^ ., . , „ 
Pyrogallol + O2 >• Oxidation products + O2 
2O2 + 2H^- ^QP > 02 + H2O2 
The change in absorbance was recorded at 420 nm. 
Protocol 
To 0.05 ml of supernatant 2.85 ml of 0.05 mM Tris-Succinate buffer, pH 8.2 
was added, mixed well and incubated at 25°C for 20 min. The reaction was 
started by adding 0.1 ml of 8 mM pyrogallol solution. Change in absorbance 
per minute was immediately recorded for the initial 3 minutes at 420 nm. A 
reference set consisting of 0.05 ml distilled water instead of the sample 
solution, was also run simultaneously. One unit of the enzyme activity is 
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defined as the amount of enzyme which causes 50% inhibition of pyrogallol 
autoxidation under assay conditions. 
(Ill) GLUTATHIONE-S-TRANSFERASE (GST, EC 2.5.1.18) 
The level of GST was determined by the method of Habig et al. [168]. The 
enzyme activity is measured by following the increase in absorbance at 340 nm 
due to CDNB-GSH (l-chloro-2, 4-dinitro-benzene (CDNB) and glutathione 
conjugate) generated as a result of GST catalysis. 
GST 
CDNB + GSH >• CDNB-GSH 
Protocol 
Different tissues of rats were homogenized in chilled 0.1 M phosphate buffer 
pH 6.5 (10% w/v) and centrifliged in cold for 15 min at 16,000 rpm. To 0.1 ml 
of supernatant, 2.7 ml glutathione solution (0.1 M in phosphate buffer, pH 6.5) 
and 0.2 ml CDNB (1.0 mM in acetone) were added and mixed thoroughly. The 
change in absorbance at 340 nm was recorded at room temperature against 
blank containing all the reagents except the enzyme. The values were 
calculated on the basis of molar extinction coefficient of CDNB (9.6 mM"' cm' 
') and specific activity of enzyme was expressed in n moles of GSH-CDNB 
conjugate formed per minute per mg protein. 
4. LIPID PEROXIDATION 
Lipid peroxidation in kidney homogenates was determined 
spectrophotometrically by the method of Ohkawa et al [169]. The method is 
based on the principle, where one molecule of malondial dehyde (MDA) reacts 
stoichiometrically with two molecules of 2-thiobarbituric acid (TBA) at pH 3.5 
according to the following mechanism. 
46. 
^ - ' + CHj .-
OH CHO - -^CH-CH = CH 
OH OH 
™A Product 
The pink chromogen is read spectrophotometrically at 532 nm. 
Protocol 
The final volume of the reaction mixture was 4 ml, which consisted of 1.5 ml 
acetic acid (20%), 0.2 ml SDS (8.1%), 1.5 ml TBA (0.8%) 0.7 ml distilled 
water and 0.1 ml of tissue homogenate (10%, w/v). It was incubated at 95°C 
for 60 min, then cooled and centrifliged at 400 rpm for 10 min. The optical 
density of MDA formed was read in the spectrophotometer at 532 nm against 
the blank, treated similarly containing 0.1ml of distilled water instead of the 
sample. The values were calculated on the basis of molar extinction coefficient 
of MDA (156m M'' cm ') and the results were expressed in n mol of MDA 
formed per mg protein. 
5. PROTEIN ESTIMATION 
Protein was measured in all serum, kidney and liver homogenates by the 
method of Lowry et al [170]. The samples were made to 0.8 ml with 0.5% 
SDS. Then 2 ml alkaline copper reagent was added. The alkaline copper 
reagent was prepared by mixing 0.5% copper sulphate 1% (w/v), sodium 
carbonate in 0.1 N NaOH in the ratio of 1:1:100. After incubation for 10 
minutes at room temperature, 0.5 ml of 1 N Foiin's reagent was added. The 
contents were rapidly mixed and colour intensity was read after 30 minutes 
against reagent blank at 660 nm. A calibration curve of standard BSA (5-80 ^g) 
was prepared simultaneously and the concentration of protein in the samples 
was determined using this standard BSA curve. 
SH 
+2H2O 
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C. STATISTICAL ANALYSIS 
All the data are expressed as means ± SE for eight animals. Statistical analysis 
of the data was performed using one way analysis of variance (ANOVA) to 
compare the means between the normal and different treatment groups. The 
differences were considered significant when p<0.05. 
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Results 
Discussion 
TREATMENT OF RATS WITH DIFFERENT ANTIBIOTICS, 
FISH OIL AND OLIVE OIL 
A. TOBRAMYCIN 
Before starting the treatment offish oil and olive oil, a preliminary experiment 
was done to investigate the time period required to induce maximum 
nephrotoxicity by a fixed dose of each antibiotic which was determined as 
mentioned in methodology. 
1. Time dependent effect of tobramycin toxicity in rat 
Tobramycin at a dose of 160 mg/kg body weight/day, was administrated \'ia 
intraperitonial route to rats for 4, 8, 10, 12, 14,16 consecutive days. The 
animals were sacrificed 12 H after each injection and serum obtained was 
subjected to analysis of urea and creatinine. The circulating urea and creatinine 
levels was found to be increased to very high levels (12.62 mg/dL and 2.59 
mg/dL) at the end of 12 days of treatment (Figure 1(a) and (b)). Thus 12 days 
treatment with tobramycin was able to induce maximum nephrotoxicity in rats. 
2. Treatment of rats with fish oil and olive oil 
The rats were divided into eight groups, each having 8 rats. All of these groups 
were treated as follows: 
Group-I (Normal) or no treatment group (N): The rats were given no 
treatment for the first 12 days only allowed free access to food and water and 
intraperitonial injection of normal saline (1ml) for the last 12 days of 24 day 
experiment. 
Group-II or tobramycin treated group (T): The animals were given no 
treatment for the first 12 days, followed by intraperitonial injection of 
tobramycin (160 mg/kg body weight/day) for the last 12 days of the 24 day 
experiment to get the measure of maximum nephrotoxicity induced. 
Group-Ill or fish oil pretreatment group (PF): The animals were given fish 
oil orally (5 ml/kg body weight/day) using catheter for 12 days and for next 12 
days injections of tobramycin was administered (160 mg/kg body 
weight/day/rat). 
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Figure 1 (a) and (b): Time dependent effect of tobramycin on the levels of 
urea and creatinine in serum. 
N 4 8 10 12 14 16 
Duration of treatment of tobramycin (days) 
N 4 8 10 12 14 16 
Duration of treatment of tobramycin (days) 
Results are mean of four different animals 
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Group-IV or fish oil coadministration group (CF): The animals were given 
no treatment for first 12 days and for next 12 days they were given both fish oil 
and tobramycin in appropriate doses as mentioned above. 
Group-V or fish oil post treatment group (PtF): Here the animals were 
given tobramycin for first 12 days and fish oil for next 12 days in the same 
doses as mentioned above. 
Group-VI (PO), VII (CO) and VIII (PtO) were duplicates of group III, IV 
and V except that rats in these groups fish oil was replaced by olive oil. The 
diet, tobramycin and oil dose was same in all groups. 
3. RESULTS 
The toxic effects of tobramycin and its remedy with the use offish and oli\'e oil 
gave the following results: 
i) General Parameters: Body and organ weight 
In all rat groups with a diet intake of (20 gm/day/rat), animals received similar 
dose of tobramycin (160 mg/kg body weight/day) and oil (5 ml/kg body 
weight/day). The body weights of different rat groups in the beginning and 
after the completion of experiment was measured (Table 1). Tobramycin 
injections, fish and olive oil administration did not bring any profound changes 
in the total body weight, weight of the kidney and liver of different treated 
groups (Table 1 and 2). There was no significant increase in weight of all rat 
groups during the 24 day experiment. 
ii) Effects on Serum Parameters 
The overall magnitude of impaired renal function by tobramycin is reflected by 
increased level of urea and creatinine in the serum of tobramycin receiving 
group compared to normal group of rats (Figure 2 (a) and (b)). The urea levels 
were decreased in groups that received pre (-54.1% change from control after 
recover)') and post (-3.6%) treatment of fish oil (Table 3). Pre oli\e oil 
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treatment did significantly lowered bring the urea levels to normal. However, 
the elevated serum creatinine levels by tobramycin were lowered (-48.2%) 
maximally by the post fish oil treatment (Table 3). Here pre fish oil treatment 
(-57%) also helped to lower the creatinine content in serum. 
The levels of other serum parameters like SCOT, SGPT inorganic phosphate 
and cholesterol is increased more than 2-3 folds with the use of tobramycin 
(Table 4 and 5). Pre fish and post fish oil treatment resulted in significant 
decrease of cholesterol levels close to normal (-9.7%, -17.5% change from 
control after recovery). Rats receiving fish oil had significantly lower 
cholesterol level in serum compared to ones receiving olive oil (Table 4). It is 
also clear that pre and post fish (+32.3%, +31.1%) and olive oil (+40.5%, 
+35.6%) treatments result in normalizing the elevated levels of inorganic 
phosphate as compared to coadministration of these oils. The restoration of 
high levels of SCOT and SGPT towards normal (-50.31%, -13.7%) was done 
maximally by post fish oil treatment (Table 5). 
iii) Effects on tissue parameters 
(a) Marker enzymes of the kidney 
Here the effect of tobramycin on the activities of certain marker enzymes of 
kidney homogenates was observed. The AlP and AcP levels decreased 
significantly on treatment with tobramycin (Fig 3(a) and (b)). In kidney 
homogenates, the levels of AlP and AcP were significantly improved to normal 
(-0.76%, +4.61%) values in post fish oil (p<0.05). 
(b) Antioxidant status of the kidney 
The effect offish oil and olive oil on kidney antioxidant status is given in Table 
6. Tobramycin injections resulted in significant decrease in the levels of CAT, 
SOD and GST (Table 6). However pre fish and post fish oil treatment results in 
significant increase in the levels of antioxidant enzymes. Olive oil treatment 
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also increased the levels of antioxidant enzymes towards normal le\el. 
However compared to fish oil, the effect produced by olive oil is less. 
c) Effects on antioxidant status in liver 
Administration of tobramycin (160 mg/kg body weight/day) for 12 days 
resulted in a significant decrease in the levels of CAT, SOD and GST as 
compared to normal saline treated rats (Table 7 and 8). Fish oil treatment both 
prior to, as well as after tobramycin treatment resulted in increase of the le\'els 
of these enzymes (pF -p<0.05, PtF - p<0.05) compared to olive oil treated 
groups, the effect of fish oil in increasing the antioxidant potential remains 
significant. 
Tobramycin also resulted in a significant enhancement of the levels of lipid 
peroxides in liver, as shown by the level of malondiadehyde (Table 8). Here 
fish oil treatment results in a slight increase in level of MDA (PtF-1.14 
nmol/mg protein) compared to olive oil treated groups (PtO-0.91 mol/mg 
protein). 
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Table 1: Effect of tobramycin, fish oil and olive oil on body weight 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Initial body 
weight (g) 
205 ±10 
205 + 11 
185±11 
225 ± 11 
190 ±10 
215±8 
201 ±4 
206 ±13 
Final body 
weight (g) 
215±11 
210±12 
189 ±9 
229±8 
200 ±15 
219±9 
207 ±10 
210±11 
Results are mean ± SE of eight different animals 
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Table 2: Effect of tobramycin, fish oil and olive oil on weight of kidney and 
liver 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Kidney weight 
(g) 
1.65 + 0.95 
1.72 ±0.3 
1.12 + 0.15 
3.10±1.1 
1.27 + 0.95 
2.47 ±1.5 
1.87 ±1.7 
1.80 ±0.6 
Liver weight 
(g) 
7.20 ±0.5 
7.99 ±0.9 
4.01 ±1.1 
8.35±0.15 
4.21 ±0.13 
8.16 ±0.9 
7.42 ± 1.2 
7.83 ± 1.3 
Results are mean ± SE of ei^ht different animals 
?:) 
Figure 2 (a) and (b): Circulating levels of serum urea and creatinine in 
various antibiotic treated rat groups. 
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K- Normal saline treated rats: T-Tobramycin treated rats; PF - Pre fish oil 
treated rats; CF - coadministererd fish oil treated rats. PtF-Post fish oil treated 
rats; PO- Pre fish oil treated rats; Co-Coadministerred fish oil treated rats; PtO-
Post fish oil treated rats 
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Table 3: Effect of tobramycin, fish oil and olive oil on levels of serum urea 
and creatinine 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Urea 
(mg/100 ml) 
5.0510.70 
11.43 ±0.40 
(-126.3%) 
7.78'±0.19 
(-54.1%) 
25.410.14 
(-402.9%) 
4.87'±0.27 
(-3.6%) 
4.82'±0.23 
(-4.6%) 
21.80 ± 1.24 
(-331.6%) 
4.91 ±0.56 
(-2.7%) 
Creatinine 
(mg/100 ml) 
1.14±0.05 
2.06±0.10 
(-80.7%) 
1.79'±0.03 
(-57.%) 
4.81 ±0.07 
(-321.9%) 
1.69'±0.04 
(-48.2%) 
1.96 ±0.04 
(-71.9%) 
3.72 ±0.12 
(-226.3%) 
2.26'±0.08 
(-98.2%) 
i 
Results are mean ± SE of eight different animals 
•'p<0.05 as compared to normal rats (ANOVA) 
Value in parenthesis represent percent change from the respective control 
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Table 4: Effect of tobramycin, fish oil and olive oil on levels of serum 
cholesterol and inorganic phosphate 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Cholesterol 
(mg/100 ml) 
29.89 ±2.72 
71.55 ±4.86 
(-139.4%) 
32.79 ±1.04 
(-9.7%) 
64.59 ±0.52 
(-83.9%) 
24.66'±2.03 
(-17.5%) 
43.57 ±4.90 
(-45.7%) 
32.56 ±0.67 
(-8.9%) 
69.13 ±7.37 
(-68.7%) 
Inorganic 
phosphate 
(mg/100 ml) 
5.33 ±0.22 
20.00 ±1.03 
(-275.2%) 
3.61'±0.54 
(+32.3%) 
19.30 ±0.01 
(-262.1%) 
3.67'±0.32 
(+31.1%) 
3.17'±0.11 
(+40.5%) 
14.39 + 0.05 
(-169.9%) 
3.43'±0.53 
(+35.6%) 
Results are mean + SE of eight different animals 
^p<0.05 as compared to normal rats (ANOVA) 
Value in parenthesis represent percent change from the respective control. 
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Table 5: Effect of tobramycin, fish oil and olive oil on levels of SGOT and 
SGPT 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
SGOT 
(n mol/min/ml) 
22.82 ±0.55 
56.51 ±1.57 
(-147.6%) 
37.03 ±0.30 
(-62.3%) 
58.82 ±0.37 
(-157.7%) 
34.3'±0.35 
(-50.31%) 
49.22 ±0.39 
(-84.32%) 
51.54 ±2.07 
(-125.8%) 
38.96 ±4.01 
(-70.7%) 
SGPT 
(n mol/min/ml) 
22.14 ±0.55 
49.22 ±0.39 
(-122.3%) 
43.51 ± 1.52 
(-96.5%) 
48.83 ±0.17 
(-120.5%) 
25.18'±0.42 
1 
(-13.7%) 
1 
37.73 ±1.22 
(-70.4%) 
50.77 ±2.56 ' 
(-129.3%) ^ 
37.03 ±0.30 : 
(-67.2%) i 
Results are mean ± SE of eight different animals 
^p<0.05 as compared to normal rats (ANOVA) 
Value in parenthesis represent percent change from the respective control 
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Figure 3 (a) and (b): Specific activity of AlP and AcP in kidney 
homogenatcs of various treated rat groups. 
CF PtF PO 
Different animal groups 
CO 
c 
Q) 
O i _ 
CL 
D) 
E 
"o 
E 
c 
CL 
O 
< 
120 
100 ^ 
CO PtO PF CF PtF PO 
Different animal groups 
Each bar represent mean ± SE of eight different animals 
N- Normal saline treated rats; T-Tobramycin treated rats; PF - Pre fish oil 
treated rats; CF - coadministererd fish oil treated rats, PtF-Post fish oil treated 
rats; PO- Pre fish oil treated rats; Co-Coadministerred fish oil treated rats; PtO-
Post fish oil treated rats 
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Table 6: Effect of tobramycin, fish oil and olive oil on levels of CAT, SOD 
and GST in kidney homogenates 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
CAT 
12.15 ±1.54 
8.92 ±0.82 
(+26.6%) 
18.25 ±1.16 
(-50.2%) 
12.75 ±0.79 
(-4.9%) 
19.65'±3.75 
(-61.7%) 
15.48 ±2.24 
(-27.4%) 
13.16±3.51 
(-8.3%) 
14.36'±3.36 
(-18.2%) 
SOD 
10.24 ±3.57 
6.25 ±1.12 
(+38.9%) 
20.35 ±1.14 
(-98.7%) 
18.42 ±1.17 
(-79.8%) 
20.4r±1.81 
(-99.3%) 
12.24 ±2.14 
(-19.5%) 
11.65±1.18 
(-13.7%) 
14.27'±2.17 
(-39.3%) 
GST 
1.24±0.13 
0.54 ±0.07 
(+56.4%) 
1.88 + 0.12 : 
(-51.6%) 
1.57±0.17 
(-26.6%) 
1.84'±0.68 
(-48.3%) 
1.29'±0.33 
(-4.03%) 
1.37±0.18 
(-10.48%) 
1.32±0.17 
(-6.4%) 
Units: CAT, SOD & GST - units/min/mg protein 
Results are mean ± SE of eight different animals 
''p<0,05 as compared to normal rats (ANOVA) 
Value in parenthesis represent percent change from the respective control 
Table 7: Effect of tobramycin, fish oil and olive oil on levels CAT and SOD 
in liver homogenates 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
CAT 
40.18 ±1.47 
21.31 ±3.42 
(+46.9%) 
78.65'±2.81 
(95.7%) 
72.17'±3.21 
(-79.6%) 
79.41'±1.84 
(-97.6%) 
60.13 ±2.78 
(-49.6%) 
61.26 ±2.07 
(-52.5%) 
61.85'±2.98 
(-53.9%) 
SOD 
71.13±2.21 
39.53 ±0.98 
(+44.4%) 
77.27 ±3.36 
(-8.6%) 
75.38'±1.74 
(-5.9%) 
78.46'±2.11 
(-10.3%) 
69.65 ±3.52 
(+2.0%) 
70.23 ±3.42 
(+1.2%) 
68.27'±3.63 
(+4.0%) 
Units: CAT, SOD - units/min/mg protein 
Results are mean ± SE of eight different animals 
^p<0.05 as compared to nonrial rats (ANOVA) 
Value in parenthesis represent percent change from the respective control 
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Table 8: Effect of tobramycin, fish oil and olive oil on levels GST and 
MDA in liver homogenates 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtFj 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
GST 
4.98 ±0.17 
1.35 + 0.11 
(+72.9%) 
7.87'±0.36 
(-58.0%) 
7.51 ±0.06 
(-50.8%) 
8.87'±0.75 
(-78.1%) 
6.97 ±0.42 
(-39.9%) 
7.43 ±0.12 
(-49.2%) 
7.27'±0.74 
(-45.98%) 
MDA 
0.96 ±0.01 
2.72±0.33 
(-183.9%) 
1.17±0.06 
(-21.8%) 
1.2'±0.07 
(-25%) 
1.14'±0.13 
(-18.7%) 
0.89 ±0.86 
(+7.3%) 
0.9 ±0.12 
(+6.2%) 
0.91'+ 0.08 
(+5.2%) 
Units: GST - units/min/mg protein; MDA- n mol/mg protein 
Results are .mean + SE of eight different aniinais 
'p<0.05 as compared to normal rats (ANOVA) 
Value in parenthesis represent percent change from the respective control 
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4. DISCUSSION 
Kidney plays vital role in the maintenance of body fluid volume and chemical 
composition and also maintain acid-balance by virtue of its reabsorptive 
properties [1,2]. The organ is of paramount significance since it is also 
concerned with many other homeostatic functions and excretion of many drugs 
and chemicals, some of which are toxic to mammalian systems. Antibiotics, 
which are antimicrobial substances potentially effect the kidney organ s>stem. 
Therefore investigations into the reversal of renal toxicity induced by these 
drugs becomes important. 
Tobramycin is a six membered aminocyclitol, with amino group side chain and 
is used for the treatment of bacterial conjuctivitis, cystic fibrosis and abdominal 
infections [151]. It is excreted in urine by glomerular filtration whereas some 
of it may be accumulated in renal cortical cells [36]. Tobramycin in kidneys 
causes renal impairment characterized by proteinuria and a progressive rise in 
blood urea and creatinine levels [31]. 
The present investigation was undertaken to study the renal toxicity induced by 
tobramycin and to look at ways of decreasing its potential renal effect with use 
of fish oil. Olive oil was used as a placebo for fish oil because its constituents 
are similar to, but in much lower concentration as compared to fish oil. The rats 
were given intraperitonial doses of tobramycin (160 mg/kg body weight/day) 
for 12 days to induce maximum nephrotoxicity as is evident by an increased 
serum urea and creatinine levels (Table 3). This increase suggests that renal 
injury has occurred due to tobramycin thereby effecting the filtration as well as 
the reabsorption processes [171]. Post fish oil treatment resulted in a decrease 
in nephrotoxicity, as the levels of urea (-3.6% change from control after 
recovery) and creatinine (-48.2%) decreased towards normal in this treatment 
group. This is in accordance with those reported for gentamicin induced 
nephrotoxicity [172]. The cholesterol estimations made it clear that pre and 
post fish oil treatment results in significant (-9.7% and -17.5% chanse from 
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control after recovery) decrease in the elevated levels of cholesterol by 
tobramycin (Table 4). Coadministered olive oil (-8.9%) was also found to 
lower the cholesterol to normal levels. The results are in accordance with that 
reported by Valentina and Alonso [173j which showed lower cholesterol level 
in plasma of fish oi! consuming animals. Our result indicate that fish oil 
consumption reduces cholesterol levels in blood and that it is more 
hypocholcsterolaemic than olive oil, although the mechanism by which it is 
brought about remains unclear [173]. Increase in inorganic phosphate 
(hyperphosphatemia) is also related to renal failure [36]. Tobramycin injections 
caused an increase in serum inorganic phosphate levels and this increased level 
was restored to normal in post fish oil treated group (-31.1%). Tobramycin also 
leads to increase in levels of SCOT and SGPT (Table 5). This is in accordance 
with that reported for tobramycin by Bendush and Weber [174]. This increase 
is indicative of liver damage to some extent by tobramycin. Oral administration 
of fish oil alter tobramycin injections helped in lowering the levels of SCOT (-
.50.31%) iUK\ SCil'T (-13.7%) to normal. The decreased activities of AlP and 
AcP in kidney homogenates also returned back maximally towards (AlP -
0.76%, AcP +4.61% change from control after recovery) normal in post fish oil 
treated animal group indicating the beneficial use of fish oil on tobramycin 
exposure (Fig. 3). 
Fish oil has many benefits. However, there is growing concern that habitual 
intake of large quantities of polyunsaturated fatty acids may be injurious 
probably because they are very susceptible to peroxidation [175]. Thus, 
determination of various antioxidant enzymes of kidney and liver homogenates 
were also investigated. Tobramycin injection alone induces oxidative stress as 
is evident by decreased levels of antioxidant enzymes in kidney and liver 
homogenates (Table 6-8). However, fish oil treatment resulted in a significant 
increase in the activities of CAT, SOD and GST. The level of lipid 
peroxidation was higher in fish oil treated groups compared to olive oil treated 
groups. This is supported by Valentina and Alonso [173], who reported that 
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polyunsaturated fatty acids in fish oil may render the liver of rats on fish oil 
diet more susceptible to lipid peroxidation and the activity of antioxidant 
enzymes may be induced. Olive oil, on the other hand also reduced the induced 
oxidative stress. However, in comparison to fish oil, the effect was less 
significant, probably due to lower content of polyunsaturated fatty acids. On 
the basis of these results, it is suggested that the use of fish oil (5 ml/kg bod}' 
weight/day) for two weeks after tobramycin injection helps in reverting the 
biochemical alterations induced by tobramycin. It appears likely that the 
beneficial and preventive effect of fish oil supplementation on nephrotoxicity 
may be the result of a complex interplay between altered inflammatory, 
hemodynamics, metabolic factors and antioxidant potential. Thus, dietary 
supplementation of fish oil (post treatment) offers a safe strategy to diminish 
nephrotoxicity induced by tobramycin. 
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B, GENTAMICIN 
1. Time dependent effect of gentamicin toxicity 
Nephrotoxicity was induced in rats by intraperitoneal administration of 
gentamicin (100 mg/kg/day) for 4, 8, 10, 12, 14 consecutive days. The animals 
were sacrificed 12 H after each injection, at the end of above given days of 
treatment. The extent of nephrotoxicity induced by the antibiotic was evaluated 
by determination of levels of urea and creatinine. Very high levels of urea 
(11.99 mg/dL) and creatinine (1.30 mg/dL) was obtained after 10 days of 
treatment with gentamicin (Fig 4 (a) and (b)) indicating that maximum 
nephrotoxicity develops after 10 day treatment with gentamicin. 
2. Treatment of rats with fish oil and olive oil 
The rats were divided into eight groups, each having 8 rats. All of these groups 
were treated as follows: 
Group-I (Normal) or no treatment group (N): The rats were given no 
treatment for the first 10 days and intraperitonial injection of normal saline 
(1ml) for the last 10 days of 20 day experiment. Animals were allowed free 
access to food and water. 
Group-II or gentamicin treated group (G): The animals were given no 
treatment for the first 10 days, followed by intraperitonial injecfion of 
gentamicin (100 mg/kg body weight/day) for the last 10 days of the 20 day 
experiment to get the measure of maximum nephrotoxicity induced. 
Group-Ill or fish oil pretreatment group (PF): The animals were given fish 
oil orally (5 ml/kg body weight/day) using catheter for 10 days and for next 10 
days injections of gentamicin was administered (100 mg/kg body 
weight/day/rat). 
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Figure 4 (a) and (b): Time dependent effect of gentamicin on the levels of 
urea and creatinine in serum. 
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Group-IV or fish oil coadminisfration group (CF): The animals were given 
no treatment for first 10 days and for next 10 days they were given both fish oil 
and gentamicin. 
Group-V or fish oil post treatment group (PtF): Here the animals were 
given gentamicin for first 10 days and fish oil for next 10 days. 
Group-VI (PO), VII (CO) and VIII (PtO) was duplicates of group III, IV 
and V except that rats these groups given olive oil. The diet, gentamicin and oil 
intake was same in all groups. 
3. RESULTS 
Gentamicin, an aminoglycoside was injected in adult male rats alone or prior 
to, after and together with fish oil or olive oil. The results of impaired renal 
function by gentamicin and its restoration to normal function with the use of 
fish and olive oil is as follows: 
i) General parameters : Body and organ weight 
All animal groups consumed some amount of standard pellet rat diet (20 
gm/day/rat). Body weights of different animal groups also did show any 
profound increase with use of antibiotic or oils, at the end of 20 days of 
experimentation (Table 9). The weight of organs i.e. kidney and liver of 
various animal groups is given in Table 10. No significant change was 
observed among various rat groups with the use offish and olive oil. 
ii) Effects on serum parameters 
Significant changes were seen in serum levels of urea and creatinine after 
gentamicin treatment (Fig. 5(a) and (b)). Serum creatinine and urea levels 
showed a maximum enhancement after 10 day treatment (urea 11.95 mg/dl, 
creatinine 1.25mg/dl) compared to control group (urea 5.032mg/dl, creatinine 
0.954mg/dl). This increased level of urea and creatinine recovered to normal in 
coadministration offish oil (-29.9%, -6.1% change from control after recovery) 
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and olive oil (-19.3%. +14.9%) groups (Table 11). Genlamicin causes 
hyperholesterolaemia as is evident b} rise in level of cholesterol in gentamicin 
treated group. Table 12 gives that animals fed on fish oil (CF -22.5%) had 
significantly lower cholesterol content compared to those fed on olive oil 
accept coadminstered olive oil group which gave a significant decrease of 
cholesterol (-44.9%). 
The level of inorganic phosphate, SCOT and SGPT measured showed a 
significant increase in gentamicin treated group (Table 12 and 13). Co-
treatment of fish oil was found to bring these high levels of inorganic 
phosphate (-22.7%), SCOT (-9.9%) and SGPT (-2.2%) back towards normal 
compared to all other oil treated groups. 
iii) Effects on tissue parameters 
(a) Marker enzymes of the kidney 
The effect of gentamicin was also observed on the activities of marker enzymes 
of kidney. The AlP and AcP level was found to change significantly in the 
kidney homogenates on treatment with gentamicin (Fig 6 (a) and (b)). The 
level of AlP was found to be significantly lowered in pre (+10%)) and 
coadministrafion fish oil (+8.3%)) treated group where as the level of AcP was 
normalized significantly in coadministration fish oil group (-11%)). 
(b) Antioxidant status of the kidney 
Gentamicin also induces oxidative stress as is evident by decrease in the levels 
of CAT, SOD and GST (Table 14). Fish oil treatment (CF- CAT-P<0.05, SOD-
P<0.05, GST-P<0.05) resulted in significant increase in the levels of the 
antioxidant enzymes compared to oli\'e oil treated groups. 
c) Effects on hepatic antoxidant potential 
Administration of gentamicin (100 mg/kg body weight/day) for 10 days also 
results in a significant decrease in hepatic levels of CAT, SOD and GST as 
compared to normal rat group (Table 15 and 16). Fish oil treatment together 
with gentamicin brought an increase in the levels of these enzymes maximally 
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(CF-P<0.05). Among Olive oil treated group, the effect of restoration of 
antioxidant levels towards normal was done maximally by coadministration of 
olive oil group. 
The level of malondiadehyde also increased in gentamicin receiving rat group 
(Table 16). Here fish oil administration resulted in a slight increase in the level 
of MDA compared to olive oil treated groups. 
Table 9: Effect of gentamicin, fish oil and olive oil on body weight 
Groups 
Normal saline treated control (N) 
Gentamicin treated (G) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Initial body 
weight (g) 
195 ±10 
215 + 10 
199 ±3 
200 ±5 
197110 
200113 
201110 
18519 
Final body 
weight (g) 
200 1 11 
22215 
205 114 
207112 
203 1 9 
20617 
2141 10 
193 1 10 
Results are mean ± SE of eight different animals 
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Table 10: Effect of gentamicin, fish oil and olive oil on weight of kidney 
and liver 
Groups 
Normal saline treated control (N) 
Gentamicin treated (G) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Kidney vk'eight 
(g) 
1.35 ±0.03 
4.46 + 0.06 
2.00 ±0.10 
3.15±0.11 
2.35 ±0.15 
2.84 ±0.25 
3.80 ±.30 
1.29 ±0.07 
Liver weight 
(g) 
3.99 ±0.15 
10.10±0.12 
6.87 ±0.21 
9.83 ±0.64 
8.57 ±0.51 
9.01 ±0.72 
9.94 ±0.76 
3.73 ±0.15 
Results are mean ± SE of eight different animals 
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Figure 5 (a) and (b): Circulating levels of serum urea and creatinine in 
various treated rat groups. 
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N- Normal saline treated rats; G-Gentamicin treated rats; PF - Pre fish oil 
treated rats; CF - coadministererd fish oil treated rats, PtF-Post fish oil treated 
rats; PO- Pre fish oil treated rats; Co-Coadministerred fish oil treated rats; PiO-
Post fish oil treated rats 
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Table 11: Effect of gentamicin, fish oil and olive oil on levels of serum urea 
and creatinine 
Groups i Urea 
(nig/100 ml) 
Normal saline treated control (N) ! 5.03 ± 0.52 
1 
Gentamicin treated (G) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
11.95± 1.16 
(-137.6%) 
11.18±0.606 
(-122.2%) 
6.53'±0.323 
(-29.9%) 
^ 11.63 + 0.93 
Post fish oil treated (PtF) \ 
i (-131.2%) 
6.91'±0.78 
Pre olive oil treated (PO) 
\ (-37.4%) 
6.00'±0.38 
Co-administered olive oil treated (CO) 
(-19.3%) 
10.9± 1.12 
Post olive oil treated (PtO) 
! (-116.6%) 
1 
Creatinine 
(mg/100 ml) 
1.14 + 0.05 
1.25 ±.07 
(-9.6%) 
1.17'±0.69 
(-2.6%) 
1.07'±0.05 
(-6.1%) 
1.22'±0.08 
(-7.0%) 
1.09±0.16 
(+4.38%) 
0.97'±0.16 
(+14.9%) 
1.24 ±0.09 
(-8.7%) 
Results are mean + SE of eight different animals 
^p<0.05 as compared to nonnal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Table 12: Effect of gentamicin, fish oil and olive oil on levels of serum 
cholesterol and inorganic phosphate 
Groups 
Normal saline treated control (N) 
Gentamicin treated (G) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Cholesterol 
(mg/100 ml) 
40.88 ±3.68 
107.88 ±1.16 
(-163.9%) 
64.25'±1.32 
(-57.21%) 
50.09'±2.96 
(-22.5%) 
58.38'±1.56 
(-42.8%) 
70.08 ±2.50 
(-71.4%) 
59.24'±2.59 
(-44.9%) 
72.61 ±0.90 
(-77.6%) 
Inorganic 
phosphate 
(mg/100 ml) 
2.47 ±0.17 
9.25 ±0.16 
(-274.5%) 
5.46±0.17 
(-121%) 
3.03'±0.15 
(-22.7%) 
5.98 ±0.11 
(-142.1%) 
6.96±0.12 
(-181.8%) 
6.23'±0.23 
(-152.2%) 
7.90 ±0.32 
(-219.8%) 
Results are mean ± SE of eight different animals 
''p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Table 13: Effect of gentamicin, fish oil and olive oil on levels of SGOT and 
SGPT 
Groups 
Normal saline treated control (N) 
Gentamicin treated (G) 
Pre fish oil treated (PF) 
Coadministered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
SGOT 
(n mol/min/ml) 
25.6910.22 
90.90 ± 0.45 
(-253.8%) 
30.38'±0.35 
(-18.2%) 
28.25'+ 0.70 
(-9.9%) 
50.30 + 0.27 
(-95.8%) 
55.49 + 0.19 
(-115.9%) 
31.26'+ 0.30 
(-21.7%) 
61.0610.31 
(-137.6%) 
SGPT 
(n mol/min/ml) 
30.0710.15 
94.5710.44 
(-68.2%) 
32.16^10.29 
(-6.9%) 
30.76^10.13 
(-2.2%) 
43.5410.12 
(-44.8%) 
40.9410.16 
(-36.1%) 
35.05'10.32 
(-16.5%) 
52.3510.53 
(-74%) 
Results are mean ± SE of eight different animals 
''p<0.05 as compared to normal rats (ANO\'.A) 
Values in parenthesis represent percent change from the respective control 
'foa 
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Figure 6 (a) and (b): Specific activity of AlP and AcP in kidney 
homogenates of various treated rat groups. 
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N- Normal saline treated rats; G-Gentamicin treated rats; PF - Pre fish oil 
treated rats: CF - coadministererd fish oil treated rats, PtF-Post fish oil treated 
rats; PO- Pre fish oil treated rats; Co-Coadministerred fish oil treated rats; PlO-
Posl fish oil treated rats 
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Table 14: Effect of gentamicin, fish oil and olive oil on levels of CAT, SOD 
and GST of kidney homogenates 
Groups 
Normal saline treated control (N) 
Gentamicin treated (G) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
CAT 
16.5213.81 
10.34 + 2.10 
(+37.4%) 
18.23 ±2.75 
(-10.3%) 
17.2'±4.80 
(-4.1%) 
17.61'±4.46 
(-6.6%) 
13.05 ±3.15 
(+21%) 
15.96'±4.49 
(+3.4%) 
15.74 ±2.45 
(+4.7%) 
SOD 
13.83 ±3.54 
7.22 ±1.23 
(+47.8%) 
15.05 ±3.04 
(-8.8%) 
16.86'±2.89 
(-21.9%) 
16.45'±3.00 
(-18.9%) 
12.96 ±2.47 
(+6.3%) 
13.28'±5.13 
(+3.9%) 
12.50'±5.02 
(+9.6%) 
GST 
1.96 ±0.03 
0.83 ±0.16 
(+57.6%) 
2.20 ±0.18 
(-12.2%) 
3.44'±0.34 
(-75.5%) 
2.84 ±0.30 
(-44.9%) 
1.89 ±0.44 
(+3.6%) 
2.53 ±1.03 
i 
(-29.1%) i 
2.99±1.15 ! 
(-52.5%) 
Units: CAT, SOD & GST - units/min/mg protein 
Results are mean ± SE of eight different animals 
''p<0.05 as compared tc normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Table 15: Effect of gentamicin, fish oil and olive oil on levels CAT and 
SOD of liver homogenates 
Units: CAT, SOD - units/min/mg protein 
Results are mean ± SE of eight different animals 
''p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
Groups 
Normal saline treated control (N) 
Gentamicin treated (G) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
CAT 
36.05 + 3.18 
12.23 ±3.46 
(+66.1%) 
70.75 ±4.35 
(-96.2%) 
89.03'±4.16 
(-146.9%) 
71.49 ±5.03 
(-98.3%) 
57.40 ±2.23 
(-59.2%) 
59.12'±1.69 
(-63.9%) 
59.52 ±7.04 
(-65.1%) 
SOD 
68.38 ±2.82 
39.17±4.14 
(+42.7%) 
91.74 ±5.50 
(-34.2%) 
94.30'±7.75 
(-37.9%) 
92.80 ±7.09 
(-35.7%) 
79.01 ±3.16 
(-15.5%) 
80.68'±6.73 
(-17.9%) 
71.43 ±5.45 
(-4.5%) 
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Table 16: Effect of gentamicin, fish oil and olive oil on levels GST and 
MDA of liver homogenates 
Groups 
Normal saline treated control (N) 
Gentamicin treated (G) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
GST 
3.3511.97 
1.85 + 0.29 
(+44.8%) 
7.40 ±1.06 
(-120.8%) 
8.22'±1.83 
(-145.3%) 
8.42 ±1.56 
(-151.3%) 
4.82 ±0.93 
(-43.9%) 
5.92'±0.76 
(-76.7%) 
6.03 ±1.78 
(-80%) 
MDA 
1.36 ±0.03 
2.93 + 0.02 
(-115.4%) 
2.01 ±0.02 
(-47.8%) 
1.83'±0.03 
(-34.5%) 
1.95 ±0.02 
(-43.4%) 
1.56±0.10 
(-14.7%) 
1.67'±0.08 
(-22.8%) 
1.45 ±0.07 
(-6.6%) 
Units: GST - units/min/mg protein; MDA- n mol/mg protein 
Results are mean ± SE of eight different animals 
''p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
4. DISCUSSION 
It is an established fact that acute renal failure results in loss of renal function 
that may eventually lead to necrosis and cell death. Nephrotoxicty associated 
with antibiotics like gentamicin is a major complication associated with its use 
as antimicrobial agent, it has therefore, attracted considerable attention due to 
its potential nephrotoxic elTcct. Gentamicin has achieved a widespread clinical 
use as chemotherapeutic agent. It is clinically stable with free aminogroup and 
a net cationic charge that correlates well with its nephrotoxicity. About 30% of 
the patients treated with aminoglycosides show some signs of nephrotoxicity 
[152]. Like other antibiotics it is also eliminated by glomerular filtration but as 
a result of absorptive endocytosis, it is partially reabsorbed by proximal tubular 
cells. Drug loaded endocytic vacuoles fuse with lysosomes where it 
accumulates [176]. Gentamicin induces conspicuous and characteristic changes 
in lysosomes, with accumulation of electron dense lamellar material i.e. 
myeloid bodies consisting of undigested phospholipids. This occurs in tandem 
with lysosomal swelling and subsequently other changes become evident 
including decrease in activity of enzymes of lysosomal membrane. Thus, 
gentamicin accumulation leads to development of lysosomal phospholipidosis 
caused by an impairment of phospholipase A and sphingomyelinase. Following 
lysosomal injury, damage to renal proximal tubular cell continues, as reflected 
by mitochondrial swelling and increasing loss of brush border membrane [48]. 
In the present study, a series of experiments were designed to characterize in 
detail the nephrotoxic effect of gentamicin, using rat as a model animal. 
Animals were given intraperitoneal injection of gentamicin at 100 mg/kg body 
weight/day for 10 days to induce nephrotoxicity. However, this dose was not 
lethal to them. No significant changes in food intake, body weight and weight 
of the organs (kidney and liver) was observed in the animals after gentamicin 
injections. Fish oil was reported to have some beneficial effects on gentamicin 
nephrotoxicity [172]. So, it was thought worthwhile to investigate in detail 
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which mode of fish oil helps in prevention of gentamicin induced 
nephrotoxicity and the results were further compared to olive oil, an oil rich in 
monounsaturated fatty acids. Different oil treatment groups i.e. pretreatment, 
co-treatment and post treatment groups were studied to know the mode of oil 
treatment that is more beneficial in antagonizing gentamicin induced toxicity. 
Serum urea and creatinine levels are the two important parameters which have 
been used in detecting renal function. Gentamicin induces renal failure, as is 
evident by increased serum urea and creatinine level (Table 11). The increase 
in serum urea may be due to failure in excretion of urea whereas increased 
level of creatinine in serum may be due to defect in glomerular filtration, due to 
which creatinine in not filtered properly and retained more in serum [172]. Our 
study indicate the beneficial effects of fish oil in combafing nephrotoxicity, 
which is shown by the levels of urea and creatinine recovered (-29.9% and -
6.1%) to normal in coadministered fish oil treated group. The beneficial effects 
of fish oil may be due to its constituent fatty acids, n-3 FA present in good 
quantity in this oil. 
To see any cholesterol lowering effects, the level of cholesterol was determined 
in fish and olive oil treated groups. Gentamicin alone is hypercholesterolaemic 
(Table 12). Fish oil coadministration resulted in significant recovery (-4.8%) 
change from control after recovery) of the cholesterol levels to normal. Olive 
oil, on the other hand also brought a significant lowering in the cholesterol 
level however, the effect produced is less than that of fish oil. This is in 
accordance with those reported by Valentina and Alonso [173], who reported 
the hypochoiesterolemic effect offish oil. Many clinical studies have indicated 
that diets rich in fish oil are associated with cardiovascular health and the 
responsible component seems to be the polyunsaturated fatty acids of n-3 series 
[177]. Our results also indicate that gentamicin causes an increase in levels of 
iP. SCOT and SGPT (Table 12-13). This is in accordance with that reported for 
other antibiotics where clinical trials have shown an increase in the level of 
SOOT and SGPT in patients receiving tobramycin treatment [174]. This 
elevated levels of iP, SGOT and SGPT is indicative of liver toxicity, which was 
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amclioraled with coadminislration of fish oil (-22.7%, -9.9%, -2.2%) along 
with gentamicin injections (Table 13). The decreased activities of AlP and AcP 
in kidney homogenates also returned back maximally towards normal in 
coadministration of fish oil treated group (+8.3%, -11.17%) indicating the 
beneficial use offish oil on gentamicin exposure (Fig. 6). 
Antioxidant and free radical scavenging systems exist in the cell to protect it 
from the damaging effect of free radicals, produced as a part of normal cell 
respirafion and other cellular processes [178]. Free radicals and free radical 
reactions are involved in the etiology and development of a number of diseases, 
some of which are life limiting [179]. Gentamicin has been reported to enhance 
the generation of hydroxyl radical by renal cortical mitochondria. Hydroxyl 
radical scavengers and iron chelators are found to have a protective effect in 
gentamicin induced acute renal failure in rats [21]. In the present study, several 
parameters have been studied that reflect the antioxidant status of the kidney 
and liver i.e. CAT, SOD and GST. There was significant decrease in the levels 
of these antioxidant enzymes in kidney and liver homogenates of gentamicin 
treated rat group indicating that gentamicin induces oxidative stress. However, 
the levels of these enzymes increased significantly in kidney and liver tissues 
of fish oil treated rats (Table 14-16). Lipid peroxidafion as given by MDA 
level, was increased in fish oil groups as compared to olive oil treated groups. 
However, the increase of antioxidant enzymes in kidney and liver tissue 
probably efficiently combated the toxic effects produced due to increased lipid 
peroxidation. Thus, in order to maintain the stability of living organism it is 
necessary to reach a balance between the oxidative actions and the antioxidant 
defence. From the results it is clear that fish oil is the effective antagonist of 
gentamicin induced toxicity. Studies further suggest that fish oil is more 
beneficial than olive oil and among the different treatment groups studied, the 
maximum recover}' effect was observed in coadministration offish oil group in 
reducing the gentamicin side effects without compromising its antibiotic 
activity. 
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C. STREPTOMYCIN 
l.Time dependent effect of streptomycin toxicity 
Streptomycin at a dose of 300 mg/kg body weight/day was given via 
intraperitonial route to animals for 4, 8, 10, 14, 16 consecutive days. The 
animals were scarified 12 H after each injection, at the end of above mentioned 
days of treatment, rats were scarified and the serum obtained was subjected to 
analysis of urea and creatinine to evaluate the nephrotoxicity induced by the 
antibiotic. High levels of urea and creatinine (8.07 mg/dL, 3.22 mg/dL 
respectively) were found after 10 days of treatment with streptomycin (Figure 7 
(a) and (b)). 
2. Treatment of rats with fish oil and olive oil 
The rats were divided into eight groups, each having 8 rats. All of these groups 
were treated as follows: 
Group-I (Normal) or no treatment group (N): The rats were given no 
treatment for the first 10 days and intraperitonial injection of normal saline 
(1ml) for the last 10 days of 20 day experiment. Animals were allowed free 
access to food and water. 
Group-II or streptomycin treated group (S): The animals were given no 
treatment for the first 10 days, followed by intraperitonial injection of 
streptomycin (300 mg/kg body weight/day) for the last 10 days of the 20 day 
experiment to get the measure of maximum nephrotoxicity induced. 
Group-Ill or fish oil pretreatment group (PF): The animals were given fish 
oil orally (5 ml/kg body weight/day) using catheter for 10 days and for the next 
10 days injections of streptomycin was administered (300 mg/kg body 
weight/day/rat). 
Group-IV or fish oil coadministration group (CF): The animals were given 
no treatment for first 10 days and for next 10 days they were given both fish oil 
and streptomycin. 
85 
Figure 7 (a) and (b): Time dependent effect of streptomycin on the levels of 
urea and creatinine in serum. 
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Groiip-V or fish oil post treatment group (PtF): Here the animals were 
given streptomycin for first 10 days and fish oil for next 10 days. 
Groiip-VI (PO), VII (CO) and VIII (PtO) were duplicates of group III, IV 
and V except that rats these groups were given olive oil. The diet, streptomycin 
and oil dose was same in all groups. 
3. RESULTS 
The following results were obtained in the study to evaluate the effect of fish 
oil and olive oil on streptomycin induced nephrotoxicty and oxidative stress. 
i) General parameters: Body and organ weight 
All animals consumed same amount of diet i.e. 20 gm/day/rat and received 
similar dose of streptomycin (300 mg/kg body weight/day). The initial and 
final body weight of different treatment groups of animals is given in Table 17, 
which suggest that no significant change in weight has occurred during the 20 
day experimentafion. The weight of kidney and liver of rats receiving different 
treatments is given in Table 18. Neither the drug nor administrafion of two oils 
resulted in any significant change in the total body weight of animals. 
ii) Effect on Serum parameters 
The values of various serum parameters determined for different animal groups 
is given in Table 19, 20. 21. From Figure 8 (a) and (b), it is clear that animals 
treated with streptomycin alone produced a two fold increase in serum urea and 
creatinine concentrations compared to normal rat groups. However, treatment 
of such experimental 1}' induced nephrotoxic rats with fish oil resulted in 
significant decrease in serum urea and creatinine concentrations (CF-p<0.05, -
15T%, -30.6% change from control after recovery). Pre fish treatment also 
helped to bring the levels of urea and creatinine to normal values. Among olive 
oil treatment groups, this decrease in level of urea and creatinine was obtained 
by pre olive oil (-46.5%. -59.4%) treatment, although in comparison to pre fish 
oil treatment, the effect produced remains to be less. Table 20 gives that 
streptomycin is hypercholesterolaemic as shown by increased level of 
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cholesterol in slreptomycin treated group compared to normal saline treated 
group. The hypocholesterolaemic effect of fish oil was found to be more 
pronounced in pre fish oil (-28.8%) as well as in coadministered fish oil (-
6.8%) treated groups. Compared to coadministered olive oil treated groups, fish 
oil (CF - P<0.05) was found to exert maximum effect in lowering the 
cholesterol levels towards normal. However, pre olive oil treatment did also 
reduce cholesterol level to normal (-2.7%). 
Streptomycin also led to an increase in level of inorganic phosphate (Table 20) 
SCOT and SGPT, (Table 21). Coadministration offish oil (iP -9.1%, SGOT 
-31%, SGPT -7% change from control after recovery) as well as pretreatment 
(iP +9.1%, SGOT -36.5%, SGPT -23.6%) of fish oil to returned these higher 
levels towards normal. Among the olive oil receiving groups, pretreatment 
brought maximum reversal effect (PO - p<0.05, IP -62.8%, SGOT -37%, 
SGPT -56.8%). 
iii) Effect on tissue parameters 
(a) Marker enzymes of the kidney 
The deleterious effects of streptom}"cin on the activifies of various kidney 
enzyme is given in Figure 9 (a) and (b), which gives the level of AlP and AcP 
in kidney homogenates of various animal groups. The level of AlP and AcP 
was reduced significantly with use of streptomycin. Coadministration of fish 
oil returned these reduced tissue le\els to normal (+3.6%), +8.4%o). Among 
olive oil treated groups, pre olive oil treatment (+16.4%), +10.7%)) was 
beneficial in returning this reduced level to normal. Although the effect in 
comparison to fish oil remained less. 
(b) Antioxidant status of the kidney 
The results of kidney antioxidant status is given in Table 23, which shows that 
levels of CAT, SOD and GST decreased significantly in streptomycin receiving 
animal group. Fish oil treatment resulted in significant increase in the levels of 
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these antioxidant enzymes. (CF- CA'r-P<0.05, SOD-P<0.05, GST-P<0.05). 
Among olive oil treated groups, varied results were obtained. The level of CAT 
was returned towards normal by pre olive oil treatment where as SOD levels 
increased in post olive oil treated group. 
c) Effects on hepatic antioxidant potential 
The administration of streptomycin induces oxidative stress is shown by 
significant decrease in the activities of CAT, SOD and GST in liver tissue 
comparison to non-stressed normal rats. The change in the levels of various 
antioxidant enzymes is given in Table 23 and 24. Fish oil treatment both 
together and prior to streptomycin gave a significant rise in the activities of the 
CAT, SOD and GST. Olive oil treatment gave a less significant alteration of 
these parameters as compared to fish oil treatment. Table 24 also shows that 
fish oil intake gave a slight increase in levels of MDA in liver homogenates 
compared to groups that were given olive oil. 
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Table 17: Effect of streptomycin, fish oil and olive oil on body weight 
Groups 
Normal saline treated control (N) 
Streptomycin treated (S) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Initial body 
weight (g) 
202.38 ±3.08 
202.48 ±1.97 
208.33 ±4.67 
202.37 ±1.57 
202.89 ±2.08 
206.63 ±1.96 
206.18 ± 1.32 
210.88 ±2.87 
Final body 
weight (g) 
206.21 ±2.91 
206.70 ±1.50 
210.86 ±2.43 
206.80 ±1.55 
207.90 ±1.45 
210.32 ± 1.45 
212.38 ±2.65 
218.36 ±4.09 
Results are mean ± SE of eight different animals 
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Table 18: Effect of streptomycin, fish oil and olive oil on weight of kidney 
and liver 
Groups 
Normal saline treated control (N) 
Streptomycin treated (S) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Kidney weight 
(g) 
1.25 ±0.109 
1.48±0.115 
1.71 ±0.147 
1.43 ±0.376 
1.76±0.131 
1.35 ±0.168 
1.45 ±0.173 
1.63 ±0.146 
Liver weight 
(g) 
5.49 ±0.413 
6.23 ±0.216 
7.52 ±0.352 
8.05 ±0.264 
8.69 ±0.099 
5.06 ±0.371 
6.33 ±0.182 
7.85 ±0.146 
Results are mean ± SE of eight different animals 
Figure 8 (a) and (b): Circulating levels of serum urea and creatinine in 
various treated rat groups 
N S PF CF PtF PO CO PtO 
Different animal groups 
3 -o 
o 
C 
'c 
CO o 
o 
(b) 
PF CF PtF PO 
Different animal groups 
CO Pto 
Results are mean of eight different animals 
N- Normal saline treated rats; S-Slreptomycin treated rats; PF - Pre fish oil 
treated rats; CF - coadministererd fish oil treated rats, PtF-Post fish oil treated 
rats; PO- Pre fish oil treated rats; Co-Coadministerred fish oil treated rats; PtO-
Post fish oil treated rats 
Table 19: Effect of streptomycin, fish oil and olive oil on the levels of 
serum urea and creatinine 
Groups 
Normal saline treated control (N) 
Streptomycin treated (S) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Urea 
(mg/100 ml) 
3.63 ±0.010 
7.28 ±0.201 
(-100.5%) 
5.08 ±0.047 
(-39.9%) 
4.18'±0.58 
(-15.1%) 
5.38 ±0.40 
(-48.2%) 
5.32'±0.060 
(-46.5%) 
7.04 ±0.335 
(-93.9%) 
5.55 ±0.067 
(-52.9%) 
Creatinine 
(mg/100 ml) 
1.11 ±0.027 
3.24 ±0.033 
(-191.9%) 
1.69'± 0.010 
(-52.2%) 
1.45'±0.036 
(-30.6%) 
i 
1.75 ±0.58 
(-57.6%) 
i 
1.77'±0.058 1 
(-59.4%) 
1.92 ±0.043 
(-72.9%) 
2.19 ±0.244 
(-97.3%) 
Results are mean ± SE of eight different animals 
'p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Table 20: Effect of streptomycin, fish oil and olive oil on levels of serum 
cholesterol and inorganic phosphate 
Groups 
Cholesterol 
(mg/100 ml) 
Inorganic 
phosphate 
(mg/100 ml) 
Normal saline treated control (N) 30.67 ±0.515 2.74 + 0.097 
Streptomycin treated (S) 89.43 ±0.935 
(-191.6%) 
7.74 ±0.277 
(-182.5%) 
Pre fish oil treated (PF) 39.52 ±1.173 
(-28.8%) 
2.49'±0.027 
(+9.1%) 
Co-administered fish oil treated (CF) 32.76'±0.411 
(-6.8%) 
2.99 ±0.021 
(-9.1%) 
Post fish oil treated (PtF) 71.76 ±0.709 
(-133.9%) 
5.26 ±0.040 
(-91.9%) 
Pre olive oil treated (PO) 31.5r±0.898 
(-2.7%) 
4.46'±0.021 
(-62.8%) 
Co-administered olive oil treated (CO) 85.79 ±0.964 
(-179.7%) 
4.80 ±0.025 
(-75.2%) 
Post olive oil treated (PtO) 84.64 ±3.53 
(-175.9%) 
6.39±0.16 
(-133.2%) 
Results are mean ± SE of eight different animals 
p^<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Table 21: Effect of streptomycin, fish oil and olive oil on levels of SGOT 
and SGPT 
Groups 
Normal saline treated control (N) 
Streptomycin treated (S) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
SGOT 
(n mol/min/ml) 
27.77 ±1.042 
89.02 ±1.356 
(-220.5%) 
37.89'± 0.835 
(-36.5%) 
36.40 ±0.616 
(-31%) 
44.02 ± 0.354 
(-58.5%) 
38.06'±1.320 
(-37%) 
67.53 ±1.320 
(-143.2%) 
57.53 ±2.00 
(-107.2%) 
SGPT 
(n mol/min/ml) 
34.79 ±1.02 
87.09 ±0.799 
(-150.3%) 
43.0r± 0.544 
(-23.6%) 
37.23'± 1.216 
(-7%) 
57.29 ±2.960 
(-64.7%) 
54.56'±1.213 
(-56.8%) 
67.84 ± 1.213 
(-94.9%) 
74.19 ±0.96 
(-113%) 
Results are mean ± SE of eight different animals 
''p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Figure 9 (a) and (b): Specific activity of AlP and AcP in kidney 
honiogenates of various treated rat groups 
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Each bar represent mean ± SE of eight different animals 
N- Normal saline treated rats; S-Streptomycin treated rats; PF - Pre fish oil 
treated rats; CF - coadministererd fish oil treated rats, PtF-Post fish oil treated 
rats; PO- Pre fish oil treated rats; Co-Coadministerred fish oil treated rats; PtO-
Post fish oil treated rats 
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Table 22: Effect of streptomycin, fish oil and olive oil on levels of CAT, 
SOD and GST in kidney homogenates 
Groups 
Normal saline treated control (N) 
Streptomycin treated (S) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
CAT 
13.09 ±0.02 
8.92 ±0.08 
(+31.8%) 
16.68H0.12 
(-27.4%) 
15.72'±0.10 
(-20%) 
14.89'±0.19 
(-13.7%) 
15.32±0.07 
(-17%) 
14.25±0.04 
(-8.9%) 
13.62^0.31 
(-4%) 
SOD 
8.99 ±0.29 
6.08 ±0.06 
(+47.8%) 
10.19'±0.12 
(-13.3%) 
12.59'±0.03 
(-40%) 
11.90±0.18 
(-32.4%) 
9.33'±0.05 
(-3.8%) 
9.02±0.21 
(-0.3%) 
10.42±0.13 
(-15.9%) 
GST 
2.69 ±0.02 
0.945±0.03 
(+64.8%) 
2.99'±0.05 
(-11.2%) 
3.09'±0.03 
(-14.9%) 
1.95±0.06 
(+27.5%) 
1.79±0.04 
(+33.4%) 
1.82±0.03 
(+32.3%) 
1.99'±0.06 
(+26%) 
Units: CAT, SOD & GST - units/min/mg protein 
Results are mean ± SE of eight different animals 
''p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Table 23: Effect of streptomycin, fish oil and olive oil on levels CAT and 
SOD in liver homogenates 
Groups 
Normal saline treated control (N) 
Streptomycin treated (S) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
CAT 
24.00 ±0.03 
16.65 ±0.10 
(+30.6%) 
25.8lH0.06 
(-7.5%) 
27.75'±0.07 
(-15.6%) 
24.21 ±0.05 
(-0.8%) 
24.03'±0.06 
(-0.1%) 
22.92 ± 0.23 
(+4.5%) 
23.13 ±0.47 
(+0.9%) 
SOD 
58.77 + 0.04 
41.08 ±0.20 
(+30.1%) 
62.21'±0.18 
(-5.8%) 
64.17'±0.03 
(-9.2%) 
60.21 ±0.13 
(-2.4%) 
58.0'±0.17 
(+1.3%) 
58.62 + 0.09 
(+0.2%) 
56.89+0.15 
(+3.2%) 
Units: CAT, SOD - units/min/ing protein 
Results are mean ± SE of eight different animals 
'p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Table 24: Effect of streptomycin, fish oil and olive oil on levels GST and 
MDA in liver homogenates 
Groups 
Normal saline treated control (N) 
Streptomycin treated (S) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
GST 
1.94 + 0.01 
0.98 ±0.07 
(+49.5%) 
2.92H0.01 
(-50.5%) 
2.41H0.02 
(-24.2%) 
2.24±0.05 
(-15.5%) 
2.19'±0.00 
(-12.9%) 
1.82+0.02 
(+6.2%) 
1.48+0.02 
(+23.8%) 
MDA 
0.72+0.01 
0.92+0.01 
(-27.8%) 
1.16'±0.01 
(-61.2%) 
1.24^+0.01 
(-72.3%) 
1.25+0.02 
(-73.6%) 
0.74'±0.05 
(-2.8%) 
1.44+0.03 
(-100%) 
0.99+0.06 
(-37.5%) 
Units: GST - units/min/mg protein; MDA- n mol/mg protein 
Results are mean ± SE of eight different animals 
^p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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4. DISCUSSION 
The notion that the therapeutic administration of antibiotics leads to some 
degree of renal injury is likely to remain undisputed. However, the major point 
to consider is, whether the frequent studies are useful in influencing clinical 
practice. Streptomycin, an aminoglycoside antibiotic is used for the treatment 
of tuberculosis, streptococcal bacterial endocarditis, tularemia and plague 
[158]. However the nephrotoxicity thus produced by it, limits its clinical 
usefulness and the underlying mechanism remains unclear. Like all other 
aminoglycosides, it is also excreted rapidly by glomerular filtration. However, 
monitoring of renal function still becomes important due to renal deterioration 
because of the accumulation of the drug [36]. 
In the present study, an attempt has been made to evaluate the effect of fish oil 
and olive oil on streptomycin induced nephrotoxicity along with a modulation 
of induced oxidative stress.Rats after streptomycin treatment as well as fish and 
olive oil treatment gave a normal weight gain indicating that the oils are not 
effecting the gastrointestinal tract. The most prominent abnormality in 
streptomycin receiving animals was the elevated serum urea and creatinine 
levels (Table 19). Damage to renal membrane due to antibiotic was that it 
effected its filtration and reabsorption processes as a result of which serum urea 
and creatinine levels increased many folds. Coadministration with fish oil 
resulted in significant decrease in serum urea (-15.1%) and creatinine (-30.6%) 
levels indicating streptomycin induced changes in rat kidney are completely 
reversible with a dose offish oil (5ml/kg body weight/day) for 10 days (Table 
19). Olive oil treatment (pre olive treated group) did help in reducing the levels 
of urea and creatinine to normal (-46.5%, -49.4%) however in comparison to 
fish oil, the effect produced remains less. Besides urea and creatinine, the level 
of several other serum metabolites were determined for detection of altered 
kidney function. Streptomycin was found to produce hypercholesterolaemia, 
which is in accordance with the secondary hypercholesterolaemia associated 
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with antibiotics [172]. Coadministered fish oil and pre fish oil treatment was 
found to bring a maximum hypocholesterolaemic effect (-6.8%, -28.8% change 
from control after recovery) as compared to coadministered olive oil group. 
This hypocholesterolaemic effect of fish oil along with other factors is 
attributed to enhanced fecal steroid excretion and to the inhibition of hepatic 
synthesis of very low density lipoproteins (LDL) and an increase in high 
density lipoproteins (HDL) [102]. 
Streptomycin causes toxicity to different organs of rat system, as is given by 
elevated levels of inorganic phosphate, SCOT and SGPT in streptomycin 
treated rat group. Streptomycin damages renal membrane, thereby effecting its 
function, as a result the level of inorganic phosphate in serum elevates [124] 
Coadministration of fish oil also reduced the higher level of inorganic 
phosphate (-9.1%), SGOT (-31%) and SGPT (-7%) towards normal, thus 
indicating that the use of fish oil antagonizes the alterations caused by 
streptomycin (Table 21). 
The determination of activities of AlP and AcP gave the measure of the 
deleterious effects of streptomycin on renal function. The reduced levels of AlP 
and AcP in tissues returned to normal (+3.6%, +8.4%) by coadministered fish 
oil treatment. Olive oil on the other hand produced a slightly less recovery 
effect as compared to fish oil treatment (AlP +16.4%, AcP +10.7%). The 
recovery in the levels of AlP and AcP to normal, which are abimdant in kidney, 
is an indication that fish oil administration produces beneficial effects on the 
restoration of kidney structure and thereby its function. 
The administration of streptomycin also induces oxidative stress as is evident by 
significantly altered activities of CAT, SOD and GST in kidney and liver 
homogenates. There are evidences that support the fact that aminoglycoside 
induces nephrotoxicity may be free radical mediated [180,181]. Fish oil treatment 
gave a significant rise in the activities of these enzymes where as olive oil brought 
about a less significant alteration of these parameters (Table 22-24). This 
enhanced antioxidant potential of fish oil treated groups is in accordance 
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with the effect reported by others [182]. This higher activity of antioxidant 
enzymes may contribute to the hypothesis that fish oil consumption extends 
lifespan [182]. Lipid peroxidation was significantly higher in streptomycin 
alone, treated groups as compared to control. However, this value of lipid 
peroxidation was increased to a lesser extent in coadministered pre fish oil 
treated rat group. This also proves the beneficial effect of fish oil in 
enhancing/inducing the activity of antioxidant enzymes [183] in the presence of 
fish oil, so that lipid peroxidation no longer remains a factor to further 
potentiate the renal damage by streptomycin. Olive oil on the other hand 
reduced the increased oxidative stress by levels of CAT, SOD and GST without 
a significant increase in lipid peroxidation probably due to tocopherol as wells 
as polyphenols present in it [184]. However, in comparison to fish oil, the 
effect produce by olive oil in enhancing the antioxidant potential remain less. 
The study thus, leads to conclude that there is a beneficial role of fish oil when 
administered together with streptomycin in reverting the metabolic, 
biochemical and functional alterations induced by the antibiotic. 
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D. AMIKACIN 
I. Time dependent effect of amikacin toxicity 
Nephrotoxicity was induced in rats by intraperitonial administration of 
amikacin (250 mg/kg body weight/day) for 4, 6, 8, 12, 14 consecutive da}s. 
The animals were scarified 12 H after each injection and the serum obtained 
was then subject to analysis of urea and creatinine to evaluate the 
nephrotoxicity induced by the antibiotic. Maximum nephrotoxicity was 
developed after 8 days of treatment with amikacin (Figure 10 (a) and (b)). as 
given by elevated levels of urea (10.32 mg/dl) and creatinine (3.97 mg/dl). 
2. Treatment of rats with fish oil and olive oil 
The rats were divided into eight groups, each having 8 rats. These groups were 
treated as follows: 
Group-I (Normal) or no treatment group (N): The rats were given no 
treatment for the first 8 days and intraperitonial injection of normal saline (1ml) 
for the last 8 days of 16 day experiment. Animals were allowed free access to 
food and water. 
Group-II or amikacin treated group (A): The animals were given no 
treatment for the first 8 days, followed by intraperitonial injection of amikacin 
(250 mg/kg body weight/day) for the last 8 days of the 16 day experiment to 
get the measure of maximum nephrotoxicity induced. 
Group-Ill or fish oil pretreatment group (PF): The animals were given fish 
oil orally (5 ml/kg body weight/day) for 8 days using catheter and for next 8 
days injections of amikacin was administered (250 mg/kg body weight/da}'/rat). 
Group-IV or fish oil coadministration group (CF): The animals were given 
no treatment for first 8 days and for next 8 days they were given both fish oil 
and amikacin. 
Group-V or fish oil post treatment group (PtF): Here the animals were 
given amikacin for first 8 days and fish oil for next 8 days. 
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Figure 10 (a) and (b): Time dependent effect of ami!<acin on the levels of 
urea and creatinine in serum. 
N 4 6 8 12 14 
Duration of treatment of amikacin (days) 
4 6 8 12 14 
Duration of treatment (days) of amikacin 
Results are mean of four different animals 
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Group-VI (PO), VII (CO) and VIII (PtO) were duplicates group III, IV 
and V except that rats in these groups were given olive oil. The diet, amikacin 
and olive oil dose was same as in above mentioned groups. 
3. RESULTS 
The toxic effects of amikacin and its removal with the use offish oil and olive 
oil was studied and the following results were obtained. 
i) General parameters: Body and organ weight 
The diet intake (20 gm/day/day), amikacin dose (250 mg/kg body weight/day) 
and oil (5 ml/kg body weight/day) was same in all rat groups. The body 
weights of different rat groups before and after the completion of 16 days 
experiment is given (Table 25). Amikacin treatment alone did not produce any 
major change in the overall weight of animals. Fish and olive oil administration 
also did not bring any significant change in the total body weight and in weight 
of kidney and liver of different treated groups (Table 26). 
ii) Effect on serum parameters 
The determination of the levels of various serum metabolites gave the indices 
of damage caused by amikacin to various organs. Amikacin treatment alone 
gave a two fold increase in urea and creatinine levels (Figure 11 (a) and (b)). 
Fish oil treatment for 8 days together with amikacin helped in reversion of 
amikacin induced nephrotoxicity as is given by normalized urea (-6.8%) and 
creatinine (-33%) levels in these two groups (Table 27). Among olive oil 
treated groups, pre olive oil treatment brought the maximum lowering of these 
increased levels of urea (-34.9%) and creatinine (-62.3%) (PO-P<0.05). 
However, the fact remains that compared to fish oil, the effect produced by 
olive oil is much less (p<0.05). Coadministration treatment of the two oils also 
lower the elevated cholesterol levels of amikacin (Table 28). This 
hypocholesterolaemic effect was again more pronounced in fish oil (CF 
-9.5%) than olive oil treated groups. 
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Amikacin also caused an increase in circulating levels of inorganic phosphate, 
SGOT and SGPT (Table 28 and 29). The maximum reduction in elevated 
levels of above given parameters was done maximally by coadministration (iP 
-3.1%, SGOT -9.7%, SGPT -1.5% change from the control after recovery) as 
well as pre fish oil treatment. 
iii) Effects on tissue parameters 
(a) Marker enzyme of the kidney 
Amikacin injections reduced the levels of AlP and AcP in tissue homogenates 
to half indicating that amikacin damages renal membrane (Figure 12 (a) and 
(b)). However, the activity of AlP was restored to normal by coadministration 
offish oil (+2.9%)) where as level of AcP was restored to normal maximally by 
coadministration of olive oil (+8%). Among fish oil treated groups, 
coadministration of fish oil (+20.8%) restored maximally activity of AcP in 
kidney homogenates. 
(b) Antioxidant status of the kidney 
The effect offish oil and olive oil on kidney antioxidant status is given in Table 
30. Amikacin treatment resulted in a decrease in the levels of CAT, SOD and 
GST. Fish oil administration showed a significant increase in the levels of these 
antioxidant enzymes. Among the olive oil groups, pre olive oil treatment gave a 
maximum increase of the antioxidant enzymes. However, among the two oils, 
fish oil exerts maximum beneficial effect by increasing the antioxidant 
(c) Effect on liver antioxidant enzymes 
The activities of various antioxidant enzymes of liver of different animal 
groups were determined. The levels of CAT, SOD and GST in the liver were 
much reduced with the use of amikacin (Table 31 and 32) as compared to 
nontreated normal rats. Rats given fish oil exhibited significant level of 
activities of CAT, SOD and GST compared to amikacin treated rats. However, 
use of olive oil did not give such elevated levels of antioxidant enzymes when 
compared to normal saline treated rat. Malondialdehyde (MDA), an end 
product of lipid peroxidation was found to be elevated in amikacin treated rats. 
Further fish oil fed animals gave a slightly higher levels of MDA as compared 
to olive oil receiving groups (Table 32). 
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Table 25: Effect of amikacin, fish oil and olive oil on body weight 
Groups 
Normal saline treated control (N) 
Amikacin treated (A) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Initial body 
weight (g) 
200.88 + 7.80 
198.20 + 8.13 
210.37 + 7.22 
208.65 ±10.75 
202.37 + 6.29 
206.38110.94 
200.09 ±11.02 
202.32 ± 7.66 
Final body 
weight (g) 
207.21 ±8.07 
206.91 ±7.21 
215.45 ±7.80 
210.43 ±7.44 
207.86 ±8.51 
218.10 ±9.02 
202.36± 10.93 
207.21 ±9.76 
Results are mean ± SE of eight different animals 
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Table 26: Effect of amikacin, fish oil and olive oil on weight of kidney and 
liver 
Groups 
Normal saline treated control (N) 
Amikacin treated (A) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Kidney weight 
(g) 
1.87 ±0.89 
1.72 ±0.28 
2.01 ±0.36 
1.95 ±0.60 
1.75 ±0.76 
2.23 ±0.39 
1.42 ±0.44 
1.85 ±0.45 
Liver weight 
(g) 
6.13 ±0.40 
6.20 ±0.51 
9.45 ±0.59 
7.08 ± 0.43 
6.98 ±0.13 
10.88 ±0.19 
5.97 ±0.48 
6.63 ±0.28 
Results are mean ± SE of eight different animals 
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Figure 11 (a) and (b): Circulating levels of serum urea and creatinine in 
various treated rat groups 
PF CF PtF PO 
Different animal groups 
N A PF CF PtF PO CO PtO 
Different animal groups 
Results are mean of eight different animals 
N- Normal saline treated rats; A-Amikacin treated rats; PF - Pre fish oil treated 
rats; CF - coadministererd fish oil treated rats, PtF-Post fish oil treated rats; 
PO- Pre fish oil treated rats; Co-Coadministerred fish oil treated rats; PtO-Post 
fish oil treated rats 
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Table 27: Effect of amikacin, fish oil and olive oil on levels of serum urea 
and creatinine 
Groups 
Normal saline treated control (N) 
Amikacin treated (A) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Urea 
(mg/100 ml) 
4.53 ±0.08 
9.68 ±0.06 
(-113.7%) 
5.63'±0.01 
(-24.3%) 
4.84'±0.02 
(-6.8%) 
7.14 ±0.01 
(-57.6%) 
6.ir±o.oi 
(-34.9%) 
7.69 ±0.03 
(-69.7%) 
6.34 ±0.10 
(-39.9%) 
Creatinine 
(mg/100 ml) 
1.09 ±0.00 
3.24 ±0.03 
(-197.2%) 
1.69'±0.03 
(-55%) 
1.45'±0.01 
(-33%) 
1.75 ±0.05 
(-60.5%) 
1.77'±0.06 
(-62.3%) 
1.91 ±0.04 
(75.2%) 
2.19 ±0.24 
(-25.7%) 
Results are mean ± SE of eight different animals 
^p<0.05 as compared to nomial rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
Table 28: Effect of amikacin, fish oil and olive oil on levels of serum 
cholesterol and inorganic phosphate 
Groups 
Normal saline treated control (N) 
Amikacin treated (A) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Cholesterol 
(mg/100 ml) 
31.91 ±0.29 
66.87 ±0.38 
(-109.5%0 
38.56'±0.11 
(-20.8%) 
34.94'±0.16 
(-9.5%) 
42.55 ±0.19 
(-33.3%) 
52.98 ±0.16 
(-66%) 
58.56 ±0.14 
(-83.5%) 
56.51 ±0.17 
(-77%) 
Inorganic 
phosphate 
(mg/100 ml) 
3.17 ±0.02 
9.13±0.10 
(-188%) 
4.72'±0.03 
(-48.9%) 
3.27'±0.02 
(-3.1%) 
5.21 ±0.04 
(-64.3%) 
5.57 ±0.02 
(-75.7%) 
6.78 ±0.05 
(-113.8%) 
6.44 ±0.03 
(-103.1%) 
Results are mean ± SE of eight different animals 
^p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
Table 29: Effect of amikacin, fish oil and olive oil on levels of SGOT and 
SGPT 
Groups 
Normal saline treated control (N) 
Amikacin treated (A) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
SGOT 
(n mol/min/ml) 
25.74 ±0.18 
90.99 ±0.45 
(-253.5%) 
30.4'±0.18 
(-18.1%) 
28.23'±0.19 
(-9.7%) 
49.91 ±0.15 
(-93.9%) 
32.23'±0.29 
(-25.2%) 
60.85 ±0.19 
(-136.4%) 
60.59 ±0.08 
(-135.4%) 
SGPT 
(n moI/min/ml) 
30.13 ±0.06 
93.71 ±0.07 
(-211%) 
43.67'±0.05 
(-44.9%) 
30.60'±0.09 
(-1.5%) 
50.60 ±0.11 
(-67.9%) 
34.72'±0.12 
(-15.2%) 
61.02±0.12 
(-102.5%) 
52.02 ±0.28 
(-72.6%) 
Results are mean ± SE of eight different animals 
''p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Figure 12 (a) and (b): Specific activity of AlP and AcP in kidney 
homogenates of various treated rat groups 
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N- Normal saline treated rats; A-Amikacin treated rats; PF - Pre fish oil treated 
rats; CF ~ coadministererd fish oil treated rats, PtF-Post fish oil treated rats; 
PO- Pre fish oil treated rats; Co-CoadministeiTed fish oil treated rats; PtO-Post 
fish oil treated rats 
Table 30: Effect of amikacin, fish oil and olive oil on levels of CAT, SOD 
and GST in kidney homogenates 
Units: CAT, SOD & GST- units/min/mg protein 
Results are mean ± SE of eight different animals 
^p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
Groups 
Normal saline treated control (N) 
Amikacin treated (A) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
CAT 
14.00 + 0.03 
8.89 ±0.06 
(+36.5%) 
16.75'±0.01 
(-19.6%) 
15.8r±0.02 
(-12.9%) 
14.59 ±0.07 
(-4.2%) 
14.68'±0.05 
(-4.8%) 
13.48 ±0.09 
(+3.7%) 
13.62 ±0,06 
(+2.7%) 
SOD 
8.84 ±0.05 
6.18 ±0.04 
(+30%) 
9.16'±0.02 
(-3.6%) 
12.68'±0.03 
(-43.4%) 
10.67 ±0.07 
(-20.7%) 
10.3r±0.03 
(-16.6%) 
9.16±0.21 
(-3.6%) 
9.69 ±0.09 
(-9.6%) 
GST 
0.97 ±0.00 
0.58 ±0.00 
(+40.2%) 
2.86'±0.01 
(-194.8%) 
2.08'±0.02 
(-114.4%) 
1.91 ±0.01 
(-96.9%) 
1.65'±0.04 
(-70.1%) 
1.41 ±0.02 
(-45.3%) 
1.35 ±0.05 
(-39.2%) 
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Table 31: Effect of amikacin, fish oil and olive oil on levels CAT and SOD 
in liver homogenates 
Groups 
Normal saline treated control (N) 
Amikacin treated (A) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
CAT 
37.80 ±0.23 
19.54 + 0.15 
(+48.3%) 
45.13'±0.17 
(-19.4%) 
47.33'±0.21 
(-25.2%) 
43.46 + 0.27 
(-14.9%) 
38.27'±0.10 
(-1.2%) 
39.09 + 0.12 
(-3.4%) 
37.16 ±0.17 
(+1.7%) 
SOD 
74.29 ± 0.49 
39.62 ±0.58 
(+46.6%) 
83.20'±0.64 
(-11.9%) 
82.50'±0.92 
(-11%) 
80.85 ±0.99 
(-8.8%) 
77.13'±0.89 
(-3.8%) 
77.69 ±0.53 
(-4.6%) 
75.33 ±0.46 
(-1.4%) 
Units: CAT, SOD - units/min/mg protein 
Results are mean ± SE of eight different animals 
'^ p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
Table 32: Effect of amikacin, fish oil and olive oil on levels GST and MDA 
in liver homogenates 
Groups 
Normal saline treated control (N) 
Amikacin treated (A) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
GST 
2.97 + 0.01 
2.58 ±0.01 
(+13.1%) 
4.86'+ .01 
(-63.6%) 
4.08'±0.09 
(-37.4%) 
3.91 ±0.01 
(-31.6%) 
3.65'±0.04 
(-22.9%) 
3.41 ±0.04 
(-14.8%) 
3.35 ±0.05 
(-12.8%) 
MDA 
0.79 ±0.01 
0.94 ±0.01 
(-18.9%) 
0.99'±0.01 
(-25.3%) 
0.97 ±0.02 
(-22.7%) 
1.01 ±0.01 
(-27.8%) 
0.78'±0.02 
(+1.2%) 
0.85 ±0.02 
(-7.6%) 
0.83 ±0.01 
(-5%) 
Units: GST - units/min/mg protein; MDA- n mol/mg protein 
Results are mean + SE of eight different animals 
''p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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4. DISCUSSION 
Amikacin is an antibiotic, used as antimicrobial agent. It possess nephrotoxic 
properties and acute deterioration in renal function leading to serious 
complication which is a limiting factor to the use of this drug. Amikacin is a 
semi synthetic aminocyclitol, used for treatment of pulmonary infection, 
urinary tract infections and mycobacterial infections [153]. Morphological 
changes of this aminoghcoside nephrotoxcity are mainly characterized by 
reduced renal excretory capacity and by proximal tubular necrosis. Like all 
antibiotics, amikacin enters renal proximal tubule through pinocytosis and is 
then sequestered in lysosomes thereby influencing renal tubular metabolism 
and functions in a variety of ways. Though, it is eliminated from the kidney by 
glomerular filtration, some deposition in kidney cortex occurs which appears to 
be related to its nephrotoxicty [181]. The nephrotoxic potential of amikacin 
appears in the form of renal manifestation of toxicity as enzymuria and 
polyuria. Aminoglycosides inhibit phospholipases in membranes, thereby 
affecting the activities of various enz)'mes modulated by phospholipids [189]. 
Since, morphological changes of antibiotic nephrotoxicity are primarily the 
consequences of damage to cell membrane. Investigating the effect of dietary 
oils like fish oil and olive oil on modulation of toxicity induced by amikacin 
may provide an important tool for reversal of toxic effects by this drug. In view 
of this, the comparative effect of fish and olive oil on amikacin toxicity was 
done. 
The results of the study indicated that amikacin alone leads to increased serum 
urea and creatinine levels. Thus, indicating that renal injury has occurred due to 
which glomerular filtration and reabsorption processes have been affected [31]. 
The diet intake and bod\ weights was not effected with the use of amikacin, 
fish oil or olive oil. The supplementation offish oil together with amikacin in 
rats substantially ameliorated the renal damage associated with amikacin use as 
is given by return of increased levels of serum urea and creatinine levels 
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towards normal (-6.8%, -33% change from control after recovery, respectively) 
(Table 27). This is in accordance with those reported for other aminoglycoside 
[172]. However the olive oil treatment could not bring much pronounced effect 
on serum urea and creatinine levels when compared to fish oil. 
Cholesterol estimation made it clear that amikacin is hypercholesterolemic. The 
result is again in line with a study for gentamicin, where secondary hyper-
cholesterolaemia is an established fact [172]. The use of fish oil in 
coadministration and pre treatment restored the cholesterol level (Table 28) to 
normal (-9.5%, -20.8%). Our study also gives that fish oil is more 
hypocholesterolacmic than olive oil, which is in accordance with others [172]. 
It has also been reported that high n-3 fatty acid content may be responsible for 
this effect [186]. The level of inorganic phosphate increases with the use of 
amikacin. However this increased level of inorganic phosphate was restored to 
normal (-3.1%)) by coadministered fish oil treatment giving the varied role of 
fish oil supplementation on kidney metabolism (Table 28). Amikacin also 
effects liver, as the levels of SGOT and SGPT were significantly increased 
with the use of amikacin. However, coadministered fish oil treatment again 
helped in restoration of the levels of these serum metabolites to normal (SGOT 
-9.7%, SGPT -1.5%) (Table 29). 
Enzymes like alkaline and acid phosphatases are abundant in kidney and any 
change in their levels is an indication of renal damage. The decreased levels of 
AlP and AcP in kidney homogenates by amikacin, a nephrotoxic agent was 
restored to normal maximally (AlP +2.9%), AcP +28.8%) by coadministration 
of fish oil suggesfing the role of fatty acids present in fish oil in restoration of 
renal membrane structure and thereby its function (Fig. 12). 
Besides the changes discussed above, amikacin also results in the inhibifion of 
the activity of antioxidant enzymes in renal and liver tissues (Table 30-32). 
Lipid peroxidation, determined by malondialdehyde content was increased 
after amikacin treatment. The increase in lipid peroxidation may be due to the 
damage caused by free radicals generated which react with membrane Hpids 
[21]. The peroxidation of membrane lipids can result in enzyme leakage. 
Significant recovery in the activities of CAT, SOD and GST with fish oil 
supplementation, led to reduction in lipid peroxidation. These antioxidant 
enzymes protect cellular components with the help of endogenously derived 
antioxidants. Although fish oil as compared to olive oil shows higher peroxide 
levels, this increase was not critical, since the inducfion of antioxidant enzymes 
was much higher and this increase in the level of enzymes was effective to 
overcome the toxic effects of lipid peroxides. Fish oil is also known to possess 
good content of vitamin E, which functions in vivo as a chain breaking 
antioxidant that prevents the propagation of free radical damage in biological 
membranes [187]. This could be one of the reasons for beneficial effects offish 
oil. Results of this study indicate that olive oil also helps to lower the oxidative 
stress induced by amikacin (Table 30-31) although the effect was less, when 
compared to fish oil. The recovery by olive oil was probably due to the various 
components present in it like oleic acid and polyphenols [184]. 
Concluding the whole study, it seems that fish oil supplementation for 8 days 
together with amikacin may offer advantages in combating the toxicity induced 
by this particular antibiotic. 
E. KANAMYCIN 
l.Time dependent effect of kanamycin toxicity 
Kanamycin (200 mg/kg body weight/day) was given via intraperitonial 
injections to rats for 4, 8, 10, 14, 16 consecutive days to induce nephrotoxicity. 
The animals were scarified after 12 H after each injection and the serum 
obtained was subjected to analysis of urea and creatinine to evaluate the extent 
of nephrotoxicity induced by the antibiotic. Maximum nephrotoxicity was 
developed after 8 days of treatment with kanamycin (Figure 13 (a) and (b)), as 
given by many fold increase in the levels of urea and creatinine in this animal 
group. 
2. Treatment of rat with fish oil and olive oil 
The rats were divided into eight groups, each having 8 rats. These groups were 
given the following treatment. 
Group-I (Normal) or no treatment group (N): The rats were given no 
treatment for the first 8 days and intraperitonial injection of normal saline (1ml) 
for the last 8 days of 16 day experiment. Animals were allowed free access to 
food and water. 
Group-II or kanamycin treated group (K): The animals were given no 
treatment for the first 8 days followed by intraperitonial injection of kanam\cin 
(200 mg/kg body weight/day) for the last 8 days of the 16 day experiment to 
get the measure of maximum nephrotoxicity induced. 
Group-Ill or fish oil pretreatment group (PF): The animals were given oral 
treatment of fish oil (5 ml/kg body weight/day) using catheter, for 8 days and 
for next 8 days injections of kanamycin (ip) was administered (200 mg/kg body 
weight/day/rat). 
Group-IV or fish oil coadministration group (CF): The animals were gi\ en 
no treatment for first 8 days and for next 8 days they were given both fish oil 
and kanamycin. 
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Figure 13 (a) and (b): Time dependent effect of kanamycin on the levels of 
urea and creatinine in serum 
N 4 8 10 14 16 
Duration of treatment of kanamycin (days) 
N 4 8 10 14 16 
Duration of treatment of kanamycin (days) 
Results are mean of four different animals 
Group-V or fish oil post treatment group (PtF): Here the animals were 
given kanamycin for first 8 days and fish oil for next 8 days. 
Group-VI (PO), VII (CO) and VIII (PtO) were duplicate of group III, IV 
and V except that rats in these groups were given olive oil. The diet, kanamycin 
and olive oil dose was similar as in fish oil group. 
3. RESULTS 
Kanamycin is nephrotoxic and modulation of its toxicity with the use of fish 
and olive oil is established in this study. The results of the study for different 
parameters are as follows: 
i) General parameters: Body and organ weight 
The diet intake (20 gm/day/rat), dose of the oils and kanamycin was same in all 
treated group. The initial and final body weights is given in Table 33, which 
suggest that no major weight gain during the 16 day experimentation has 
occurred. The weight of kidney and liver of various rat groups is given in Table 
34. Neither the two oils nor kanamycin treatment resulted in any significant 
change in liver and kidney weight of the animals. 
ii) Effects on serum parameters 
As shown in Figure 14 (a) and (b), the rats receiving kanamycin gave a 
significant two fold increase in serum urea and creatinine concentration 
compared to normal saline treated rats. However, fish oil given in combination 
with kanamycin resulted in normalizing the increased levels of urea (-6%) and 
creafinine (-1.6%) towards control values (Table 35). Kanamycin injections 
produced an increase in levels of serum cholesterol and inorganic phosphate. 
The levels of SGOT and SGPT were also increased significantly (Table 36 and 
37). Coadministration of fish oil (5 ml/kg body weight/day) for eight days 
caused reducfion in the above, menfioned elevated serum parameters towards 
normal. After oil treatment the difference from control were Cholesterol -1.9%. 
iP -2.3%, SGOT -3.5%, SGPT -1.7%. 
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iii) Effects on tissue parameters 
(a) Marker enzymes of the kidney 
The deleterious effect of kanamycin on kidney function was estimated by 
determination of levels of renal marker enzymes. The renal tissue AlP and AcP 
activities were significantly reduced by kanamycin treatment (Figure 15 (a) and 
(b)). However, this reduced activity was restored to normal by feeding fish oil 
together with kanamycin (AlP +8.8%, AcP +2.9%). Among the two given oils, 
fish oil exerted maximum effect in bringing the levels of these enzymes 
towards normal. 
(b) Antioxidant potential of the kidney 
Table 38, gives the level of oxidative stress induced by kanamycin. Fish oil 
administration gave a significant rise in the levels of CAT, SOD and GST to 
combat the induced stress by kanamycin. The olive oil treatment was not much 
effective in lowering the induced stress and comparative data of the two oils 
showed that the effect of fish oil was more pronounced. 
(c) Effects on hepatic antioxidant potential 
Administration of kanamycin (200 mg/kg body weight/day) for eight days 
resulted in a significant decreased in the levels of CAT, SOD and GST in liver 
as compared to normal rats (Table 39 and 40). Fish oil treatment both prior to 
and together with kanamycin resulted in increase of the levels of these 
antioxidant enzymes, thereby reducing the oxidative stress induced by 
kanamycin. Again compared to olive oil, the effect of fish oil in increasing the 
levels of antioxidant enzymes remains significant. The level of MDA is 
significantly enhanced with the use of kanamycin showing the increased level 
of lipid peroxidation (Table 40). The fish oil administration was found to be 
more beneficial in reducing the oxidative stress as compared to olive oil. 
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Table 33: Effect of kanamycin, fish oil and olive oil on body weight 
Groups 
Normal saline treated control (N) 
Kanamycin treated (K) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Initial body 
weight (g) 
191.9±6.7 
201.3 + 3.0 
207.2 ±2.5 
205.0 ±2.7 
195.3 ±8.9 
203.9 ±11.8 
189.5 ±3.7 
207.7 ±2.1 
Final body 
weight (g) 
203.2 ±5.3 
202.9 ±4.3 
215.5±2.5 
210.4 ±3.2 
204.0 ±2.9 
207.9 ±13.5 
200.8 ±7.3 
214.2 ±8.1 
Results are mean + SE of eight different animals 
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Table 34: Effect of kanamycin, fish oil and olive oil on weight of kidney 
and liver 
Groups 
Normal saline treated control (N) 
Kanamycin treated (K) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Kidney weight 
(g) 
1.16±0.16 
1.35 ±0.29 
1.95 ±0.37 
1.74±0.18 
1.20 ±0.70 
1.61 ±0.85 
1.12 ±0.46 
2.20 ±0.25 
Liver weight 
(g) 
3.94 ±0.48 
5.70 ±0.61 
8.30 ±0.30 
7.39 ±0.51 
4.94 ± 0.75 i 
1 
6.32 ±0.76 
3.81 ±0.20 
7.05 ±0.38 
Results are mean ± SE of eiaht different animals 
Figure 14 (a) and (b): Circulating levels of serum urea and creatinine in 
various treated rat groups 
o 
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Results are mean of eight different animals 
N- Normal saline treated rats; K-Kanamycin treated rats; PF - Pre fish oil 
treated rats; CF ~ coadministererd fish oil treated rats, PtF-Post fish oil treated 
rats; PO- Pre fish oil treated rats; Co-Coadministerred fish oil treated rats; PtO-
Post fish oil treated rats 
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Table 35: Effect of kanamycin, fish oil and olive oil on levels of serum urea 
and creatinine 
Groups 
Normal saline treated control (N) 
Kanamycin treated (K) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Urea 
(mg/100 ml) 
4.52 ±0.08 
9.46 ±1.02 
(-109.3%) 
4.96'±0.41 
(-9.7%) 
4.79'±0.81 
(-6%) 
5.14±1.10 
(-13.7%) 
7.01 ±1.30 
(-55.1%) 
6.97 ±1.21 
(-54%) 
6.67 ±1.46 
(-47.6%) 
Creatinine 
(mg/100 ml) 
1.20±0.11 
3.50 ±0.10 
(-191.6%) 
1.39'±0.08 
(-15.8%) 
1.22'±0.03 
(-1.6%) 
1.48 ±0.18 
(-23.3%) 
2.44 ±0.17 
(-103.3%) 
2.26 ±0.74 
(-88.3%) 
2.51 ±0.13 
(-108.3%) 
1 
Results are mean ± SE of eight different animals 
''p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
i.27 
Table 36: Effect of kanamycin, fish oil and olive oil on levels of serum 
cholesterol and inorganic phosphate 
Groups 
Normal saline treated control (N) 
Kanamycin treated (K) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
Cholesterol 
(mg/100 ml) 
29.49 + 2.16 
50.13 ±7.42 
(-69.9%) 
32.96 + 32.74 
(-11.8%) 
30.05'±3.58 
(-1.9%) 
36.59 ±4.18 
(-24.1%) 
40.06 ±3.47 
(-35.8%) 
42.76 ±5.85 
(-44.9%) 
40.19 ±4.90 
(-36.3%) 1 
Inorganic 
phosphate 
(mg/100 ml) 
3.49 ±0.37 
10.05 ±0.90 
(-187.9%) 
3.85'±0.24 
(-10.3%) 
3.57'±0.32 
(-2.3%) 
3.99±0.16 
(-14.3%) 
5.47'±0.76 
(-56.7%) 
5.61 ±0.80 
(-60.7%) 
6.72 ±0.56 
(-92.5%) 
Results are mean ± SE of eight different animals 
''p<0,05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Table 37: Effect of kanamycin, fish oil and olive oil on levels of SGOT and 
SGPT 
Groups 
Normal saline treated control (N) 
Kanamycin treated (K) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
1 SGOT 
(n mol/min/ml) 
31.06 ±4.04 
72.12 ±3.70 
(-132.2%) 
33.89'±2.08 
(-9.1%) 
32.15'±3.12 
(-3.5%) 
35.78± 1.16 
(-15.2%) 
42.65 ±3.71 
(-37.3%) 
40.54'±0.19 
(-30.5%) 
42.48 ±7.66 
(-36.8%) 
SGPT 
(n mol/min/ml) 
38.29 ±2.25 
74.65 ±4.10 
(-94.9%) 
40.31'±5.06 
(-5.3%) 
38.95'±3.18 
(-1.7%) 
42.55 ±1.01 
(-11.1%) 
43.60 ±6.12 
(-13.9%) 
41.32'±1.88 
(-7.9%) 
42.06 ±4.16 
(-9.8%) 
Results are mean + SE of eight different animals 
^p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Figure 15 (a) and (b): Specific activity of AlP and AtP in kidney 
homogenates of various treated rat groups 
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N- Normal saline treated rats; K-Kanamycin treated rats; PF - Pre fish oil 
treated rats; CF - coadministererd fish oil treated rats, PtF-Post fish oil treated 
rats; PO- Pre fish oil treated rats; Co-Coadministerred fish oil treated rats; PlO-
Post fish oil treated rats 
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Table 38: Effect of kanamycin, fish oil and olive oil on levels of CAT, SOD 
and GST of kidney homogenates 
Groups 
Normal saline treated control (N) 
Kanamycin treated (K) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
CAT 
18.0910.95 
10.01 ±1.72 
(+44.7%) 
23.01'±1.29 
(-27.2%) 
25.39'±0.82 
(-40.3%) 
23.82 ±0.69 
(-31.7%) 
19.73'±1.75 
(-9.1%) 
18.89 ±1.83 
(-4.4%) 
19.99±1.50 
(-10.5%) 
SOD 
10.8110.10 
5.9810.13 
(+44.70/^) 
13.43H0.08 
(-24.2%) 
14.66^10.22 
(-35.6%) 
14.80±0.17 
(-36.9%) 
10.53'±0.12 
(-25.9%) 
9.11 ±0.94 
(+15.7%) 
9.81±0.10 
(+9.3%) 
GST 
1.09 ±0.03 
0.75±0.25 
(-31.2%) 
1.45'±0.16 
(-33%) 
1.38^0.43 
(-26.6%) 
1.5010.24 
(-37.6%) 
1.1210.32 
(-2.7%) 
0.9910.23 
(+9.2%) 
1.0610.37 ; 
(+2.8%) 
Units: CAT, SOD & GST - units/min/mg protein 
Results are mean ± SE of eight different animals 
^p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Table 39: Effect of kanamycin, fish oil and olive oil on levels CAT and 
SOD in liver homogenates 
Groups 
Normal saline treated control (N) 
Kanamycin treated (K) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
CAT 
42.24+3.75 
23.47 ±2.26 
(+44.40/0) 
45.98H3.889 
(-8.9%) 
48.10'±2.15 
(-13.9%) 
45.17±3.15 
(-6.9%) 
43.55'±4.18 
(-3.1%) 
40.86±5.20 
(+3.3%) 
39.98+4.75 
(+5.4%) 
SOD 
90.7114.84 
52.51±3.53 
(+42.1%) 
96.19+5.17 
(-6%) 
97.25'±4.20 
(-7.2%) 
98.56+4.09 
(-8.7%) 
85.84'±3.15 
(+5.9%) 
89.62+4.18 
(+1.2%) 
88.90±4.09 
(+2%) 
Units: CAT, SOD - units/min mg protein 
Results are mean ± SE of eight different animals 
''p<0.05 as compared to nonnal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Table 40: Effect of kanamycin, fish oil and olive oil on levels GST and 
MDA in liver homogenates 
Groups 
Normal saline treated control (N) 
Kanamycin treated (K) 
Pre fish oil treated (PF) 
Co-administered fish oil treated (CF) 
Post fish oil treated (PtF) 
Pre olive oil treated (PO) 
Co-administered olive oil treated (CO) 
Post olive oil treated (PtO) 
GST 
5.30±0.35 
3.9110.29 
(+26.2%) 
6.01'±0.29 
(-13.4%) 
5.82'±0.38 
(-9.8%) 
6.01±0.29 
(-13.4%) 
4.20±0.16 
(+20.8%) 
4.0r±0.12 
(+24.3%) 
4.42±0.20 
(+16.6%) 
MDA 
0.64±0.03 
1.99+0.10 
(-210.9%) 
0.87'+0.07 
(-35.9%) 
0.68"+0.02 
(-6.3%) 
0.92±0.01 
(-43.8%) 
0.76'±0.04 
(-18.8%) 
0.6910.40 
(-7.8%) 
0.7810.06 
(-21.9%) 
Units: GST - uiiits/min/mg protein; MDA- n mol/mg protein 
Results are mean ± SE of eight different animals 
^p<0.05 as compared to nonnal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
4.DISCUSSION 
Kanamycin, an aminoglycoside prototype is used in management of severe 
bacterial infections i.e. enterobacteriacae and mycobacterium. Studies indicate 
that kanamycin accumulates in the renal cortex intracellularly, with long half 
life, therefore nephrotoxicity is most untoward effect associated with its use 
[154-156]. Once inside the cortex, it subsequently causes tubular necrosis and 
thus, glomerular filtration is decreased [25]. Nephrotoxicity is usually mild at 
low doses. However, at higher doses and when given for prolonged time, 
toxicity by drug manifests itself [31]. Therefore, identification of certain agents 
that may modulate this drug induced toxicity becomes important. During the 
last decade, the efficacy and clinical utility of fish oils in various renal diseases 
have been established [124-129]. This study was shows the protective effects of 
fish oil on toxicity induced by kanamycin. Olive oil was used as placebo, to 
compare the effect of fish oil. Kanamycin injection (200 mg/kg body 
weight/day) to rats for eight days resulted in a two fold increase in levels of 
serum urea, creatinine, SCOT and SGPT indicating that the drug effects 
various organ systems (Table 35,37). Fish oil with its principle omega-3-fatty 
acid constituents, at a dose of 5 ml/kg body weight /day together with 
kanamycin for eight days exerted a good protecfion, as is evident by 
normalized circulating levels of urea (-6% change from control after recovery), 
creatinine (-1.6%), SCOT (-3.5%) and SGPT (-1.7%) (Table 35, 37). This 
finding is in line with those reported for gentamicin induced nephrotoxicity 
[172]. However, in comparison to fish oil, no much pronounced effect was 
observed in animals supplemented with olive oil, a major source of omega-6-
fatty acids (Table 35, 37). 
For gentamicin induced nephrotoxicity association of hypercholesterolaemia is 
an establish fact [172]. In accordance with this, the present study also shows 
association of hyperchleslerolaemia with kanamycin treatment (Table 36). The 
study also suggests that coadministration of fish oil with kanamvcin was 
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accompanied b}' normalization of serum cholesterol level with a small 
difference from control (-1.9%) [172]. Coadministration offish oil as compared 
to olive oil also helped in restoration of otherwise increased levels of inorganic 
phosphate to normal (CF -2.3%, CO -60.7%) in an efficient way (Table 36). 
Alkaline and acid phosphatase levels were also altered in kidney homogenates 
indicating a functional and biochemical alteration in kidney due to kanamycin 
(Fig. 15). This decreased level was again restored to normal with difference 
from control (AlP +8.8%, AcP +2.9%) maximally by coadministered fish oil 
(Fig. 15) showing the beneficial effects of fish oil on kidney function. 
Kanamycin did also altered the levels of antioxidant enzymes i.e. CAT, SOD 
and GST of kidney and liver homogenates, thus inducing an oxidative stress 
(Table 38-40). Fish oil treatment gave a significant rise in the activities of these 
enzymes in kidney and liver to ameliorate the oxidative stress induced. This is 
in accordance with the effect reported by others [173] where fish oil 
adminstration induces the activity of hepatic antioxidant enzymes. This study 
also shows that fish oil causes a slight increase in peroxide levels, which may 
inducing the levels of antioxidant enzymes [173]. The antioxidant potential was 
increased to the extent that lipid peroxidation in fish oil treated groups no 
longer remains critical to renal damage. Olive oil, on the other hand did reduce 
the oxidative stress, probably due to the presence of polyphenols and 
tocopherol in this oil. However, no major change in alteration of antioxidant 
potential was observed [184]. The study leads to conclude that fish oil 
supplementation together with kanamycin may offer advantages in reverting 
the toxicities induced by the antibiotic, besides increasing the anfioxidant 
potential. 
3:) 
F. PROTECTIVE EFFECT OF LINOLENIC ACID AND VITAMIN E ON 
TOBRAMYCIN INDUCED NEPHROTOXICITY 
The results of the previous study indicate that out of the five antibiotics studied, 
tobramycin at a dose of 160 mg/kg body weight/day for 12 days leads to a 
significant alterations in kidney physiology. The data also indicates that fish 
oil, an oil rich in polyunsaturated fatty acids have beneficial effect on the 
recovery of nephrotoxicity induced by tobramycin (Fig.2). Fish oil has a high 
content of polyunsaturated fatty acids (PUPA) of the n-3 series, and this 
component seems to be responsible for the beneficial profile associated with 
diets rich in fish. Pish oil has also been shown to provide the high antioxidant 
capability. Among the various non-fatty acid components of fish oil, 
tocopherols (vitamin E) is found in much higher concentration. Mammals 
cannot synthesise fatty acid with double bonds distal to the ninth carbon atom, 
although they are able to some extent to elongate and further desaturate the 
aliphatic chain. Therefore essential fatty acids like a-linolenic acid (CI8:3 n-3) 
is required and derived from external diet source. Considering this, the 
following experiment was designed to determine whether the protective effect 
offish oil against tobramycin induced damage to the kidney was due to specific 
components i.e. linolenic acid & vitamin E present in this oil. The animals were 
given orally linolenic acid and vitamin E separately and together after 
tobramycin injections (post treatment). After 24 days of treatment, the 
following results were obtained. 
1. TREATMENT OF THE RATS WITH LINOLENIC ACID AND 
VITAMIN E 
The animals were classified into five groups each having eight rats. 
Group I or non treated control group: The rats were given no treatment for 
the first 12 days of 24 day experimentation and then followed by an 
intraperitonial injection of normal saline (1ml) for the last 12 days. Animals 
were given free access to water and diet. 
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Group [1 or Tobramycin treated group: The rats were given no treatment for 
first 12 days and then intraperitonial injection of tobramycin (160mg/kg body 
weight/day) was given for the last 12 days to measure the induction of 
maximum nephrotoxicity by the drug. 
Group III or post linolenic acid treated group: Here the animals were given 
tobramycin for the first 12 days and then followed by a dose of linolenic acid 
(250mg/kg body weight/day) orally with the help of catheter for next 12 days. 
Group IV or post vitamin E treated group: Here the animals were given 
tobramycin for 12 days and vitamin E (250mg/kg body weight/day) [76] orally 
for the next 12 days 
Group V or post linolenic acid + vitamin E group: the animals here were 
given tobramycin for the first 12 days followed by administration of both 
linolenic acid and vitamin E (each 250mg/kg body weight/day/rat) for the next 
12 days of 24 day experimentation. 
2. RESULTS 
i) General parameters: Body and organ weight 
All animal groups consumed similar amounts of rat pellet diet (20 gm/day/rat). 
Neither tobramycin treatment nor the linolenic acid (250 mg/kg body 
weight/day and vitamin E treatment (250 mg/kg body weight/day) induced any 
significant changes in body weights of animals of all groups (Table 41). The 
weight of kidney and liver of different rat groups is given in Table 42. 
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ii) Effects on serum and tissue 
'Hie earlier results have shown that tobramycin administration resulted in 
elevation of serum urea and creatinine levels and post fish oil treatment was 
most effective in decreasing the elevated levels to control value. Therefore 
effect of linolenic acid and vitamin E was studied in post treatment only. Thus 
linolenic acid and vitamin E was given to rats after 12 days of injection of 
tobramycin and the reduction in toxicity was determined by measuring the 
levels of urea, creatinine, (Fig. 16 (a) and (b)) inorganic phosphate, cholesterol, 
SCOT and SGPT (Table 43, 44). The result show that post treatment of 
linolenic acid and vitamin E, when given separately brought about less 
protective effect as compared to when given together. Maximum restoration of 
the levels of these serum metabolites to normal was observed in the 
combination group of linolenic acid and vitamin E (urea -14.8%, creatinine 
-9.6%, cholesterol -5.6%, iP -14.4%, SGOT -1.8%, SGPT -3.7% change from 
the control after recovery). Rats treated with linolenic acid and vitamin E in 
combination showed a significant change in reversal of decreased level of AlP 
and AcP in tissue homogenate towards normal values (AlP +1.8%, AcP +0.8%) 
(Fig. 17 (a) and (b)). 
iii) Effects on antioxidant potential of kidney and liver homogenates 
Treatment of rats with tobramycin resulted in a decrease in the levels of 
antioxidant enzymes of both kidney and liver homogenates (Table 45 and 46) 
as compared to their respective control levels. Linolenic acid and vitamin E 
treatment resulted in a significant increase in the activities of CAT, SOD and 
GST of kidney and liver. However, maximum effect in increasing the levels of 
antioxidant enzymes was found to be in linolenic acid + Vitamin E post treated 
group (Table 45, 46 and 47)). 
Tobramycin caused an increase in MDA levels (peroxides) which is toxic to 
liver. The level of the peroxides was also high in linolenic acid post treatment 
group (Table 47), where as linolenic acid + vitamin E post treated group gave a 
less significant rise in the levels of MDA in liver homogenates of this group. 
Thus a combination of linolenic acid with vitamin E is beneficial in 
amelioration of tobramycin induced MDA production in liver. 
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Table 41: Effect of vitamin E and linolenic acid on body weight of 
tobramycin induced nephrotoxic rats 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Post linolenic treated 
Post vitamin E treated 
Post linolenic + vitamin E treated 
Initial body 
weight (g) 
200+11 
195+ 14 
197 ± 8 
205 ±4 
200 ± 3 
Final body 
weight (g) 
205 ±8 
200 ±5 
209 ±6 
212 + 10 
207 + 10 
Results are means ± SE of eight different animals 
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Table 42: Effect of vitamin E and linolenic acid on weight of organs of 
tobramycin induced nephrotoxic rats 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Post linolenic treated 
Post vitamin E treated 
Post linolenic + vitamin E treated 
Kidney weight 
(g) 
2.17±0T2 
8.75 + 1.32 
1.83 ±0.84 
3.22 ±0.90 
2.99 ±0.72 
Liver weight 
(g) 
8.72 ± 1.00 
5.01 ±1.01 
7.00 ±0.97 
I0.03± 1.11 
8.95 ±0.59 
Results are mean ± SE of eight different animals 
140 
Fig. 16 (a) and (b) Effect of vitamin E and linolenic acid on levels of serum 
urea and creatinine in tobramycin induced nephrotoxic rats. 
o 
o 
g 
0) 
I - normal saline treated 
II - tobramycin treated 
III - post linolenic acid treated 
IV - pos t vitamin E t r ea t ed 
V - pos t linolenic acid + vitamin E t rea ted 
II III IV V 
Different animal groups 
I V II III I V 
Different animal groups 
Each bar represent mean ± SE of eight different animals 
Table 43: Effect of vitamin E and linolenic acid on levels of serum 
cholesterol and inorganic phosphate in tobramycin induced nephrotoxic 
rats 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Post linolenic treated 
Post vitamin E treated 
Post linolenic + vitamin E treated 
Cholesterol 
(mg/100 ml) 
30.2110.93 
69.57 + 2.32 
(-130.3%) 
38.87+1.05 
(-27.7%) 
30.80'±0.93 
(-1.9%) 
31.91'±0.33 
(-5.6%) 
Inorganic 
phosphate 
(mg/100 ml) 
6.03 ±0.52 
19.45 ±1.01 
(-222%) 
8.01 ±0.97 
(-32.8%) 
7.87'±0.23 
(-30.5%) 
6.90'±0.31 
(-14.4%) 
Results are mean ± SE of eight different animals 
'p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Table 44: Effect of vitamin E and linolenic acid on levels of SGOT and 
SGPT in tobramycin induced nephrotoxic rats 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Post linolenic treated 
Post vitamin E treated 
Post linolenic + vitamin E treated 
SGOT 
(n mol/min/ml) 
23.30+1.31 
60.61+0.97 
(-160.1%) 
26.01'±2.01 
(-11.6%) 
26.32 ±2.31 
(-12.9%) 
23.72'±1.36 
(-1.8%) 
SGPT 
(n mol/min/ml) 
24.21 ±1.05 
46.93 ±0.98 
(-93.8%) 
27.10'±2.70 
(-11.9%) 
31.91 ±2.33 
(-31.8%) 
25.12'±1.98 
(-3.7%) 
Results are mean ± SE of eight different animals 
''p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Fig. 17 (a) and (b) Effect of vitamin E and linclenic acid on levels of AlP 
and AcP in tobramycin induced nephrotoxic rats 
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Table 45: Effect of vitamin E and linolenic acid on levels of renal CAT, 
SOD and GST in tobramycin induced neplirotoxic rats 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Post linolenic treated 
Post vitamin E treated 
Post linolenic + vitamin E treated 
CAT 
23.34 ±3.69 
9.29 ±3.39 
(±60.2%) 
25.29 ±2.19 
(±8.3%) 
26.23'±2.23 
(-12.4%) 
28.72'±4.55 
(-23%) 
SOD 
29.57 ±3.32 
19.00 ±2.16 
(±14.7%) 
36.12'±1.09 
(-43.2%) 
36.01 ±3.85 
(-42.8%) 
37.95'± 16.12 
(-49.4%) 
GST 1 
1.36 ±0.32 : 
1 
0.62 ±0.90 
(±54.4%) i 
1.67 ±0.37 1 
(-22.8%) i 
1.73 ±0.48 ! 
(-27.2%) ' 
1.95'±1.06 : 
(-43.4%) 
Units: CAT, SOD &. GST - units/min/mg protein 
Results are mean ± SE of eight different animals 
^p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Table 46: Effect of vitamin E and linolenic acid on CAT and SOD of liver 
homogenates in tobramycin induced nephrotoxic rats 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Post linolenic treated 
Post vitamin E treated 
Post linolenic + vitamin E treated 
CAT 
86.43 ±5.88 
79.99 + 5.46 
(+7.4%) 
94.57 ±3.52 
(-9.4%) 
93.89 ±6.89 
(-8.6%) 
96.11'±4.31 
(-11.2%) 
SOD 
69.02 ±4.51 
41.12±3.86 
(+40.4%) 
75.37 ±7.74 
(-9.2%) 
76.50 ±3.80 
(-10.8%) 
77.03'±2.11 
(-11.6%) 
Units: CAT, SOD - units/min/mg protein 
Results are mean + SE of eight different animals 
''p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
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Table 47: Effect of vitamin E and linolenic acid on GST and MDA of liver 
homogenates in tobramycin induced nephrotoxic rats 
Units: GST - units/min/mg protein; MDA - n mol/mg protein 
Results are mean ± SE of eight different animals 
^p<0.05 as compared to normal rats (ANOVA) 
Values in parenthesis represent percent change from the respective control 
Groups 
Normal saline treated control (N) 
Tobramycin treated (T) 
Post linolenic treated 
Post vitamin E treated 
Post linolenic + vitamin E treated 
GST 
7.01 ±1.02 
3.83 ±0.97 
(+45.3%) 
8.14 ±0.30 
(-16.1%) 
8.84 ±0.62 
(-26.1%) 
9.01'±0.62 
(-28.5%) 
MDA 
1.02±0.11 
2.93 ±0.85 
(-187.2%) 
1.15 ±0.47 
(-12.7%) 
1.09±0.18 
(-6.8%) 
1.20'±0.30 
(-17.6%) 
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3.DISCUSSION 
Tobramycin is an antimicrobial antibiotic and nephrotoxicity associated with 
its usage becomes a Hmiting factor to its cHnical utility. In this study, 
tobramycin was selected as potential nephrotoxic drug and a possible approach 
to prevent the toxicity associated with it was investigated. To the best of our 
knowledge, this is the first report showing the effect of fish oil on the reversal 
of tobramycin toxicity. Although great deal of studies have been done on 
gentamicin [75-79] which is equally nephrotoxic to it [162-168]. Therefore, a 
potential therapeutic approach to protect the damage by tobramycin is, 
therefore very important. Our previous results indicate that fish oil when given 
as post treated therapy successfully helps in the protection of tobramycin 
nephrotoxicity whereas olive oil couldnot bring such recovery effects. Taking 
into account the above information, further study to explore the components of 
fish oil in the possible protective role was undertaken. The various fatty acid 
and nonfatty acid components of fish oil are well characterized (Table 2-
introduction). Fish oil is rich in essential fatty acids(n-3 fatty acids) like 
linolenic acid, eicosapentanaenoic acid (EPA) and docosahexanoiec acid 
(DHA). Linolenic acid is required by every mammal from external diet sources 
since mammalian systems are unable to synthesise it; whereas EPA and DHA 
can be made from linolenic acid by elongation processes. Among the various 
nonfatty acid components, tocopherols are present in good amount in fish oil, 
which acts as an important cellular antioxidant in cellular systems. Thus, 
linolenic acid and vitamin E, the two components of fish oils were selected and 
thereby given in different modes of treatment i.e. either alone or together to 
nephrotoxic rats. 
Tubular damage by tobramycin, which is shown by higher levels of urea and 
creatinine was restored to normal control levels (urea -14.8%, creatinine -9.6% 
change from control after recovery) when the linolenic acid and vitamin E was 
given together (Fig. 16). Other elevated serum parameters i.e. cholesterol, 
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inorganic phosphate, SCOT and SGPT was also restored maximally to normal 
(cholestrol -5.6%, iP -14.4%, SCOT -1.8% and SGPT -3.7%) by the 
combination group of linoienic acid and vitamin E (Table 43-44). It was found 
that this combination group ameloriated tubular damage and helped in recovery 
of AlP and AcP levels of kidney homogenates to normal (AlP +1.8%, AcP 
+0.8%) (Fig. 17). 
The biology and the effects of essential fatty acids (n-3 FA) of fish oils, form 
an intense area of research. Promising results have also been observed in 
various renal diseases e.g. IgA nephropathy, kidney transplant recipients and 
the list is increasing [127-135].The metabolism of such long chain 
polyunsaturated fatty acids (PUFA) is well characterized in tissues like liver. 
However, kidney also possess the ability to desaturate long chain fatty acids to 
some extent but the requirement of essential fatty acid remains significant, 
which is largely supplied from external diet sources. Linoienic acid is one such 
n-3 essential fatty acid, which is to be supplied from outside [100]. However, 
once inside, this fatty acid can be metabolized to longer chain fatty acids i.e. 
eiosapentaenoic Aid (EPA) and docosahexaenoic Aid (DHA), which are the 
precursors of metabolic products called as eicosanoitis, that exert a variety of 
biological effects on metabolism. Thus, linoienic acid when supplied to rats, 
due to elongation processes is converted to EPA and DHA, which then replaces 
a n-6 FA, especially arachidonic acid (AA) in the cell membranes. As a result 
of which a series of effects take place especially a decrease in levels of potent 
vasoconstrictors and inflammators [100]. PUFA are indispensable functional 
constituents in membranes. They act as modulators of membrane permeability, 
fluidity and may influence membrane enzymes besides affecting signal 
transduction and transport activities [185-189]. The fatty acid composition of 
kidney cell membranes has been reported to be involved in deficient renal 
functions [185-189]. Thus a diet rich in essential fatty acids becomes important 
due to its ability to alter membrane lipid composition and function. Complex 
interactions and displacement of n-3 and n-6 FA may occur after dietary 
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manipulations suggesting that these essential fatty acids affect cell processes 
[190]. 
However, linolenic acid when given alone could not prevent the renal damage 
completely and the fatty acids was unable to protect completely all the 
functional and structural tubular alterations. This result indicates that other 
mechanisms are also involved. On the other hand the combination group of 
linolenic acid with vitamin E, efficiently and completely prevented the renal 
damage caused by tobramycin when these results were compared with fish oil 
(Table 3), it seems that indeed linolenic acid and vitamin E of fish oil are the 
responsible factors in reducing the induced toxicity by tobramycin. This also 
suggested that the protective effect may involve an antioxidant property of 
vitamin E, since it has been already found that reactive oxygen species (ROS) 
are involved in impairment of glomerular filtration in antibiotic treated subjects 
[182]. The elevation in antioxidant enzymes i.e. CAT, SOD and GST of liver 
and kidney homogenates in the rat group which received linolenic acid and 
vitamin E in combination, (Table 45-46) supported the above speculation that 
antioxidant property is involved.]. Vitamin E is the most important cellular 
antioxidant and therefore may prevent free radical mediated damage to 
biological membrane lipids. Thus following consumption of vitamin E, 
changes in status of antioxidants occur that may have detrimental effect on 
tobramycin nephrotoxicity. Therefore, the results of this study indicate the 
possible implication as well as the role of linolenic acid (n-3 FA) and vitamin E 
as therapeutic when given together as dietary supplementation for tobramycin 
nephrotoxicity. 
Linolenic acid when given alone also showed an increased lipid peroxide level, 
which is related to the tissue fatty acid composition. This lipid peroxide level 
(Table 47) is higher than obtained lor post fish oil treated tobramycin rats 
(Table 8), which clearly indicates that some other component of fish oil is 
helping in reduction of lipoperoxidation. The dietary combination group of 
linolenic acid and vitamin E however, gave reduced le\ els of lipid peroxides 
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(Table 47) indicating that vitamin E of fisli oil with its antioxidant properly acts 
as a scavenger of free radicals thereby exerting a protective effect to counteract 
the action of lipid peroxides formed from dietary linolenic acid. 
Tobramycin nephrotoxicity was associated with low activity of CAT, SOD and 
GST in kidney and liver homogenates (Table 45-47). This decreased 
antioxidant enzymatic defence aggravates the oxidative damage in these 
nephrotoxic rats. However, the increase in levels of antioxidant enzymes 
together with prevention of lipid peroxidation helped in ameliorative effect of 
the combination diet group of linolenic acid and vitamin E on tobramycin 
nephrotoxicity. The results are in line with those obtained for post fish oil 
receiving tobramycin nephrotoxic rats, where an increased level of antioxidant 
enzymes was observed (Table 7) thus, suggesting that the synergistic action of 
linolenic acid and vitamin E of fish oil, when given as post treatment in 
prevention of tobramycin toxicity. 
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G. COMPARATIVE STUDIES OF THE RESULTS OBTAINED FOR 
VARIOUS ANTIBOITICS 
Our results clearly indicate that all aminoglycosides cause alterations in renal 
functions i.e. all of them are nephrotoxic. Oral supplementation offish oil and 
olive oil was given, to determine which oil is helpful in reversal of nephrotoxic 
effects of different antibiotic. The two oils were given in three different modes 
like pre, post and in coadministration together with different antibiotic to see 
which of the treatment results in maximum restoration of altered renal function 
to normal. The results also showed that fish oil gives better protection in 
reversal of nephrotoxicity as compared to olive oil. Considering the results of 
previous studies it was thought worthwhile to evaluate a comparative data 
regarding the treatment of fish oil for different antibiotics. The aim was to 
determine in general which treatment of fish oil could protect against antibiotic 
induced damage and in which treatment group this beneficial effect was 
maximum. 
(i) Effects on serum parameters 
The earlier results had shown that antibiotics i.e. tobramycin, gentamicin, 
streptomycin, amikacin or kanamycin administration results in elevation of 
serum parameters like urea, creatinine, cholesterol, inorganic phosphate, SGOT 
and SGPT. Among the two oils given, fish oil treatment showed a beneficial 
effect on the recovery of these above mentioned serum parameters to normal 
levels. The results indicate that coadministration offish oil, gives this reco\ery 
effect to maximum in gentamicin, streptomycin, amikacin and kanamycin 
whereas in tobramycin, post fish oil treatment brought about maximum effect 
in reversal of induced nephrotoxic effects (Fig. 18, 19, 20). Coadministration of 
fish oil in gentamicin treated rat group gave a maximum recovery in the levels 
of creatinine (+2.7%), inorganic phosphate (+4.1%), SGOT (-23.8%) and 
SGPT (-38.9% change from control after recovery) towards normal level (Fig. 
18(b), 19(b), 20(b)). Urea and Cholesterol levels were normalized to a 
maximum in post fish oil treated group of tobramycin (urea -3.6%, cholesterol 
+ 17.5%) (Fig. 18 (a) and 19(b)). 
(ii) Effects on marker enzymes of the kidney 
Post fish oil treatment on tobramycin receiving animals showed a maximum 
restoration of AlP (-0.7%) and AcP (+4.6%)) levels to normal values. However, 
coadministration of fish oil on gentamicin treated rats (AlP +9.8%), AcP 
+29.8%) also gave a good effect on the recovery of the activities of these 
enzymes close to control group (Fig. 21) although not completely restored to 
normal values. 
Again oxidative stress induced by administration of aminoglycoside was 
ameliorated with use of fish oil. The levels of antioxidant enzymes i.e. CAT, 
SOD and GST were increased to higher levels with coadministration of fish oil 
treatment (Fig. 22). In kanamycin receiving group, there was a high increase in 
level of CAT with coadministration of fish oil. SOD level was increased 
towards higher level in tobramycin treated animals receiving fish oil as post-
treatment (Fig.22). 
(iii) Effects on hepatic antioxidant potential 
Previous result indicate fish oil treatment brought a significant increase in 
levels of hepatic antioxidant enzymes. For gentamicin, coadministration offish 
oil produced a significant increase in levels of CAT, SOD and GST compared 
to coadministered fish oil treated groups for streptomycin, Amikacin and 
kanamycin (Fig. 23, 24(a)). Post fish oil treatment of tobramycin ga\e a 
significant increase similar to that of gentamicin fish oil coadministered group. 
A minimum effect in increasing the hepatic antioxidant enzyme levels was 
observed in coadministered fish oil treated group for streptomycin. The level of 
MDA was also higher in coadministered fish oil treated group of gentamicin 
(Fig. 24(b)) whereas a low value of peroxides in liver was obtained in 
coadministered fish oil kanamycin group. 
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Fig. 18 (a) and (b) Difference from the control in the level of urea and creatinine 
for various antibiotic after fish oil treatment 
N - normal saline treated 
T - post fish oil tobramycin treated 
G - coadministered fish oil gentamicin treated 
S - coadministered fish oil streptomicin treated 
A - coadministered fish oil amikacin treated 
K - coadministered fish oil kanamicin treated 
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Fig. 19 (a) and (b) Difference from the control in the level of cholesterol and 
inorganic phosphate for various antibiotic after fish oil treatment 
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Fig. 20 (a) and (b) Difference from the control in the level of SCOT and SCPT 
for various antibiotic after fish oil treatment 
N - normal saline treated 
T - post fisti oil tobramycin treated 
G - coadministered fish oil gentamicin treated 
S - coadministered fisti oil streptomicin treated 
A - coadministered fish oil amikacin treated 
K - coadministered fish oil kanamicin treated 
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Fig. 21 (a) and (b) Difference from the control in the level of renal AlP and AcP 
for various antibiotic after fish oil treatment 
N - normal saline treated 
T - post fish oil tobramycin treaied 
G - coadministered fish oil gentamicin treated 
S - coadministered fish oil streptomicin treated 
A - coadministered fish oil amikacin treated 
K - coadministered fish oil kanamicin treated 
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Fig. 22 (a) and (b) Difference from the control in the level of renal CAT and SOI) 
for various antibiotic after fish oil treatment 
N - normal saline treated 
T - post fish oil tobramycin treated 
G - coadministered fish oii gentamicin treated 
S - coadministered fish oil streptomicin treated 
A - coadministered fish oil amikacin treated 
K - coadministered fish oil kanamicin treated 30 
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Fig, 22 (c) Difference from the control in the level of renal GST for various 
antibiotic after fish oil treatment 
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Fig. 23 (a) and (b) Difference from the control in the level of hepatic CAT and 
SOD for various antibiotic after fish oil treatment 
N - normal saiine treated 
T - post fish oil tobramycin treated 
G - coadministered fish oil gentamicin treated 
S - coadministered fish oil streptomicin treated 
A - coadministered fish oil amikacin treated 
K - coadministered fish oil kanamicin treated 
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Fig. 24 (a) and (b) Difference from the control in the level of hepatic GS7' and 
MDA for various antibiotic after fish oil treatment 
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2. DISCUSSION 
Antibiotics have long been one of the commonest cause of drug induced 
nephrotoxicity. Our studies strongly support this concept. Tubular necrosis is 
the primary cause of such renal functional toxicity of aminoglycosides. It has 
been shown that drug accumulation occurs in renal cortex followed by luminal 
uptake which then induces an array of tubular alterations including the release 
of brush border and lysosomal enzymes, mitochondrial alterations and 
alterations of the tubular functions [171]. 
Our previous results indicate that dietary fish oil provides protection against 
induced renal injury by all the aminoglycosides included in the study. 
However, the percentage recovery as well the mode of fish oil treatment in all 
the used aminoglycoside differed from one another. Therefore, a comparative 
result offish oil treatment on these antibiotics is evaluated. 
Each antibiotic induced renal damage which was a dose dependent i.e. each 
antibiotic gave an increase in serum urea and creatinine levels at a particular 
dose, after a particular period of time specific for each aminoglycoside. 
However, fish oil dosage was the same in all treatment groups for all antibiotics 
used (5 ml/kg body weight/day). Post fish oil treatment on tobramycin treated 
rats gave a maximum recovery on the level of urea (-3.6%) towards normal 
whereas coadministered treatment of fish oil in gentamicin treated rats gave 
maximum effect in normalizing the level of creatinine (+2.7%) to normal. 
The results of all previous studies showed that coadministration of fish oil 
helps in better protection of drug induced nephrotoxicity for gentamicin, 
streptomycin, amikacin and kanamycin, whereas for tobramycin treated rats, 
post fish oil therapy gave better results (Fig. 18). However, we were not able to 
interpret the difference why post fish oil treatment offers better protection in 
tobramycin and compared to fish oil coadministration for other antibiotics. 
Studies on antibiotic induced nephrotoxicity especially for gentamicin have 
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been found lo be associated with increased excretion of a vasoconstrictor, 
thromboxane- TxB2 [191]. The above given report suggesting that the 
beneficial effect of fish oil on antibiotic nephrotoxicity, could possibh' be 
through repression of renal production of vasoconstrictive prostonoids from 
arachidonic acid (AA), a n-6 fatty acid. This may occur by displacement of AA 
in the phopholipids of glomerular membrane by n-3 FA of fish oil, resulting in 
production of non-inflammatory series of thromboxanes [124]. 
Association of secondary hypercholesterolaemia for gentamicin induced 
nephrotoxicity is an established fact [172]. The result of the study are in 
accordance with above report, where the elevated serum choesterol levels play 
a major role in the progression of induced nephrotoxicity by different 
antibiotics (Fig. 19). Such secondary dyslipidemia was attributed to increased 
hepatic cholesterol biosynthesis, as a result of increased availability." of 
mevalonate, the precursor of cholesterol, due to its reduced catabolism b\" the 
injured kidney [192]. Comparative data shows that post fish oil treatment on 
tobramycin treated rats gave a lower cholesterol level (+17.5%) as compared to 
best recovery treatment in gentamicin (coadministered fish oil) (Fig. 19a). Like 
in gentamicin, coadministration of fish oil in amikacin, streptomycin and 
kanamycin treated rats gave almost similar effect in lowering the cholesterol 
levels to normal. The hypocholesterolemic effect of fish oil could be due to a 
redistribution of cholesterol from blood to tissues and to inhibition of hepatic 
synthesis of very low density liporoteins [102]. 
The coadministration of fish oil in gentamicin treated rats also ga\e a 
maximum recovery of increased serum inorganic phosphate and transaminases 
level to normal. The increased levels of inorganic phosphate by all five 
antibiotics suggest that these antibiotics induce hyperphosphatemia, which may 
be due to decreased tubular reabsorbtion of phosphate whereas an increase in 
serum transaminases (SCOT & SGPT) suggest that all these drugs cause injury 
to liver tissue as well. The data shows that the coadministration of fish oil 
helped in restoration of function of different organs in a efficient way, as gi\en 
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by normalized levels of inorganic phosphate (+4.1%), SCOT (-23.8%) and 
SGPT (-38.9%), giving the varied effect fish oil on metabolism. 
Antibiotic treatment damages the renal membrane which further causes 
sloughing of marker enzymes and other components into the tubular lumen, 
thus given the significant increase in AlP and AcP levels in kidney 
homogenates of antibiofic treated rats. Post treatment offish oil for tobramycin 
treated rats gave a significant recovery (AlP -0.7%, AcP +4.6%) of these 
aJtered ]eveJs of marker enzymes to the normal (Fig.21). Coadministration of 
fish oil on gentamicin treated rats also gave a good recovery, although not 
complete on the levels of AlP (+9.8%) and AcP (+29.8%). 
The pathophysiology of antibiotic induced nephrotoxicity is incompletely 
understood. However, reactive oxygen species (ROS) have been found to be 
involved in such induced nephrotoxicity [21]. Renal cortical lipidperoxidation, 
and renal H2O2 generation were found to be increased in gentamicin treated 
rats. Use of hydroxyl radical scavengers prevent the gentamicin induced 
reduction in glomerular filtration rate and the severity of the tubular damage 
[21]. All aminoglycosides induce oxidative stress as is given by decreased level 
of antioxidant enzymes in kidney and liver homogenates. Fish oil treatment 
resulted in a significant rise in the activities of the antioxidant enzymes to 
ameliorate the induced oxidative stress (Fig. 22-24). Coadministration of fish 
oil in gentamicin treated rats and post fish oil treatment in tobramycin treated 
rats gave a maximum increase in levels of antioxidant potential in kidney and 
liver homogenates. Because the lipid composition of the liver of rats reflect the 
lipids composition of the diet, therefore the livers of rats given fish oil have 
higher levels of PUFA. This fact might render the livers of rats fed on fish oil 
more susceptible to lipid peroxidation and the activity of antioxidant enzymes 
are induced to a greater extent [182-183]. 
The results showed (hat coadministratered fish oil group for gentamicin 
followed by post fish oil treated group for tobramycin, gave an increase in lipid 
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peroxide levels, thereby inducing the hepatic antioxidant enzyme expression 
(Fig. 22-24). 
In summary, the results of comparative data clearly indicate that maximum 
protection was observed with the use of post fish oil treatment on tobramycin 
treated rats and coadministration offish oil for other antibiotics. 
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Conclusion 
CONCLUSION 
Antibiotics are effectively used for the treatment of various bacterial infections. 
However, they themselves carry risks of adverse side effects. Nephrotoxicity is 
one such cause of concern in clinical practice, associated with usage of 
aminoglycosides. Besides there is no consensus of the fact or opinion 
concerning the primary mechanism responsible for the pathophysiologic 
manifestation of acute renal failure. ARF is a process in which the kidneys stop 
their excretory function and it manifests by increase in serum urea and 
creatinine levels. 
Animal studies have shown that different antibiotic induce nephrotoxicity 
which is dose related i.e. each antibiotic - tobramycin, gentamicin, 
streptomycin, amikacin and kanamycin included in the study result in profound 
alterations on the metabolism and functions of kidney which depends on their 
dosage as well as time (days) of exposure. The doses patterns for different 
antibiotics included in the study are: tobramycin - 160 mg/kg body weight/day 
for 12 days; gentamicin - 100 mg/kg body weight/day for 10 days; 
streptomycin - 300 mg/kg body weight/day for 10 days; amikacin - 250 
mg/kg body weight/day for 8 days; kanamycin - 200 mg/kg body weight/day 
for 8 days. Thus, rats were given above doses of particular aminoglycoside for 
a particular period of time to induce maximum renal damage, as given by an 
elevated levels (two fold increase) of serum urea, creatinine and cholesterol 
together with loss of functional renal marker enzymes i.e. AlP and AcP. 
Besides kidney these drugs also effected other organs like heart and liver, as is 
given by hypercholesterolemia and a significant rise in serum transaminases 
associated with the use of these antibiotics. Besides, antioxidant defence 
system was also effected as is shown by decrease in the levels of free radical 
scavenging enzymes i.e. CAT, SOD and GST. To gain an insight into the 
reversal of nephrotoxic effects of these drugs, fish oil and olive oil were given 
orally to examine the possible protective role of these oils on various organs of 
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the rats. Fish oil administration in nephrotoxic rats gave an improvement in the 
damaged tissues as indicated by normal level of serum urea, creatinine, 
cholesterol, inorganic phosphate and transaminases. Post fish oil treatment was 
found to be most effective in bringing the reversal of tobramycin induced 
nephrotoxicity as is given by normalized levels of serum metabolites studied 
whereas the pretreatment offish oil showed less significant effect. However, in 
case of gentamicin, streptomycin, amikacin and kanamycin, coadministration 
of fish oil gave a maximum attenuation of the induced damage. However, this 
difference in beneficial modes of treatment among tobramycin and all other 
included antibiotics could not be explained. Such modes of fish oil treatment 
also gave a significant restoration of the activities of marker enzymes of renal 
membrane and lysosomal membrane suggesting the role of fatty acids present 
in fish oil in restoration of renal membrane structure, thereby its function. 
Olive oil treatment on the other hand could not bring profound and consistent 
recovery of different serum metabolites studied, giving an edge of fish oil 
usage over olive oil administration in prevention of nephrotoxicity. 
Fish oil administration also gave a significant increase in the levels of 
antioxidant enzymes in kidney and liver. This higher antioxidant potential was 
able to cope with the increased lipid peroxidation associated with fish oil 
usage. In tobramycin treated rat, post fish oil treatment gave a maximum 
induction of antioxidant enzymes whereas for gentamicin, streptomycin, 
amikacin and kanamycin, coadministration of fish oil gave significantly 
increased antioxidant potential. On the other hand, olive oil treatment was 
found to lower oxidative stress to some extent which could be probably due to 
the fact that although some of its components ^re similar to fish oil which are 
however, present in much lower concentration (vitamin E). 
The study was further extended to find the specific components of fish oil 
responsible for its beneficial profile. Linolenic acid and vitamin E that are 
piesent in significant amounts in fish oil, when given as post treatment in 
tobramycin treated rats, were found to give better protection against 
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nephrotoxicity suggesting tliat structural integrity, altered metabolic and 
functional aspects of renal membrane are regained back. Treatment with 
linolenic acid or vitamin E alone did not gave such recovery effects on the 
metabolic parameters studied suggesting the synergistic role of n-3 fatty acids 
and vitamin E (as antioxidant) on renal membrane. Comparative results show 
that maximum protection was observed in tobramycin, when fish oil was 
administered after the drug for a week. Coadministration of fish oil in 
gentamicin treated rats also gave a similar effect in amelioration of changes 
induced by the antibiotic. Thus, fish oil administration offers a better strategy 
to combact the toxicity associated with the use of antibiotics, without 
compromising its antibacterial properties. 
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Effect of dietary n-3 and n-6 fatty acids on tobramycin induced nephrotoxicity 
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Post fish oiI(n-3 fatty acids) treatment (5mg/kg/day for 12 days) was effective in bringing the reversal of tobramycin 
(160mg/kg/day,ip for 12 days) induced nephrotoxicity in albino rats as was evident by normal urea, creatinine, cholesterol 
and inorganic phosphate levels in the serum of the treatment group compared with group receiving tobramycin only. The 
return of normal levels of alkaline and acid phosphatase in kidney homogenates of post fish oil treatment group also 
indicated the beneficial effect of dietary n-3 fatty acids(fish oil) more than n-6 fatty acids(olive oil).The results suggest that 
oral supplements of dietary n-3 fatty acids (fish oil) for nearly two weeks after tobramycin exposure is more beneficial than 
n-6 fatty acids (olive oil) as it results in reversal of nephrotoxicity induced by tobramycin. 
Keywords; Aminoglycosid'^s, Tobramycin, Nebramycin, Nephrotoxicity, n-3 fatty acids. Fish oil, n-6 fatty acids, Olive oil. 
Urea, Creatinine. 
IPC Code: Int.Cl'A61K 
All aminoglycosides are antimiax)bial substances with 
similar antibacterial spectra and their potential 
toxicities effect the same organ systems. However, 
certain subtle differences do exist. Tobramycin 
(Nebramycin) a six-membered aminocyclitol ring with 
amino group side chain, is produced by Streptomyces 
tenehrarious\ It is active against all the 
enterobacteriaceae^"^ and is used for treatment of 
bacterial conjunctivitis, cystic fibrosis and 
intraabdominal infections. For the treatment of mild to 
moderate infections, tobramycin is administered in a 
dose of 3-4.5mg/kg body weight/day, given in three 
divided doses^ '^  and can be increased to 5-8 mg/kg/day 
for serious infections .^ Aminoglycosides have broad 
antibacterial spectrum extending from positive aerobic 
cocci to gram-negative bacilli. About 30% of patients 
treated with aminoglycosides show some signs of 
nephrotoxicity .^ Tobramycin is excreted in urine by 
glomerular filtration and in normal renal functioning 
patients, 60% of administered dose is secreted within 
6hr . However, some of tobramycin is accumulated in 
renal cortical cells''"'^ with half-life of 74hr, making it 
nephrotoxic. Tobramycin in kidneys causes renal 
impairment characterized by oligouria, proteinuria and 
a progressive rise in blood urea and creatinine 
values ''' together with a decrease in glomerular 
*CoreKpondcnl author 
E mail: shecmabiochcni@yahoo.co.in 
Phone:+91-571-2700741 
r;:v :+91-.'i71-2702755 
filtration rate'^ .Tobramycin induced renal damage may 
be aggravated by concomitant use of other nephrotoxic 
drugs. Wood et al. demonstrated that vancomycin 
potentiated tobramycin nephrotoxicity"^. Similarly, use 
of cephalotin increased the risk of nephrotoxicity 
induced by tobramycin '^'^ ''^ . However increased renal 
toxicity has not been observed when tobramycin was 
used either with carbenicillions or ticarcillin or 
cephalosporins 13,17,19-21 . It has also been reported that 
the ceftriaxone reduces significantly the renal toxicity 
of Tobramycin in experimental rats^ .^ 
Fish oil protects against proteinuria in passive 
Heymann nephritist '^', against cyclosporine 
nephrotoxicity in rats^ ** and in renal transplant 
recipients'^ .^ In addition, fish oil has been reported to 
protect against acetaminophen (paracetamol) induced 
.26 hepatotoxicity , ethanol induced gastric mucosal 
injury in rats^', and in number of inflammatory 
diseases^ .^ Very recently, the beneficial effects of fish 
oil supplementation in reverting back the 
nephrotoxicity induced by gentamycin was observed in 
rats '^. Keeping this in, the present study has been 
undertaken to make comparative investigation of 
impact of fish oil (n-3 fatty acids) and oli\'e oil (n-6 
fatty acids) in reducing the biochemical alterations 
induced by tobramycin. Olive oil was used as a placebo 
for fish oil because its constituents are similar to, but in 
much lower concentration. Indeed, olive oil has been 
used almost exclusively as the placebo in fish oil 
studies'". 
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Materials and Methods 
Animals—^Adult male wistar rats weighing 100-
150g were used in all the experiments. Animals were 
stabilized for 8 days prior to the experiment on 
standard pellet rat diet and allowed free access to 
water. 
All the chemicals used for study of biochemical 
parameters of serum and homogenate, were of 
analytical grade obtained from commercial sources. 
Fish oil from Seven Sea Ltd., UK and olive oil from 
Milano, Italy was orally administered (5ml/kg-body 
weight) to rats with the help of catheter. Tobramycin 
vials of 2ml, having concentration of tobramycin 
sulphate as 80 mg in 2ml, obtained from Aristo 
Pharmaceuticals, India, were given intraperitonially 
(ip) in one daily dose (160 mg/kg body wt) in volume 
adjusted to 1 ml with 0.9% saline for 12 days. 
Time dependent effect of tobramycin in 
rats—^Maximum nephrotoxicity was induced in rats 
by ip administration of tobramycin (160 mg/kg/day) 
for 4,6,8,10,12,14 consecutive days. The animals 
were sacrificed 12 hr after each injection and serum 
obtain was subjected to analysis of urea and creatinine 
to evaluate the nephrotoxicity induced by the 
antibiotic. Maximum nephrotoxicity was developed 
after 12 day treatment with tobramycin. 
Treatment of animals—The rats were divided into 
8 groups of 10 each. All of these groups were treated 
as follows: 
Group I (normal) or no treatment group—The rats 
were given ip injection of normal saline for the last 12 
days of the 24 day experiment and were allowed free 
access to food and water. 
Group II (control) or tobramycin treated 
group—The animals were given ip injection of 
tobramycin for last 12 days of the 24day experiment 
to get the measure of maximum nephrotoxicity 
induced by tobramycin. 
Group III or oil pre-treatment group—The animals 
were given oil orally for 12 days and for next 12 days 
both oil and tobramycin were administered. 
Group IV or oil co-administration group—The 
animals were given no treatment for first 12 days and 
for next 12 days they were given both oil and 
tobramycin. 
Group V or oil post-treatment group—Here the 
animals were given tobramycin for first 12 days and 
oil for next 12 days. 
Groups III, IV and V were in duplicates, one set 
being given fish oil and other olive oil. The diet intake 
was same in all groups. 
Biochemical analysis—The animals were given 
pre, post and co-administration of either of the oils 
with tobramycin injections and were sacrificed 12hr 
after they received the last treatment. Blood was 
withdrawn and serum was obtained by centrifugation 
of blood at 2000 rpm for 10 min. The serum was then 
deproteinized with 3% TCA in the ratio of 1:3. After 
incubation for 10 min at room temperature the 
samples were centnfuged at 1500 rpm for 10 min to 
obtain protein free serum, which was subjected to 
various assays. 
(i) Quantitative determination of urea by Dam 
method as described by Fingerhunt et al?^ 
using a reagent kit from Techno. Pharm. Chem; 
India, 
(ii) Creatinine estimation was done by method of 
Tausky and Bonses^^ using a reagent Kit 
obtained from Span diagnostics Ltd., India, 
(iii) Estimation of cholesterol content by method of 
Wybenga and Pillegi" using reagent Kit from 
Span diagnostics Ltd., India, 
(iv) Quantitative determination of inorganic 
phosphate by the method of Tausky and Shorr 
34 
(v) SCOT and SGPT levels were determined by 
method of Reitman and Frankel'^ using a kit 
obtained from Span diagnostics Ltd., India. 
Kidney and liver homogenates—Kidney and liver 
were removed rapidly and were homogenized 
separately in mannitol (50 mAf) using a high-speed 
Turrex Kunkel homogenizer. Supernatant was 
obtained by centrifugation of homogenate at 4°C for 
10 min at 20,000 rpm. Supernatant was then subjected 
to assay of marker enzymes. 
Alkahne phosphatase assay (Alkpase, E.C.3.1.3.1): 
The activity of AlP was determined according to the 
method of Shah et al?^. 
Acid phosphatase assay (AcPase, E.G.3.1.3.2); The 
AcP activity was measured quantitatively by the 
method of Verjee". 
Statistical analysis—Statistical analysis of the data 
was performed using one way analysis of variance 
(ANOVA) using SPSS computer software. The 
difference was considered significant when P<0.05. 
Values shown as means +SE for 10 animals. 
Results 
In the present study, rats in the eight experimental 
groups consumed similar amounts of food. The over-
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all magnitude of impaired renal function is reflected 
by increased level of urea and creatinine in the serum 
of tobramycin receiving group compared to normal 
saline treated one. The rise in levels of other serum 
parameters like inorganic phosphate, cholesterol, 
SCOT, SGPT, as well as decrease in activities of 
various markers like AlP and Ac? in liver and kidney 
homogenates also suggest that tobramycin is toxic for 
various organs. 
To see the effect of oils in preventing the induced 
alterations in renal system by tobramycin, serum urea 
and creatinine levels were determined. The urea 
concentrations in serum-measured show that 
increased levels of urea was decreased in groups that 
received pre and post treatment of both the oils 
(Fig.l). This effect was most pronounced in n-6 fatty 
acid as compared to n-3 fatty acids receiving animal 
group. 
The elevated serum creatinine levels by tobramycin 
were lowered maximally by the post fish oil treatment 
(Fig.2). Here pre fish oil treatment also helped to 
lower the creatinine content in serum, reflecting that 
renal function is reverting back toward the normal 
functioning of filtration. The effect of dietary lipids 
on the cholesterol content of serum is given in 
Table 1. Animals fed on n-3 fatty acids (fish oil) had 
significantly lower cholesterol content in serum 
compared to those fed on n-6 fatty acid diet (olive 
oil). Further, it is clear that pre fish and post fish oil 
treatment results in significant decrease of cholesterol 
levels close to normal, which otherwise was elevated 
by tobramycin alone. 
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Fig. 1— T^otal urea levels in serum. Values are expressed as 
mg/IOO ml and represent mean ± SE of 10 different 
animals."P<0.0.') as compared to normal saline treated. 
Significance between normal and experimental groups(ANOVA). 
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Fig. 2— T^otal creatinine levels in serum. Value are expressed as 
nig/IOO ml and represent mean ± SE of 10 different animals. 
"PKO.QS, V < 0 . 0 1 as compared to normal saline treated. 
Significance between normal and experimental groups(ANO\'.Al. 
GROUPS 
Cholesterol 
(mg/lOOml) 
Inorganic 
Phosphate 
(mg/ml) 
SCOT 
(nmol/min/ml) 
SGPT 
(nmol/min/ml) 
N 
29.89 
±2.72 
5.33 
+0.22 
22.82 
±0.55 
22.14 
±0.55 
Table I—Circulating levels of 
C 
71.55 
+4.86 
20.00 
±1.03 
56.51 
±1.57 
49.22 
±0.39 
[Values are 
FI 
32.79 
±1.04 
3.61 
+0.54" 
37.03 
+0.30 
43.51 
±1.52 
various biochemical parameters in serum 
mean± SE of 10 different animals] 
Fll 
64.59 
+0.52 
19.30 
±0.01 
58.82 
±0.37 
48.83 
±0.17 
Fill 
24.66 
±2.03" 
3.67 
+0.32" 
34.33 
±0.35" 
25.18 
±0.42" 
01 
43.57 
±4.90 
3.17 
±0.11" 
49.22 
±0.39 
37.73 
±1.22 
on 
132.56 
±0.67 
14.39 
±0.05 
51.54 
±2.07 
50.77 
±2.56 
Olli 
69.13 
±7.37 
3.43 
+0.53" 
38.96 
±4.01 
37.03 
±0.30 
"P<0.05- as compared to normal treated rats (ANOVA) 
N-normal saline treated; C-conlrol or tobramycin treated; Fl- pretieated llsh oil; Fll-coadministration fish oil; Fill-post treated llsh oil 
01- pretreated fish oil; Oil- coadministration olive oil; OIII- post treated olive oil 
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It is clear that pre and post fish oil treated group 
results in normalizing the elevated levels of inorganic 
phosphate. Here pre and post olive oil was also 
significant in reducing the level of inorganic 
phosphate to normal. 
One of the common observation was that co-
administration of both fish and olive oil together with 
tobramycin injections resulted in many fold increase 
of all measured serum parameters like urea, creatinine 
(Fig. 2, 2), cholesterol, inorganic phosphate, SGOT 
and SGPT (Table 1). 
The serum SGOT and SGPT levels showed a 
significant increase in tobramycin treated animal 
groups. Again, in post fish oil treated animals, these 
high levels of SGOT and SGPT were reduced 
maximally compared to other oil treated groups. 
Although this level of SGOT was much higher than 
normal value but it was still significantly low as 
compared to very high level in tobramycin treated 
only. 
The effect of tobramycin was also observed in the 
activities of certain enzymes of kidney and liver. The 
AlP and AcP level decreased significantly in the 
homogenates on treatment with tobramycin injections 
(Table 2). In kidney homogenate, the levels of AlP 
and AcP were significantly lowered in post fish and 
post olive oil groups (Table 2). It is also evident that 
in liver homogenate, AIP level returned towards 
normal level in post fish as well as in post olive oil 
treated groups. Similar results were obtained, when 
level of AcP was determined. 
Discussion 
Tobramycin is nephrotoxic. The present study was 
designed to determine whether feeding PUFA oil 
polyunsaturated fatty acid (PUFA;n-3 oil) or MUFA 
oil monounsaturated fatty acid (MUFA;n-6 oil), helps 
in reverting the nephrotoxicity induced by 
tobramycin. This study also determined the effect of 
the two oils on cholesterol levels in serum or the 
cardiovascular health. Acute renal failure, induced by 
tobramycin exposure resulted in an increased serum 
urea and creatinine levels. The rise of urea and 
creatinine levels in tobramycin treated animals ' 
compared to normal saline treated animals suggest 
that due to renal injury, glomerular filtration rate 
(GFR) and reabsorbtion processes have been 
effected'^. The present results indicate the beneficial 
effects of n-3 fatty acids in combating nephrotoxicity, 
as the levels of urea and creatinine decreased from 
higher levels in post fish oil treated group (Fig.l, 2). 
This is in accordance with those reported for 
gentamycin induced nephrotoxicity^'. 
Hyperphosphatemia usually is related to renal 
failure. The increased level of inorganic phosphate by 
tobramycin injection means decrease GFR and 
increased reabsorbtion by renal tubules. A decrease in 
GFR limits the renal excretions of phosphate, and 
develops hyperphosphatemia. Phosphate in serum is 
mostly protein bound or complexed with calcium, 
with some of it free. Phosphate is critical for activity 
in several important enzyme systems. Hyper-
phosphatemia, however, does not result in any 
definable disorder. The abnormalities attributed to 
hyperphosphatemia are secondary to changes in 
calcium homeostasis e.g. soft tissue calcification and 
possible tumoral calcinosis. The increased level of 
inorganic phosphate by tobramycin was restored to 
normal in post fish oil treated group (Tablel), 
suggesting varied effects of n-3 fatty acids on 
metabolism. 
Bendush and Weber'' have already reported that 
SGOT level increases in patients receiving tobramycin 
GROUPS 
kidney AIP 
(nmol/mg/ml) 
kidney AcP 
(nmol/mg/ml) 
liver AIP 
(nmol/mg/ml) 
liver AcP 
(nmol/mg/ml) 
N 
50.2 
±0.09 
J 13.57 
+0.33 
15.96 
±.037 
39.96 
±0.08 
Table 2—Alkal 
C 
30.56 
±0.25 
81.20 
±0.55 
13.69 
±0.11 
32.97 
±0.31 
ine and acid 
[Values are 
FI 
38.66 
±0.45 
88.44 
±0.47 
14.73 
±0.39'' 
35.87 
±0.06 
phosphatase levels in kidney and livei 
mean± SE of 10 different animals] 
FII 
28.18 
±0.04 
81.91 
±0.29 
13.37 
±0.19 
31.29 
±0.23 
Fill 
50.58 
±0.48" 
108.34 
±0.45" 
14.57 
±0.18" 
37.97 
±0.05" 
• homogenates 
01 
46.29 
±0.67" 
105.97 
±0.14" 
14.02 
±0.03 
35.01 
±0.08 
on 
35.47 
±0.64 
78.67 
±0.86 
13.54 
±0.16 
30.89 
±0.32 
OIII 
48.98 
±0.43" 
I i 1.33 
±0.90" 
14.92 
±0.25" 
38.57 
±0.49 
"P<0.05- as compared to normal treated rats (ANOVA) 
N-normal saline treated; C-control or tobramycin treated; FI- pretreated fish oil; Fll-coadministration fish oil; Flll-post treated fish oil; 
01- prelreaied fish oil: Oil- coadminislralion olive oil; 0111- post treated olive oil 
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injections. This was in accordance witi: the present 
observations, where animals receiving tobramycin 
injections were found to have elevated levels of SCOT 
and SGPT thereby indicating that liver damage may 
have occurred to some extent. Oral administration of n-
3 fatty acids after tobramycin injections helped to some 
extent in lowering the levels of SGOT and SGPT, 
which otherwise were increased by tobramycin alone 
(Table 1). 
It seems that the co-administration of n-3 and n-6 
fatty acids together with tobramycin exposure, 
somehow potentiated the damage caused by 
tobramycin as was evident by many fold increase of 
serum urea, creatinine (Fig.l, 2) and cholesterol 
(Table 1). This may be due to the reason that 
tobramycin is not excreted by the kidneys, thereby 
increasing the nephrotoxicity. It has already been 
shown that fish oil does not reduce the renal cortical 
gentamycin accumulation^'. Content of gentamicin has 
been related to the severity of nephrotoxicity"". In 
agreement with this, the increase in all nephrotoxic 
parameters in coadministration group in the present 
study may be related to the extent drug uptake by the 
kidney cortex. Further studies are required to know the 
actual mechanism involved. 
To see any cholesterol lowering effects, the level of 
cholesterol was determined and it was clear that pre and 
post fish oil treatment resulted in significant decrease by 
tobramycin alone (Table 1). Pre olive oil was also found 
to lower cholesterol to same extent when compared to 
normal. Lower cholesterol level in plasma of fish oil 
consuming animals have been reported'". In accordance 
with this, the present comparative study shows that fish 
oil is better tlian olive oil in lowering the cholesterol 
level. Fish oil consumption reduces cholesterol levels in 
blood and that it is more hypocholesterolaemic than 
olive oil, although the mechanism by which it is brought 
about remains unclear''^. Many clinical studies have 
indicated that diets rich in fish oil are associated with 
cardiovascular health and the responsible component 
was found to be high content of PUFA of the n-3 
series''^ "''". Olive oil, an oil rich in MUFA is also related 
to cardiovascular health''^. It has been found that besides 
oleic acid, sterols and polyphenols in olive oil may 
contribute to these beneficial results''^ 
The decreased activities of AIP and AcP in kidney 
and liver homogenates returned back maximally towards 
normal in post fish and post olive oil treated animals, 
indicating the beneficial use of fish and olive oil in 
tobramycin exposure. 
Ush oil has many benefits, however there is 
growing concern that habitual intake of large 
quantities of PUFA may induce carcinogenesis, 
probably because they are very susceptible to 
peroxidation and production of free radicals '. The 
production of free radicals has been associated with 
ageing"* .^ However, it has also been reported that 
PUFA extends the life span of animal models of 
autoimmune diseases'*^. This is further supported by 
Valentina and Alonso'" who reported that PUFA in 
fish oil may render the liver of rats on fish oil diet 
more susceptible to lipid peroxidation and the activity 
of antioxidant enzymes may be induced. However, 
attempts have been made to define an appropriate 
proportion of dietary n-3 fatty acids that may show 
beneficial effect without having side effects like 
increased clotting time'*'. The present results could be 
helpful in formulating human clinical trials to 
examine the efficacy of fish and olive oil 
supplementation on nephrotoxicity induced by 
commonly used antibiotics i.e. aminoglycosides. 
Conclusion 
On the basis of the results, it is suggested the use of 
fish oil (5 ml/kg/day) for two weeks after tobramycin 
injection helps in reverting the biochemical alterations 
induced by the tobramycin i.e. proximal tubular 
subsegment of kidney damaged by tobramycin is 
restored structurally and functionally again. It appears 
likely that the beneficial and preventive effect of 
omega 3-supplementations on nephrotoxicity is result 
of a complex interplay between altered inflammatory, 
hemodynamics and metabolic factors. Whatever the 
mechanism, dietary omega 3 supplementations may 
offer a safe therapeutic strategy to diminish 
nephrotoxicity induced by aminoglycosides. 
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